PHYSICIAN PAYMENTS SUNSHINE ACT
SSO is compliant with the rules and regulations of the Physician Payments Sunshine Act. As a result, there may be changes in the overall annual meeting structure. SSO’s corporate supporters and partners are responsible for reporting indirect payments and/or transfers of value to physicians. SSO does not collect data, NPI numbers or any other information on behalf of vendors as it is their sole responsibility to maintain compliance with the Physician Payments Sunshine Act.
The Society of Surgical Oncology and The SSO Foundation recognize the essential role that health care organizations play in furthering the mission of the Society. SSO and The SSO Foundation thank its partners for their generous support of the 68th SSO Annual Cancer Symposium and other important SSO and The SSO Foundation programs.

**CORNERSTONE**
Amgen, Inc.
Ethicon Endo-Surgery, Inc.
Genentech, Inc.

**FOUNDER**
Merck & Co., Inc.
Susan G. Komen®

**AMBASSADOR**
Mammotome
Pfizer

**SUPPORTER**
Celegen
Covidien
Dune Medical Devices
Eight Medical Corporation
Faxitron Bioptics, LLC
Hitachi Aloka Medical, Ltd.
Hologic, Inc.
iCAD, a subsidiary of Xoft
John Wayne Cancer Foundation
Myriad Genetics, Inc
Vector Surgical LLC

**FRIEND**
American Cancer Society
American College of Surgeons Commission on Cancer and National Accreditation Program for Breast Centers
AngioDynamics
Carl Zeiss
Colon Cancer Challenge Foundation
ImpediMed
Memorial Healthcare System
The SSO Foundation

*As of February 28, 2015*
2014-2015
SSO OFFICERS & EXECUTIVE COUNCIL

Officers
President Ronald J. Weigel, MD, PhD (2015)
President-Elect Jeffrey A. Drebin, MD, PhD (2015)
Vice President Daniel G. Coit, MD (2015)
Secretary Armando E. Giuliano, MD (2016)
Treasurer David L. Bartlett, MD (2017)

Executive Council Members
Monica Morrow, MD Past President (2015)
V. Suzanne Klimberg, MD Immediate Past President (2016)
John M. Kane, III, MD (2015)
Hong Jin Kim, MD (2016)
Augusto Leon, MD (2015)
Robert C.G. Martin, II, MD, PhD (2017)
Nipun B. Merchant, MD (2016)
Christopher M. Pezzi, MD (2016)
Sharon M. Weber, MD (2017)
Sandra L. Wong, MD, MS (2015)

Councilors-at-Large
Tari A. King, MD (2017)
Kevin K. Roggin, MD (2016)
David Shibata, MD (2015)

Ex Officio
Executive Director M. Eileen Widmer, CAE, CFRM
President,
The SSO Foundation Mitchell C. Posner, MD
Editor,
Annals of Surgical Oncology Charles M. Balch, MD
2014-2015
SSO STAFF

Executive Director       M. Eileen Widmer, CAE, CFRM
Chief Financial Officer   Steven M. Burger, CPA
Associate Executive Director, Administration
Director, Education & International Programs
Director, Communications
Asst. Director, CME & Educational Products
Senior Accountant
Manager, Training Programs
Manager, Scientific Programs
Manager, International Programs
Membership Coordinator
Governance Coordinator
Operations Coordinator
Education Coordinator
IT Coordinator

Senior Vice President, Healthcare Events
Senior Director of Meeting Logistics
Meetings Manager
Exhibit Sales Associate, Healthcare Events
Exhibit Operations Manager
Senior Registration Account Manager
Registration Account Manager
Housing Account Manager
Housing Account Manager

HEADQUARTERS OFFICE
9525 W. Bryn Mawr Ave., Suite 870
Rosemont, IL 60018
847-427-1400 • info@surgonc.org • surgonc.org

ANNUAL SYMPOSIUM EXHIBITION TEAM

Senior Vice President, Healthcare Events       Sue Deveaux
Senior Director of Meeting Logistics           Tiffany Melton, CMP
Meetings Manager                               Kaynce Henderson
Exhibit Sales Associate, Healthcare Events     Darnella Bradley
Exhibit Operations Manager                    Shirley Harris
Senior Registration Account Manager           Anna Roscigno
Registration Account Manager                  Debbie Kennedy
Housing Account Manager                        Erin Davis
Housing Account Manager                        Angela Smith
2014-2015
SCIENTIFIC PROGRAM COMMITTEE

James R. Howe, MD — Chair (2015)
Richard D. Schulick, MD, MBA — Vice Chair (2015)

Glen C. Balch, MD (2015)
Mary Sue Brady, MD (2015)
Kelli M. Bullard Dunn, MD (2015)
Aimee M. Crago, MD, PhD (2015)
E. Shelly Hwang, MD, MPH (2015)
Karyn B. Stitzenberg, MD, MPH (2015)
Brian D. Badgwell, MD, MS (2016)
Carmen C. Solorzano, MD (2016)
David J. Winchester, MD (2016)
Peter J. Allen, MD (2017)
Adam C. Berger, MD (2017)
Kenneth Cardona, MD (2017)
Electron Kebebew, MD (2017)
Jeffrey E. Gershenwald, MD - Ex Officio
(Educational Products Committee) (2015)
Stephen R. Grobmyer, MD - Ex Officio (2015)
Glenda G. Callender, MD - Ex Officio (CME) (2016)

2014-2015
CONTINUING MEDICAL EDUCATION COMMITTEE

Glenda G. Callender, MD — Chair (2016)
Brian J. Kaplan, MD — Vice Chair (2016)

David R. Brenin, MD (2015)
Marissa Howard-McNatt, MD (2017)
Elizabeth A. Mittendorf, MD (2015)
Larissa K. F. Temple, MD (2015)
Scott H. Kurtzman, MD (2015)
Anees B. Chagpar, MD, MSc, MA, MPH (2015)
Richard L. White, Jr., MD (2015)
Joseph Kim, MD (2015)
Kimberly Moore Dalal, MD (2015)
John C. Mansour, MD (2016)
John H. Stewart, IV, MD (2016)
James R. Howe, MD - Ex Officio
(Scientific Program Committee) (2015)
# TABLE OF CONTENTS

Daily Events ..................................................................................... 7
SSO 75th Anniversary Information .............................................. 12
New at SSO 2015 .............................................................................. 14
General Information (listed alphabetically) ........................... 16
SSO 2015 Mobile Access ............................................................... 22
Social Events .................................................................................. 25
Meeting Highlights ................................................................. 27
SSO Committee Meetings ............................................................. 32
Education Information ................................................................. 34
SSO and The SSO Foundation Partners and Supporters ........... 36
ACGME Core Competencies ....................................................... 38
MOC Part 2 Self-Assessment Opportunities ............................. 39

**Wednesday Program** ................................................................. 41

**Thursday Program** .................................................................. 44

**Friday Program** ......................................................................... 59
  James Ewing Lecture ................................................................. 62
  SSO Presidential Address .......................................................... 63
  Distinguished Service Award ................................................... 64
  James Ewing Layperson’s Award ............................................. 65
  American Cancer Society/SSO Basic Science Lecture ............. 66
  The Great Debates ...................................................................... 67

**Saturday Program** .................................................................. 73
  John Wayne Clinical Research Lecture ................................... 77
  Clinical Investigator Award Presentations ............................... 78
  Town Hall and Annual Business Meeting .............................. 90
  President’s Reception: SSO 75th Anniversary Celebration ....... 90

Scientific Posters ........................................................................... 91
Disclosure Information ................................................................. 131
Industry Satellite Symposia ......................................................... 139
Industry Forum .............................................................................. 140
Exhibits. ....................................................................................... 142
Faculty Index ................................................................................ 159
Convention Center and Hotel Maps ......................................... 162
The SSO Foundation Information .............................................. 166
DAILY EVENTS

For a complete committee meeting schedule and locations, please refer to pages 32-33.

TUESDAY, MARCH 24
4-6 pm  Registration Open  
GBCC-Level 3, Outside GBCC-360
4-6 pm  Speaker Ready Room Open  
GBCC-360DE

WEDNESDAY, MARCH 25
6:30 am-6 pm  Registration Open  
GBCC-Level 3, Outside GBCC-360
6:30 am-1 pm  Pre-Meeting Workshop  
(Ticket required)  
Minimally Invasive Pancreas Surgery  
Pre-Meeting Workshop - AM  
Assemble outside the Hilton Americas on the East Drive entrance at 6:30 am for the bus
6:30 am-6 pm  Pre-Meeting Workshop  
(Ticket required)  
Practical Aspects and Methodology to Minimally Invasive Groin Dissection  
Assemble outside the Hilton Americas on the East Drive entrance at 6:30 am for the bus
7 am-7 pm  Speaker Ready Room Open  
GBCC-360DE
12-6:30 pm  Pre-Meeting Workshop  
(Ticket required)  
Minimally Invasive Pancreas Surgery  
Pre-Meeting Workshop - PM  
Assemble outside the Hilton Americas on the East Drive entrance at 12 pm for the bus
1-6 pm  Pre-Meeting Workshop  
(Ticket required)  
Update Course in Surgical Oncology for the Practicing Surgeon  
Hilton, Ballroom of the Americas D (Level 2)

THURSDAY, MARCH 26
6 am-6:30 pm  Registration Open  
GBCC-Level 3, Outside GBCC-360
6 am-6 pm  Speaker Ready Room Open  
GBCC-360DE
6:45-7:45 am  Industry Forum: Tumor Immunology - A Surgeon’s Perspective  
Hilton, Ballroom of the Americas A (Level 2)
8-10 am  Joint SSO/JSGS Symposium: Management of Bile Duct Tumors (MOC)  
GBCC-332
8-10 am  Soft Tissue Sarcoma Board: A Case-Based Discussion of Ongoing Controversies (MOC)  
GBCC-320
8-10 am  Neoadjuvant Therapy for Breast Cancer (MOC)  
GBCC-310
10-10:15 am  Refreshment Break  
GBCC Grand Ballroom Foyer
10:15 am-12:15 pm  Colorectal Parallel Session  
GBCC-332
10:15 am-12:15 pm  Sarcoma and Thoracic/Esophageal Parallel Session  
GBCC-320
10:15 am-12:15 pm  Breast Parallel Session I  
GBCC-310
12:15-1:15 pm  Exhibit Hall Opening Lunch  
(See details on page 20)  
Exhibit Hall B3
12:15-1:15 pm  SSO New Member Luncheon  
(By invitation only)  
Hilton, Ballroom of the Americas D (Level 2)
12:15-6 pm  Fellows & Residents Lounge Open  
Exhibit Hall B3
12:30-1 pm  Poster Grand Rounds  
(See details on page 23)  
Exhibit Hall B3
1:15-3:15 pm  Defining Roles for Novel Techniques in HPB Oncology  
GBCC-332
1:15-3:15 pm  Cost Effective and Quality Care of the Melanoma Patient (MOC)  
GBCC-320
1:15-3:15 pm  Susan G. Komen® Symposium: Personalized Care for Early Stage Breast Cancer (MOC)  
GBCC-310
3:15-4:15 pm  Refreshment Break in the Exhibit Hall  
(See details on page 18)  
Exhibit Hall B3
3:30-4 pm  Poster Grand Rounds  
(See details on page 23)  
Exhibit Hall B3
3:30-4:10 pm  Late Breaking Videos - Thursday  
Exhibit Hall Theater, Exhibit Hall B3
4:15-5:45 pm  Microsatellite Instability: Understanding Biology & Optimizing Treatment of Colorectal Cancer (MOC)  
GBCC-332
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:15-5:45 pm</td>
<td>Issues of Cost and Value in Surgical Oncology Care (MOC)</td>
<td>GBCC-320</td>
</tr>
<tr>
<td>4:15-5:45 pm</td>
<td>Controversies in the Management of Thyroid Cancer (MOC)</td>
<td>GBCC-310</td>
</tr>
<tr>
<td>6-7:30 pm</td>
<td>Welcome Reception in the Exhibit Hall</td>
<td>Exhibit Hall B3</td>
</tr>
<tr>
<td>6:15-7 pm</td>
<td>Exhibit Hall Theater Presentation</td>
<td>Exhibit Hall Theater, Exhibit Hall B3</td>
</tr>
</tbody>
</table>

**FRIDAY, MARCH 27**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 am-4 pm</td>
<td>Registration Open</td>
<td>GBCC-Level 3, Outside GBCC-360</td>
</tr>
<tr>
<td>6 am-6 pm</td>
<td>Speaker Ready Room Open</td>
<td>GBCC-360DE</td>
</tr>
<tr>
<td>6:45-7:45 am</td>
<td>Meet the Professor Breakfasts (Ticket required)</td>
<td>For full schedule and locations, see page 59</td>
</tr>
<tr>
<td>7-8 am</td>
<td>Breakfast in the Exhibit Hall</td>
<td>Exhibit Hall B3</td>
</tr>
<tr>
<td>7-7:55 am</td>
<td>Poster Grand Rounds</td>
<td>(See details on page 23)</td>
</tr>
<tr>
<td>7 am-2:45 pm</td>
<td>Fellow &amp; Residents Lounge Open</td>
<td>Exhibit Hall B3</td>
</tr>
<tr>
<td>8-8:15 am</td>
<td>Welcome and Announcements</td>
<td>GBCC Grand Ballroom</td>
</tr>
<tr>
<td>8:15-9 am</td>
<td>Plenary Session I</td>
<td>GBCC Grand Ballroom</td>
</tr>
<tr>
<td>9-9:45 am</td>
<td>Plenary Session II</td>
<td>GBCC Grand Ballroom</td>
</tr>
<tr>
<td>9:45-10:15 am</td>
<td>Refreshment Break in the Exhibit Hall</td>
<td>Exhibit Hall B3</td>
</tr>
<tr>
<td>10:15-11 am</td>
<td>James Ewing Lecture</td>
<td>GBCC Grand Ballroom</td>
</tr>
<tr>
<td>11-11:45 am</td>
<td>SSO Presidential Address</td>
<td>GBCC Grand Ballroom</td>
</tr>
<tr>
<td>11:45 am-1:15 pm</td>
<td>Lunch in the Exhibit Hall</td>
<td>(See details on page 20)</td>
</tr>
<tr>
<td>12-12:30 pm</td>
<td>Late Breaking Videos - Friday</td>
<td>Exhibit Hall Theater, Exhibit Hall B3</td>
</tr>
<tr>
<td>12:30-1 pm</td>
<td>Poster Grand Rounds</td>
<td>(See details on page 23)</td>
</tr>
<tr>
<td>1:15-1:25 pm</td>
<td>Distinguished Service Award</td>
<td>GBCC Grand Ballroom</td>
</tr>
<tr>
<td>1:25-1:30 pm</td>
<td>James Ewing Layperson's Award</td>
<td>GBCC Grand Ballroom</td>
</tr>
<tr>
<td>1:30-2:15 pm</td>
<td>American Cancer Society/SSO Basic Science Lecture</td>
<td>GBCC Grand Ballroom</td>
</tr>
</tbody>
</table>
2:15-2:45 pm Refreshment Break in the Exhibit Hall
Exhibit Hall B3

2:45-4:15 pm The Great Debates
GBCC Grand Ballroom

4:15-4:45 pm Break
GBCC Grand Ballroom Foyer

4:30-6:30 pm Upper Gastrointestinal Parallel Session
GBCC-332

4:30-6:30 pm Melanoma Parallel Session
GBCC-320

4:30-6:30 pm Breast Parallel Session 2
GBCC-310

4:30-6:30 pm Upper Gastrointestinal Parallel Session
GBCC-332

4:30-6:30 pm Melanoma Parallel Session
GBCC-320

4:30-6:30 pm Breast Parallel Session 2
GBCC-310

6:45-8 pm Satellite Symposium Dinner: Advances in Immunotherapy for Advanced Melanoma: Integrating Intracrine and Anti-PD-1 Immunotherapies into Current Practice
Hilton, Ballroom of the Americas D (Level 2)

6:45-9:30 pm Friday Happy Hours
(See details on page 25)

**SATURDAY, MARCH 28**

6 am-2 pm Registration Open
GBCC-Level 3, Outside GBCC-360

6:45-7:45 am Meet the Professor Breakfasts
(Ticket required) For full schedule and locations, see page 73

7 am-4 pm Speaker Ready Room Open
GBCC-360DE

8-10 am The Challenges of Defining and Treating Borderline Resectable Pancreatic Cancer
GBCC-332

8-10 am Challenges of Gene Testing for Clinical Management (MOC)
GBCC-320

8-10 am Metastatic/Recurrent Colorectal Cancer in 2015: Where Are We Now? (MOC)
GBCC-310

10-10:15 am Refreshment Break
GBCC Grand Ballroom Foyer

10:15-11 am John Wayne Clinical Research Lecture
GBCC Grand Ballroom

11-11:45 am Clinical Investigator Awards Presentations
GBCC Grand Ballroom

11:45 am-12:45 pm Lunch on Your Own
(See details on page 20)
Exhibit Hall B3
12:45-2:15 pm  Endocrine and Head & Neck
Parallel Session  
GBCC-332

12:45-2:15 pm  Quality Improvement/Clinical
Outcomes Parallel Session  
GBCC-320

12:45-2:15 pm  Hepatobiliary Parallel Session  
GBCC-310

2:15-2:30 pm  Refreshment Break  
GBCC Grand Ballroom Foyer

2:30-4 pm  Great Debates in Breast Cancer  
GBCC-332

2:30-4 pm  Top Rated Videos  
GBCC-320

2:30-4 pm  Novel Paradigms for Life-Long
Learning in Surgery (MOC)  
GBCC-310

4-4:15 pm  Break  
GBCC Grand Ballroom Foyer

4:15-5:45 pm  Melanoma Multidisciplinary
Tumor Board  
GBCC-332

4:15-5:45 pm  Case Presentations with
Professors and Fellows  
GBCC-320

4:15-5:45 pm  What’s New in Gastric and
Esophageal Cancers? (MOC)  
GBCC-310

5:50-6:30 pm  Town Hall and Annual
Business Meeting  
GBCC-310

7-8:30 pm  President’s Reception: SSO 75th
Anniversary Celebration  
Hilton, Ballroom of the Americas
ABC (Level 2)

Celebrate 75 Years of SSO
at the President’s Reception:
SSO 75th Anniversary Celebration

7-8:30 pm, Saturday, March 28
(Ticket required)
Hilton, Ballroom of the Americas ABC (Level 2)

We encourage you to participate in this special
evening, which will feature a tribute to the many
leaders and members who helped shape SSO into
the thriving Society it is today. We are honoring
their contribution by inviting all the SSO Past
Presidents to attend.

Partly supported by the American College of Surgeons
Commission on Cancer and National Accreditation
Program for Breast Centers.
CELEBRATING 75 YEARS OF SSO

Founded in 1940 as the James Ewing Society, SSO celebrates its 75th Anniversary in 2015. The long-term success sustained by the Society is a testament to the outstanding leadership provided by its presidents and other leaders over the years dedicated to the advancement of the Society and the field of surgical oncology.

Celebrate 75 Years of SSO with these activities:
- 75th Anniversary Historic Walk in the George R. Brown Convention Center
- Visit the 75th Anniversary Display on the third Floor
- Purchase commemorative apparel in the SSO Membership Booth (419)

FRIDAY, MARCH 27
- 10:15 am: The James Ewing Lecture: “SSO Highlights over 75 Years: From Ewing to Weigel”
- 11 am: SSO Presidential Address: “The Next 75 Years”

SATURDAY, MARCH 28
- 7 pm: President’s Reception: SSO 75th Anniversary Celebration

SSO PAST PRESIDENTS

V. Suzanne Klimberg, MD 2013-2014
Monica Morrow, MD 2012-2013
James S. Economou, MD, PhD 2011-2012
Mitchell C. Posner, MD 2010-2011
Fabrizio Michelassi, MD 2009-2010
William G. Cance, MD 2008-2009
Nicholas J. Petrelli, MD 2007-2008
Raphael E. Pollock, MD, PhD 2006-2007
Timothy J. Eberlein, MD 2005-2006
S. Eva Singleton, MD 2004-2005
Alfred M. Cohen, MD 2003-2004
John M. Daly, MD 2002-2003
John E. Niederhuber, MD 2001-2002
William C. Wood, MD 2000-2001
Glenn D. Steele, Jr., MD, PhD 1999-2000
Edward M. Copeland III, MD 1998-1999
David P. Winchester, MD 1997-1998
Kirby I. Bland, MD 1996-1997
Murray F. Brennan, MD 1995-1996
Bernard Gardner, MD 1994-1995
<table>
<thead>
<tr>
<th>Name</th>
<th>Years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Samuel A. Wells, Jr., MD</td>
<td>1993-1994</td>
</tr>
<tr>
<td>Donald L. Morton, MD*</td>
<td>1992-1993</td>
</tr>
<tr>
<td>Charles M. Balch, MD</td>
<td>1991-1992</td>
</tr>
<tr>
<td>Alfred S. Ketcham, MD</td>
<td>1990-1991</td>
</tr>
<tr>
<td>Benjamin F. Rush, Jr., MD*</td>
<td>1989-1990</td>
</tr>
<tr>
<td>Blake Cady, MD</td>
<td>1988-1989</td>
</tr>
<tr>
<td>J. Bradley Aust, MD*</td>
<td>1987-1988</td>
</tr>
<tr>
<td>Robert V.P. Hutter, MD</td>
<td>1986-1987</td>
</tr>
<tr>
<td>Victor D. Dembrow, MD*</td>
<td>1985-1986</td>
</tr>
<tr>
<td>Hiram C. Polk, Jr., MD</td>
<td>1984-1985</td>
</tr>
<tr>
<td>Robert J. McKenna, Sr., MD*</td>
<td>1983-1984</td>
</tr>
<tr>
<td>Gerald P. Murphy, MD, DSc*</td>
<td>1982-1983</td>
</tr>
<tr>
<td>Jerome J. DeCosse, MD*</td>
<td>1981-1982</td>
</tr>
<tr>
<td>Condict Moore, MD*</td>
<td>1980-1981</td>
</tr>
<tr>
<td>Walter Lawrence, Jr., MD</td>
<td>1979-1980</td>
</tr>
<tr>
<td>LaSalle D. Leffall, Jr., MD</td>
<td>1978-1979</td>
</tr>
<tr>
<td>Harvey W. Baker, MD*</td>
<td>1977-1978</td>
</tr>
<tr>
<td>William R. Nelson, MD*</td>
<td>1976-1977</td>
</tr>
<tr>
<td>Lewis W. Guiss, MD*</td>
<td>1975-1976</td>
</tr>
<tr>
<td>Edward F. Scanlon, MD*</td>
<td>1974-1975</td>
</tr>
<tr>
<td>Robert J. Schweitzer, MD</td>
<td>1973-1974</td>
</tr>
<tr>
<td>Arthur I. Holleb, MD*</td>
<td>1972-1973</td>
</tr>
<tr>
<td>Stuart H.Q. Quan, MD</td>
<td>1971-1972</td>
</tr>
<tr>
<td>Arthur G. James, MD*</td>
<td>1970-1971</td>
</tr>
<tr>
<td>Guy F. Robbins, MD*</td>
<td>1969-1970</td>
</tr>
<tr>
<td>Sam A. Wilkins, Jr., MD*</td>
<td>1968-1969</td>
</tr>
<tr>
<td>Theodore R. Miller, MD*</td>
<td>1967-1968</td>
</tr>
<tr>
<td>Theodore Winship, MD*</td>
<td>1966-1967</td>
</tr>
<tr>
<td>Glenn H. Leak, MD*</td>
<td>1965-1966</td>
</tr>
<tr>
<td>Lemuel Bowden, MD*</td>
<td>1964-1965</td>
</tr>
<tr>
<td>Ashbel C. Williams, MD*</td>
<td>1963-1964</td>
</tr>
<tr>
<td>Calvin T. Klopp, MD*</td>
<td>1962-1963</td>
</tr>
<tr>
<td>Maus W. Stearns, Jr., MD*</td>
<td>1961-1962</td>
</tr>
<tr>
<td>William S. MacComb, MD*</td>
<td>1960-1961</td>
</tr>
<tr>
<td>John L. Pool, MD*</td>
<td>1959-1960</td>
</tr>
<tr>
<td>Ralph R. Braund, MD*</td>
<td>1958-1959</td>
</tr>
<tr>
<td>Joseph H. Farrow, MD*</td>
<td>1957-1958</td>
</tr>
<tr>
<td>Elliott Scarborough, MD*</td>
<td>1956-1957</td>
</tr>
<tr>
<td>Frank W. Foote, Jr., MD*</td>
<td>1955-1956</td>
</tr>
<tr>
<td>Gordon P. McNeer, MD*</td>
<td>1954-1955</td>
</tr>
<tr>
<td>Douglas Sunderland, MD*</td>
<td>1953-1954</td>
</tr>
<tr>
<td>Robert Brown, MD*</td>
<td>1952-1953</td>
</tr>
<tr>
<td>Thomas J. Anglem, MD*</td>
<td>1951-1952</td>
</tr>
<tr>
<td>Danley P. Slaughter, MD*</td>
<td>1950-1951</td>
</tr>
<tr>
<td>Edgar L.FrazeU, MD*</td>
<td>1949-1950</td>
</tr>
<tr>
<td>Edgar L. FrazeU, MD*</td>
<td>1948-1949</td>
</tr>
<tr>
<td>John Blady, MD*</td>
<td>1947-1948</td>
</tr>
<tr>
<td>George Sharp, MD*</td>
<td>1942-1947</td>
</tr>
<tr>
<td>William S. MacComb, MD*</td>
<td>1941-1942</td>
</tr>
<tr>
<td>William S. MacComb, MD*</td>
<td>1940-1941</td>
</tr>
</tbody>
</table>

* Deceased
NEW AT SSO 2015

Enhanced Exhibit Hall and Poster Hours and Exhibit Hall Theater
Experience a wide range of services and solutions in the Exhibit Hall, showcasing medical devices, equipment and technology exhibitors along with pharmaceutical companies. This year’s enhancements include a stream-lined two-day schedule and a new Exhibit Hall Theater and Fellows Lounge. See full details on page 18.

Exhibit Hall Passport to Prizes
Visit SSO exhibitors to earn a chance to win exciting prizes!
As you make your way through the exhibit hall, talking with company representatives and visiting their booths, collect signatures on your Passport game card and enter to win. View full details on page 18.

Fellows & Residents Lounge
This year, SSO will be hosting its first Fellows & Residents Lounge. This new lounge, dedicated for use by the fellows and residents who are attending the SSO Annual Cancer Symposium, will be located in the Exhibit Hall. Fellows can use the lounge to meet informally with SSO leaders, network with other fellows and residents, meet new friends, discuss sessions and relax between sessions. See page 19 for full details!

Friday Happy Hour
6:45-9:30 pm, Friday, March 27
Socialize with colleagues in your disease track at a casual Happy Hour in a local establishment on Friday evening. View topics and locations on page 25.

Disparities Abstracts Sub-category
New this year! Abstracts reflecting this sub-category will be denoted with a symbol throughout the guide. See page 16 for full details.
CONTRIBUTE TO THE SSO  
75 FOR 75 FUND  
TO HELP COMMEMORATE THE  
75TH ANNIVERSARY OF SSO  
AND BECOME ELIGIBLE FOR  
A RAFFLE, SPONSORED BY  
THE SSO FOUNDATION!

With your help, The SSO Foundation aims to raise $75,000 by the end of SSO 2015 in honor of 75 years of SSO. Make a contribution to The SSO Foundation by the end of SSO 2015 and become eligible for a raffle and a chance to win an array of prizes. Your chance to win increases by the amount you give. To find out more about the raffle, a listing of prizes donated, and how to make a contribution, we invite you to visit The SSO Foundation booth at the SSO Membership Booth (419) in the Exhibit Hall. You do not need to be present to win a prize.

Your generous contribution will help support The SSO Foundation’s new research initiatives, including awards encompassing the spectrum of surgical oncology research to help foster the careers of promising young surgical oncology investigators. 75 for 75 fund contributions will translate into more robust funding from extramural sources for these promising researchers.

Contribute to the 75 for 75 Fund today and help ensure future generations of surgical oncologists obtain the necessary skills and competencies to continue advancing cancer patient care for the next 75 years and beyond.

Donate and learn more at surgonc.org/75for75.
GENERAL INFORMATION
(Listed alphabetically)

Abstracts Available Electronically
Abstracts are conveniently available online at SSO2015.org and through the SSO 2015 app (eventmobi.com/SSO2015). Full app details can be found on page 22 of this guide. Note that all abstracts are numbered to correspond with presentations listed in this Program Guide.

Abstract Contests

**ANNUAL RESIDENT/FELLOW ESSAY AWARDS**
Each year, SSO offers two Resident/Fellow Essay Awards. Awards are offered for the best Clinical Research paper, and for the best Basic Science Research paper. Each award is $600, plus reimbursement of up to $600 for the recipient’s travel to the Annual Cancer Symposium. Winners will be announced during the Town Hall and Annual Business Meeting on Saturday, March 28 at 5:50 pm.

*Supported by an independent grant from The SSO Foundation.*

Abstract Poster Contest
The Society will present two Poster Awards of $500 each for Best Basic/Translational Research Poster and Best Clinical Research Poster. Please cast your votes by 1:15 pm on Friday, March 27. Poster Contest finalists are displayed in the GBCC Grand Ballroom Foyer. Ballots were handed out with this Program Guide at registration check-in. Winners will be announced at the beginning of The Great Debates Session on Friday, March 27 at 2:45 pm.

Disparities Abstracts Sub-category
This abstract sub-category, offered by SSO for the first time at SSO 2015, highlights abstracts and papers that span the complex nature of disparities as they relate to surgical oncology care and seek to understand the nature of disparities in surgical care and the factors that influence and mitigate them. Abstracts reflecting this sub-category will be denoted with a D symbol throughout this guide.

Abstracts may cover:
- Constrained resources, systems of care, quality of surgical care and surgical safety
- The lack of access to surgical oncologists and cancer outcomes (both nationally and globally)
• The role of the surgical oncologist in reaching certain disparate communities and the impact of this on surgical oncology outcomes
• Evidence-based approaches to eliminate disparities and outcomes on screening, diagnosis, treatment, follow-up and survivorship
• Disparities in the elderly and issues that may impact surgical outcomes and survival
• Disparities on race/ethnicity/gender and surgical oncologic outcomes, and disparities and surgical oncologic outcomes addressing the global burden

Annals of Surgical Oncology
CME/MOC Opportunities
Earn AMA PRA Category 1 Credits™ and self-assessment credit that can be applied towards Part 2 of the ABS MOC Program by participating in educational activities offered by SSO through the Annals of Surgical Oncology!

Copies of this Educational Review Series are available at the SSO Membership Booth (419) in the Exhibit Hall.

NEW- Manuscript Reviewer CME
Earn credit while learning about current issues, new research findings, multidisciplinary patient care and practice management in the field of surgical oncology.

Journal-Based CME/MOC
Earn credit by reading select articles from the Annals of Surgical Oncology. Two articles are available each month.

For more information on any of the Annals CME/MOC educational opportunities visit, surgonc.org or moc.surgonc.org.

Committee Meetings
A list of SSO Committee Meetings scheduled this week is published on page 32.

CLAIM CME CREDIT FOR THE 68TH ANNUAL CANCER SYMPOSIUM ONLINE
It is now easier to claim your CME credit for the 68th Annual Cancer Symposium! Simply log on to https://show.jspargo.com/ssocme15, complete one (1) meeting evaluation, choose the sessions you attended, and indicate the amount of time spent in each session to earn credit.

We encourage you to complete your evaluation and claim credit while onsite using the computer kiosks at the Internet Café located on GBCC-Level 3, outside GBCC-350. However, SSO members and other attendees may also claim credit from their home or office computers by completing this evaluation prior to Friday, May 15, 2015.
Exhibits Showcase New Products for Surgeons

Exhibit Hall B3
More than 70 technical and scientific exhibitors are expected to display their latest products in the Exhibit Hall throughout SSO 2015. SSO appreciates the support of its exhibitors and urges all attendees to visit the displays.

Exhibit Hours
Thursday, March 26 12:15-7:30 pm
Friday, March 27 7 am-2:45 pm

Exhibit Hall Passport to Prizes
Visit SSO exhibitors to earn a chance to win exciting prizes!
As you make your way through the Exhibit Hall, talking with representatives and visiting their booths, collect signatures on your Passport game card and enter to win.

1. Pick up your Passport game card at registration or the SSO Membership Booth (419).
2. Visit eight exhibiting companies and ask them to sign your Passport game card
3. Drop your Passport game card in the entry box located at the SSO Membership Booth (419).
4. Attend the closing Exhibit Hall refreshment break scheduled from 2:15-2:45 pm on Friday, March 27 to see if your game card is selected as one of the winning cards during the prize drawing.

The prize drawing will take place at 2:30 pm.

Prizes include:
- Apple Inc. iPad Air 2
- Apple iPad Air 2 Mini
- $100 Gift Certificate

Exhibit Hall Theater Presentation
6:15-7 pm, Thursday, March 26
Supported by Ethicon
The Exhibit Hall Theater Presentation offers you the opportunity to interact with select exhibitors and learn about their product and service innovations. This session will occur during the Welcome Reception in the Exhibit Hall.
Fellows & Residents Lounge
Based on direct input from a fellows focus group, SSO will be hosting its first Fellows & Residents Lounge during SSO 2015. This new lounge, dedicated for use by the fellows and residents who are attending the Symposium, is located in the Exhibit Hall and will be open during exhibit hours:

THURSDAY, MARCH 26
12:15-6 pm

FRIDAY, MARCH 27
7 am-2:45 pm

Fellows can use the lounge to meet informally with SSO leaders, network with other fellows and residents, meet new friends, discuss sessions and relax between sessions. The lounge will provide internet and virtual meeting access, as well as an opportunity to view SSO educational materials. Fellows can pick up lunch in the Exhibit Hall and gather in the lounge; refreshments will be provided throughout the day.

All SSO fellow and resident members are welcome to attend. If you are not a member, fellows and residents may also complete an application for membership at the lounge or at the SSO Membership Booth (419).
Industry Forum
(See page 140)
6:45-7:45 am, Thursday, March 26
Supported by Amgen, Inc.

Tumor Immunology: A Surgeon’s Perspective
The Industry Forum features select exhibitors addressing current issues in health care. The one-hour non-CME breakfast session is held at the Hilton, Ballroom of the Americas A (Level 2). Check registration materials for more information. Industry Forum features select exhibitors addressing current issues in health care. The one hour non-CME sessions are held at the Hilton, Ballroom of the Americas A (Level 2). The breakfast session is from 6:45-7:45 am on Thursday. Check registration materials for more information.

Industry Satellite Symposia
An Industry Satellite Symposia will be offered Friday, March 27 from 6:45-8 pm by Paradigm Medical Communications, LLC. This Friday evening session is titled Advances in Immunotherapy for Advanced Melanoma: Integrating Intralesional and Anti-PD-1 Immunotherapies into Current Practice. The session includes a complimentary dinner and symposium and is supported by educational grants from Provectus Biopharmaceuticals, Inc. and Amgen, Inc. and offers CME credit. It will be held in the Hilton, Ballroom of the Americas D (Level 2).

Internet Café
Visit the Internet Café to complete Maintenance of Certification (MOC) self-assessment exams, claim CME credit and send and retrieve email. The Café is located on GBCC-Level 3, outside GBCC-350. This service is complimentary to all meeting registrants from Thursday, March 26 through Saturday, March 27.

Lunch Options
Lunch vouchers in the amount of $16 are provided to each meeting registrant for use at lunch on Thursday and Friday. These vouchers can be used to offset the cost of meals in the Exhibit Hall. A variety of food will be available, including hot items, healthy meal options and beverages.

Exhibit Hall Lunch Hours
Thursday, March 26 12:15-1:15 pm
Friday, March 27 11:45 am-1:15 pm

On Saturday, the food courts will also be available from 11:45 am-12:45 pm in Exhibit Hall B3. Cash and credit cards will be accepted. No lunch vouchers will be provided for Saturday.
Manuscripts for Publication
Authors of all clinical papers are encouraged, but not required, to submit their manuscripts for publication in the *Annals of Surgical Oncology* prior to their presentation. Files may be dropped off for the *Annals* at the SSO Membership Booth (419) located on the Exhibit Hall or submitted online.

To upload your manuscript, log into the Journal’s online submission site: http://mc.manuscriptcentral.com/aso. Manuscripts must be prepared in accordance with the posted submission guidelines.

MEMBERSHIP
JOIN SSO TODAY!
Experience the value of SSO’s global community. Join SSO today and become part of a worldwide community of surgeons and scientists dedicated to advancing surgical oncology and cancer care. Every surgeon should be an SSO member. Enjoy these benefits and much more:

- Online access to the world-renowned *Annals of Surgical Oncology*, SSO’s official journal
- Special savings and privileges on membership dues, the SSO Annual Cancer Symposium registration and access to valuable educational products and resources
- Listing in the Find a Surgical Oncologist global database on the newly redesigned surgonc.org
- Stay current on multidisciplinary care with inclusion in SSO’s exclusive members-only website pages and social meeting groups on Twitter, Facebook and LinkedIn

For more information visit us online at surgonc.org.

Annual Meeting Membership Special
SSO will waive the application fee if you join the Society before Friday, April 30 — a savings of $150! Stop by the SSO Membership Booth (419) in Exhibit Hall B3.
MOBILE ACCESS FOR SSO 2015

Visit eventmobi.com/SSO2015 to access the Symposium mobile app and have complete conference information at your fingertips. Be sure to bookmark the app on your phone or tablet for one-touch access to the following:

• Poster, video and oral abstracts
• Interactive schedule
• Up to the minute Symposium updates
• Speaker and moderator listings
• Exhibitor listing and information
• Interactive maps

Enhance Your App Experience
Visit the app and enter your email address to log in and utilize additional features that allow you to:

• Create your own schedule
• Take notes during sessions
• Identify favorite exhibitors

The Society of Surgical Oncology gratefully acknowledges Amgen, Inc. for its support of SSO 2015 app.

SSO2015.org
Don’t forget you can also continue to visit SSO2015.org for complete Symposium information, including a mobile-friendly Program Schedule resource that helps you plan your itinerary. You also can search by track, session type, presenter or moderator.
New SSO Members
New SSO members will be identified by a new member ribbon affixed to their name badge. We encourage you to introduce yourself so new members feel welcome.

There is a special luncheon (by invitation only) for new members only from 12:15-1:15 pm on Thursday in the Hilton, Ballroom of the Americas D (Level 2).

SORRY, NO PERSONAL AUDIO OR VIDEO RECORDERS ARE ALLOWED IN MEETING ROOMS.

Photograph and Recordings
By registering for this meeting, attendees acknowledge and agree that SSO or its agents may take photographs during events and may freely use those photographs in any media for SSO purposes, including, but not limited to, news and promotional purposes.

The presentations, slides and handouts provided in this program are the property of SSO or used by permission. You may not photograph, videotape, audiotape or otherwise record or reproduce any of the presentations without express written permission from SSO. Any attendee believed to be violating this restriction will be removed from the session and may be prohibited from participating in further SSO meetings.

Poster Grand Rounds
During these interactive sessions, top-scoring poster presentations will be highlighted by moderators in each disease site category. Discussion and comments will be encouraged in the Grand Rounds, taking place in the Exhibit Hall. Meet at the beginning of the topic section being discussed to participate. Disease site Poster Grand Round participants will all be marked with a star in the program and in the Exhibit Hall.

Poster Grand Rounds Schedule

**THURSDAY, MARCH 26**

12:30-1 pm  
Colorectal  
Endocrine  
Upper Gastrointestinal

3:30-4 pm  
Breast 1  
Quality Improvement/  
Clinical Outcomes  
Sarcoma and Thoracic/  
Esophageal

**FRIDAY, MARCH 27**

7-7:25 am  
Clinical Research Poster Award Nominees*

7:30-7:55 am  
Basic/Translational Research Poster Award Nominees*

12:30-1 pm  
Breast 2  
Hepatobiliary  
Melanoma

* Taking place in the Exhibit Hall Theater
**Poster Presentations**

All Scientific Posters will be displayed from 12:15 pm on Thursday to 2:45 pm on Friday. Authors are requested to be available during the times below, as their schedules permit, to answer questions about their presentations. New this year: poster signage is color-coded by track. See full poster details starting on page 91.

**THURSDAY, MARCH 26**
- 12:15-1:15 pm
- 3:15-4:15 pm
- 6-7:30 pm

**FRIDAY, MARCH 27**
- 7-8 am
- 9:45-10:15 am
- 11:45 am-1:15 pm
- 2:15-2:45 pm

**Registration Desk Hours**

The registration desk is located on GBCC-Level 3, outside GBCC-360, and will be open during the following hours:

<table>
<thead>
<tr>
<th>Day</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday, March 24</td>
<td>4-6 pm</td>
</tr>
<tr>
<td>Wednesday, March 25</td>
<td>6:30 am-6 pm</td>
</tr>
<tr>
<td>Thursday, March 26</td>
<td>6 am-6:30 pm</td>
</tr>
<tr>
<td>Friday, March 27</td>
<td>6 am-4 pm</td>
</tr>
<tr>
<td>Saturday, March 28</td>
<td>6 am-2 pm</td>
</tr>
</tbody>
</table>

**SSO Badge Designation**

- **Blue**: SSO Member Physician, Scientist or Senior Member
- **Light Blue**: SSO Associate Member (PA, NP, RN, LPN, LVN)
- **Teal**: SSO Fellow/Resident/Medical Student
- **Gray**: Non-Member Physician or Scientist
- **Green**: Non-Member (Pharma or Other)
- **Lime**: Non-Member Allied Health Provider (PA, NP, RN, LPN, LVN)
- **Purple**: Non-Member Fellow/Resident/Medical Student
- **Yellow**: Spouse/Guest
- **Red**: Exhibitor
- **Orange**: Press

Replacement badges are available at the Registration Desk for $10 each.

**Schedule-at-a-Glance**

Please refer to the Schedule at a Glance that folds out from the cover of this Program Guide to help you navigate SSO 2015. The Schedule is color coded into seven tracks including General Education, Breast, Colorectal, Gastrointestinal, Melanoma and Sarcoma, and Other Surgical Oncology.

**Schedule: New Searchable Online Scheduler**

Find out what’s in store at SSO 2015 by accessing the program schedule tool at ssocal.djgcreate.com. This enhanced mobile-friendly resource allows you to view complete details about the Symposium’s education program, lets you download sessions to your personal calendar and search by track, type, presenter or moderator.
SOCIAL EVENTS

Network with colleagues in multidisciplinary surgical oncology care during these events:

**Welcome Reception**
6-7:30 pm, Thursday, March 26
Exhibit Hall B3

Join us in the Exhibit Hall for hors d’oeuvres, refreshments and networking as you visit the posters and exhibits. Participate in the Exhibit Hall Passport to Prizes game and win prizes by visiting with the exhibitors. (See full details on page 18.) Stop by the SSO Membership Booth (419) to purchase 75th Anniversary apparel.

This complimentary event is open to all registrants. One drink ticket is located in your attendee registration materials. This event will have a cash bar.

**Celebrate 75 Years of SSO at the President’s Reception:**
SSO 75th Anniversary Celebration
7-8:30 pm, Saturday, March 28
Ticket required
Hilton, Ballroom of the Americas ABC (Level 2)

We encourage you to participate in this special evening, which will feature a tribute to the many leaders and members who helped shape SSO into the thriving Society it is today. We are honoring their contribution by inviting all SSO Past Presidents to attend.

Partly supported by the American College of Surgeons Commission on Cancer and National Accreditation Program for Breast Centers.
Speaker Ready Room
The Speaker Ready Room is located in GBCC-360DE and is available to all program participants.

Tuesday, March 24  4-6 pm
Wednesday, March 25  7 am-7 pm
Thursday, March 26  6 am-7 pm
Friday, March 27  6 am-6:30 pm
Saturday, March 28  7 am-4 pm

All speakers should report to the Speaker Ready Room and check in with the technicians at least four (4) hours prior to the start of the session in which they are speaking.

Videos, Late Breaking
A select number of additional high-ranked video abstracts will be shown in the Exhibit Hall Theater, Exhibit Hall B3, during the Thursday afternoon and Friday lunch breaks. See pages 55 and 63 for the full schedule.

SSO 2015 VIRTUAL MEETING
Miss a session during SSO 2015? Wondering how you can still get access to the cutting edge material presented at the meeting? As a registered conference attendee, you will be able to participate in the SSO 2015 Virtual Meeting at no additional charge and view sessions from actual symposia presentations only hours after they occur.

To access the SSO 2015 Virtual Meeting, visit the SSO website at surgonc.org/vm and enter your email on file with SSO and your SSO password.
MEETING HIGHLIGHTS

Susan G. Komen® Breast Cancer Research Award
10:15 am, Thursday, March 26
GBCC-310, Breast Parallel Session 1

Mediget Teshome, MD, MPH
The University of Texas MD Anderson Cancer Center
The Society congratulates Mediget Teshome, MD, MPH, who is attending SSO 2015 as the first recipient of the Susan G. Komen® Breast Cancer Research Award for the following abstract:

28: Prognostic Value of Combined Clinical and Pathologic Staging Variables in Predicting Local-Regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer
M. Teshome*, S. Tucker, K.K. Hunt, E.A. Mittendorf, Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX

Mediget Teshome, MD, MPH is an Assistant Professor of Surgical Oncology at the University of Texas MD Anderson Cancer Center where she is a clinical breast surgeon with expertise in the surgical and multidisciplinary management of breast cancer. She also serves as the Assistant Program Director of the Breast Surgical Oncology Fellowship Program.

Dr. Teshome graduated with a Bachelor of Science degree from the University of California at Los Angeles and medical degree from the University of Michigan Medical School. She completed her general surgery training at Stanford University Hospital and Clinics, and an MPH from the Harvard School of Public Health with a concentration in health management and policy. She then completed a fellowship in breast surgical oncology at the University of Texas MD Anderson Cancer Center.

She has been recognized for her professionalism and leadership, both in residency and fellowship by being awarded the Samuel L. Kountz Humanitarian Award and the Corynne S. Uhl Award. In addition to her clinical achievements, Dr. Teshome has maintained an interest in clinical research. During her training, her research efforts focused on surgical education studying the impact of surgical simulation on trainee performance and clinical outcomes. Currently, her research is focused on analysis of the surgical management of breast cancer, patient reported outcomes, the impact of neoadjuvant treatments on local therapy in breast cancer and disparities in cancer care.

Supported by an independent grant from Susan G. Komen®.
Colorectal Cancer Research Scholar Award
12:10 pm, Thursday, March 26
GBCC-332, Colorectal Parallel Session
Andrea M. Abbott, MD, MS
H. Lee Moffitt Cancer Center
The Society congratulates Andrea Abbott, MD, MS, who is attending SSO 2015 as the fifth annual recipient of the Colorectal Cancer Research Scholar Award. The goal of the award is to recognize excellence in transitional research focused on the molecular biology of colorectal cancer.

P143: Genetic Analysis of Colorectal Cancers in Young Patients
A. Abbott*, N. Kothari, T. Srikumar, J. Teer, R. Kim, D. Reed, D. Shibata, H. Lee Moffitt Cancer Center, Tampa, FL
Andrea M. Abbott, MD, MS, received her BA/MD from the University of Kansas City six-year School of Medicine (2006). She then completed her residency in General Surgery at the University of Minnesota (2013), where she also obtained a Masters in Clinical Research (2012). While working with Dr. Todd Tuttle at the University of Minnesota, she focused on clinical outcomes and surgical techniques research. Dr. Abbott then continued her training at Moffitt Cancer Center where she is a second-year fellow in complex general surgical oncology. During her fellowship she has continued pursuing her interest in outcomes research, but also is involved in translational investigations of colorectal cancer genomics under the mentorship of Dr. David Shibata. She has authored or co-authored over 20 articles/chapters and 50 abstracts/presentations. Dr. Abbott plans on a career in academic surgical oncology with a focus on education, outcomes research and decision-making analysis.
Supported by an independent grant from the Colon Cancer Challenge Foundation.

Harvey Baker Traveling Fellow Award
9:45 am, Friday, March 27
GBCC Grand Ballroom, Plenary II Session
Vinod P. Balachandran, MD
Memorial Sloan Kettering Cancer Center
The Society congratulates Vinod P. Balachandran, MD, who is attending SSO 2015 as the recipient of the 2015 Harvey Baker Traveling Fellow Award for the following abstract:
4: An Externally Validated Prognostic Multigene Expression Assay for Survival in Resected Colorectal Liver Metastases

V. Balachandran*, A. Arora, M. Gonen, T.P. Kingham, P.J. Allen, R.P. DeMatteo, W.R. Jarnagin, M.I. D'Angelica, Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; N. Snoeren, S.V. Hooff, I.H. Borel Rinkes, University Medical Center, Heidelberglaan, Utrecht, Netherlands

Dr. Vinod P. Balachandran is a fellow in complex general surgical oncology at Memorial Sloan Kettering Cancer Center. He completed his BA in Physics at Cornell University, MD at SUNY Stonybrook, and general surgery residency at New York-Presbyterian Hospital/Cornell Medical Center in New York City. During residency, he completed a two-year immunology fellowship at MSKCC under the mentorship of Dr. Ronald DeMatteo, studying the immunobiology of gastrointestinal stromal tumors (GISTs). During this time, he obtained independent funding through a Society of University Surgeons research award, and published their findings in Nature Medicine. Their research is the basis of an ongoing clinical trial of kinase inhibition and immunotherapy in GIST. After his fellowship, he will be pursuing a career in academic HPB surgical oncology at MSKCC. He is an avid runner and triathlete, speaks five languages and spends his free time with his wife and 10-month-old son.

Supported by an independent grant from The SSO Foundation.

James Ewing Lecture: SSO Highlights over 75 Years: From Ewing to Weigel
10:15-11 am, Friday, March 27
GBCC Grand Ballroom
Charles M. Balch, MD
See page 62 for full details.

Supported by an independent grant from The SSO Foundation.

Distinguished Service Award
1:15-1:25 pm, Friday, March 27
GBCC Grand Ballroom
Leslie H. Blumgart, MD
For his major contributions to the advancement of liver surgery.
See page 64 for full details.
James Ewing Layperson’s Award
1:25-1:30 pm, Friday, March 27
GBCC Grand Ballroom
Kristen Olewine Milke
For her generosity in supporting breast cancer research and her role as a breast cancer and Ewing’s sarcoma survivor.
See page 65 for full details.
Supported by an independent grant from The SSO Foundation.

American Cancer Society/SSO Basic Science Lecture: Clinical Implications of Cancer Stem Cells
1:30-2:15 pm, Friday, March 27
GBCC Grand Ballroom
Max S. Wicha, MD
See page 66 for full details.

John Wayne Clinical Research Lecture: Challenging Paradigms in Cancer Research
10:15-11 am, Saturday, March 28
GBCC Grand Ballroom
Lee M. Ellis, MD
See page 77 for full details.

Clinical Investigator Award Presentations
11-11:45 am, Saturday, March 28
GBCC Grand Ballroom
Be sure to attend this year’s presentation of CIA recipients Jacqueline S. Jeruss, MD, PhD; Jonathan L. Wright, MD, MS and Tina W.F. Yen, MD, MS to hear the results of their research efforts. The recipient of the 2015-2017 Spring award will be announced at the conclusion of this year’s presentations.
See page 78 for full details.

GET SSO 2015 UPDATES AND INFORMATION
Stay on top of the latest Symposium updates by staying connected:
• Mobile app: mobile.SSO2015.org
• SSO 2015 site: SSO2015.org
• Twitter: Follow @SocSurgOnc and use #SSO2015
In the second year of the International Career Development Exchange program, participants have been selected by the Brazilian Society of Surgical Oncology, European Society of Surgical Oncology, Indian Association of Surgical Oncology, Japanese Society of Gastroenterological Surgery, and the Sociedad Mexicana de Oncologia, AC based upon program criteria established by SSO. The participants are attending the Symposium followed by a visit to one to three academic institutions in their specialty areas to further their knowledge.

Please join the Society in congratulating and making them feel welcome at the 68th SSO Annual Cancer Symposium:

- Marcy Junqueira Piedade, MD, was selected to participate in this program by the Brazilian Society of Surgical Oncology. Dr. Piedade is a Surgical Oncologist at the Oncology Center of Rio de Janeiro.

- Kjetil Soreide, MD, PhD, has been chosen by the European Society of Surgical Oncology. Dr. Soreide is a Professor of Surgery in the Department of Clinical Medicine at the University of Bergen, Norway. He also serves as a Consultant Surgeon in Gastrointestinal Surgery at Stavanger University Hospital in Stavanger, Norway.

- Kottayasamy Seenivasagam Rajkumar, MCh, MS, MBBS, is joining us courtesy of the Indian Association of Surgical Oncology. Dr. Rajkumar is an Assistant Professor in Surgical Oncology at the Coimbatore Medical College and Hospital in Tamil Nadu, India.

- Michitaka Honda, MD, PhD, has been selected by the Japanese Society of Gastroenterological Surgery. Dr. Honda is a Surgical Fellow of the Department of Gastroenterological Surgery at the Cancer Institute Hospital, Japanese Foundation for Cancer Research in Tokyo, Japan.

- Arizbett Uribe-Jimenez, MD, joins us on behalf of the Sociedad Mexicana de Oncologia, AC. Dr. Uribe-Jimenez is a Surgeon Oncologist in the Colorectal Tumors Department at the Mexican Institute of Social Security, Oncology Hospital National Medical Center XXI Century in Mexico City, Mexico.
SSO COMMITTEE MEETINGS

Changes to times of locations will be posted at the SSO Registration Desk or online at SSO2015.org.

WEDNESDAY, MARCH 25
8-10 am  Finance Committee
          Hilton, Board Room 331 (Level 3)
12-5 pm   Executive Council Meeting
          Hilton, Room 335 (Level 3)

THURSDAY, MARCH 26
7-8 am    Hepatobiliary/Colorectal/
          Gastrointestinal Disease Site
          Work Groups
          Hilton, Room 332 (Level 3)
8 am-12 pm Training Committee
          Hilton, Room 337 (Level 3)
10-11 am  Membership Committee
          Hilton, Board Room 331 (Level 3)
12-1 pm   CME Committee
          Hilton, Room 332 (Level 3)
12-1 pm   Surgical Oncology Program
          Directors Subcommittee
          Hilton, Room 335A (Level 3)
12:15-1:15 pm New Member Luncheon
              Hilton, Ballroom of the Americas D
              (Level 2)
1-2:30 pm  Surgical Oncology Program
            Directors Workshop
            Hilton, Room 335A (Level 3)
2-3 pm    Outreach Committee
          Hilton, Room 335BC (Level 3)
2:30-3:30 pm SCORE Committee
            Hilton, Room 337 (Level 3)
3:30-6 pm  The SSO Foundation Board Meeting
            Hilton, Room 335A (Level 3)
4:30-6 pm  Annals of Surgical Oncology
            Editors Meeting
            Hilton, Room 337 (Level 3)
7:30-9 pm  Corporate Relations Reception
            By invitation only

FRIDAY, MARCH 27
6:30-7:30 am  SOSAP Task Force
               Hilton, Board Room 334 (Level 3)
12-1 pm    Breast Program Directors Subcommittee
           Hilton, Room 335 (Level 3)
12-1 pm    Technology and
           Communications Committee
           Hilton, Room 332 (Level 3)
1:30-2:30 pm Quality Work Group
            Hilton, Board Room 334 (Level 3)
SATURDAY, MARCH 28

7-8 am  Breast Disease Site Work Group  
        Hilton, Board Room 334 (Level 3)

7:30-8:30 am  Research Committee  
             Hilton, Room 337 (Level 3)

12-1 pm  Endocrine Head/Neck and Melanoma/  
         Sarcoma Disease Site Work Group  
         Hilton, Board Room 334 (Level 3)

12-1 pm  Scientific Program Committee  
         Hilton, Room 337 (Level 3)

5:50-6:30 pm  Annual SSO Business Meeting  
               GBCC-310
EDUCATION INFORMATION

Target Audience
This activity is intended for all surgeons and other healthcare professionals who are involved in the treatment of patients with cancer.

Overall Educational Objectives
• Describe recent updates and current controversies in the multidisciplinary management of patients with breast cancer, melanoma, sarcoma, pancreas and hepatobiliary malignancies, esophageal cancer, thyroid and adrenal cancer, gastric cancer, colorectal cancer, neuroendocrine tumors and peritoneal surface malignancies
• Discuss advances in basic and translational sciences, including demonstration of an understanding of prognostic and predictive assays as applicable to cancer care, through presentations of original research performed by members of the Society
• Discuss the rationale for neoadjuvant therapy and/or genetic testing in the context of personalized cancer care
• Discuss the goals of cost, value and quality as applied to cancer care
• Describe novel techniques in cancer surgery and novel paradigms for life-long learning in surgical oncology

Accreditation
The Society of Surgical Oncology (SSO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The Society of Surgical Oncology (SSO) designates this live activity for a maximum of 34.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgement
This activity is supported by independent educational grants from Amgen, Inc., Celgene, Covidien, Ethicon Endo-Surgery, Inc., Hologic, Inc., Merck & Co., Inc., Myriad Genetics, Inc. and Pfizer.
In-kind support for the Pre-Meeting Workshop, Minimally Invasive Pancreas Surgery from Intuitive Surgical, Inc.
This activity is supported by independent educational grants from American Cancer Society, Colon Cancer Challenge Foundation, John Wayne Cancer Foundation, The SSO Foundation and Susan G. Komen®.
Complete information will be provided to participants prior to the start of the activity.
Disclaimer
The primary purpose of the SSO Annual Meeting is educational. Information, as well as technologies, products and/or services discussed, are intended to inform participants about the knowledge, techniques and experiences of specialists who are willing to share such information with colleagues. A diversity of professional opinions exists in the specialty and SSO disclaims any and all liability for damages to any individual attending this conference and for all claims which may result from the use of information, technologies, products and/or services discussed at the conference.
SOCIETY OF SURGICAL ONCOLOGY AND THE SSO FOUNDATION PARTNERS AND SUPPORTERS

Our Partners
This activity is supported, in part, by independent educational grants. The Society of Surgical Oncology (SSO) and The SSO Foundation, gratefully acknowledge the following organizations for their contributions:

American Cancer Society
Supporter of the Friday American Cancer Society/SSO Basic Science Lecture, Clinical Implications of Cancer Stem Cells

Amgen, Inc.
Partial supporter of the Melanoma Track

Celgene
Partial supporter of SSO Annual Cancer Symposium

Colon Cancer Challenge Foundation
Supporter of the Thursday Colorectal Cancer Research Scholar Award

Covidien
Partial supporter of the Colorectal Track

Ethicon Endo-Surgery, Inc.
Partial supporter of the Colorectal Track and Gastrointestinal Track. Supporter of Colorectal and Gastrointestinal Track CME/MOC Enduring Materials

Hologic, Inc.
Partial supporter of the Breast Track

John Wayne Cancer Foundation
Supporter of the Saturday John Wayne Clinical Research Lectureship, Challenging Paradigms in Cancer Research

Merck & Co., Inc.
Partial supporter of the Melanoma and Sarcoma Track

Myriad Genetics, Inc.
Partial supporter of the Saturday session, Challenges of Gene Testing for Clinical Management

Pfizer
Partial supporter of the Breast Track

The SSO Foundation
Supporter of the James Ewing Layperson’s Award, James Ewing Lecture, Harvey Baker Traveling Fellow Award, Annual Resident/Fellow Essay Awards, and the Clinical Investigator Awards Session

Susan G. Komen®
Supporter of the Thursday Komen Symposium, Personalized Care for Early Stage Breast Cancer; Susan G. Komen® Breast Cancer Research Award.
**Our Sponsors**

SSO gratefully acknowledges the following organizations for their sponsorship commitments:

**American College of Surgeons Commission on Cancer and National Accreditation Program for Breast Centers**
Partial Sponsor of Saturday’s President’s Reception

**Amgen, Inc.**

**AngioDynamics**
Sponsor of Program Guide Advertising

**Carl Zeiss**
Sponsor of Program Guide Advertising

**Ethicon Endo-Surgery, Inc.**
Sponsor of the SSO Fellows & Residents Lounge, and an Exhibit Hall Theater Presentation

**Memorial Healthcare System**
Sponsor of Program Guide Advertising

**Our In-kind Supporter of the Pre-Meeting Workshops**
SSO and The SSO Foundation gratefully acknowledge the following organization for their in-kind support:

**Intuitive Surgical, Inc.**
Pre-Meeting Workshops, *Minimally Invasive Pancreas Surgery*

**Our Clinical Investigator Award Supporter**
SSO and The SSO Foundation gratefully acknowledge the following organization for their research grant commitment:

**Genentech, Inc.**
Supporter of a 2015 *Clinical Investigator Award*
ACGME CORE COMPETENCIES

The 2015 scientific offerings assist the physician with the six core competencies first adopted by the Accreditation Council for Graduate Medical Education (ACGME) and the American Board of Specialties (ABS). Attendees are encouraged to select areas of interest from the program which will enhance their knowledge and improve the quality of patient care.

Scientific session information pages within this program guide will include the number that corresponds with the core competency listed below, so that physicians can easily identify the competencies addressed during the session.

1. **Patient Care**: Provide care that is compassionate, appropriate, and effective treatment for health problems and to promote health.

2. **Medical Knowledge**: Demonstrate knowledge about established and evolving biomedical, clinical and cognate sciences and their application in patient care.

3. **Interpersonal and Communication Skills**: Demonstrate skills that result in effective information exchange and teaming with patients, their families, and professional associates (e.g., fostering a therapeutic relationship that is ethically sound, uses effective listening skills with non-verbal and verbal communication; working as both a team member and at times a leader).

4. **Professionalism**: Demonstrate a commitment to carrying out professional responsibilities, adherence to ethical principles, and sensitivity to diverse patient populations.

5. **Systems-Based Practice**: Demonstrate awareness of and responsibility to larger context and systems of health care. Be able to call on system resources to provide optimal care (e.g., coordinating care across sites or serving as the primary care manager when care involves multiple specialties, professions or sites).

6. **Practice-Based Learning and Improvement**: Able to investigate and evaluate their patient care practices, appraise, and assimilate scientific evidence and improve their practice of medicine.
MAINTENANCE OF CERTIFICATION (MOC) PART 2 SELF-ASSESSMENT OPPORTUNITIES

Self-assessment credit that may be applied towards Part 2 of the ABS MOC program will be offered for 12 symposia occurring within the educational tracks listed below.

**Breast**
- Susan G. Komen® Symposium: Personalized Care for Early Stage Breast Cancer
- Neoadjuvant Therapy in the Modern Era

**Colorectal**
- Metastatic/Recurrent Colorectal Cancer in 2015: Where Are We Now?
- Microsatellite Instability: Understanding Biology & Optimizing Treatment of Colorectal Cancer

**Gastrointestinal**
- Joint SSO/JSGS Symposium: Management of Bile Duct Tumors
- What’s New in Gastric and Esophageal Cancers?

**Melanoma and Sarcoma**
- Cost Effective and Quality Care of the Melanoma Patient
- Soft Tissue Sarcoma Tumor Board: A Case-Based Discussion of Ongoing Controversies

**Other Surgical Oncology**
- Controversies in the Management of Thyroid Cancer

**General Education**
- Issues of Cost and Value in Surgical Oncology Care
- Challenges of Gene Testing for Clinical Management
- Novel Paradigms for Life-Long Learning in Surgery

For more information on each of the sessions listed above please visit SSO2015.org and select “MOC Information” listed under “Program” on the main menu.

**Internet Café**
To claim your self-assessment credit towards Part 2 of the American Board of Surgery (ABS) MOC program visit the SSO 2015 Internet Café from Thursday, March 26 through Saturday, March 28 to access a computer kiosk and complete the MOC self-assessment exam online. The Internet Café is located on the GBCC-Level 3, Outside GBCC-350.

**MOC Online**
To access the MOC modules online during or after SSO 2015, visit the SSO website at surgonc.org/moc.
SSO provides exceptional continuing education opportunities for surgical oncologists, general surgeons and other healthcare professionals regardless of career level.

**EDUCATION OFFERINGS INCLUDE:**

**Surgical Oncology Self-Assessment Program (SOSAP)**
Gain 60 AMA PRA Category 1 Credits™ and fulfill three years’ worth of MOC Part 2 self-assessment requirements.

**Annals of Surgical Oncology - CME Credit for Manuscript Review – NEW!**
SSO now offers AMA PRA Category 1 Credits™ for manuscript reviews of its official journal.

**Annals of Surgical Oncology - CME/MOC Credit for Reading**
Earn credit by reading select articles and completing a self-assessment exam and evaluation online.

**MOC Part 2 Online Modules**
Participate in online modules and earn self-assessment credit.

**Virtual Meeting**
View sessions from SSO Annual Cancer Symposia, including SSO 2015.

Access these resources and learn more at surg onc.org/education.
**PRE-MEETING HANDS-ON WORKSHOP**

Update Course in Surgical Oncology for the Practicing Surgeon
(Ticket Required, Limited Capacity)

1, 2, 5, 6

(See page 38 for listing of ACGME Core Competencies)

1-6 pm, Wednesday, March 25

*Hilton, Ballroom of the Americas D (Level 2)*

**Moderators:** Augusto Leon, MD; T. Salewa Oseni, MD; Ronda S. Henry-Tillman, MD and Christopher Pezzi, MD

**Introductions and Welcome**

1 pm

How the Commission on Cancer Serves the Needs of Surgical Oncologists and Patients with Cancer

Daniel P. McKellar, MD
Chair, Commission on Cancer; American College of Surgeons

Wayne HealthCare
Greenville, OH

1:45 pm

Management of Differentiated Thyroid Cancer

Ashok R. Shaha, MD
Professor of Surgery
Memorial Sloan Kettering Cancer Center
New York, NY

2:15 pm

Opportunities for Clinical Research for the Practicing Surgeon

Kelly K. Hunt, MD
Professor, Department of Surgical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX

2:45 pm

Sentinel Node Biopsy and Current Management of the Axilla in Breast Cancer

Armando E. Giuliani, MD
Executive Vice Chair of Surgery, Chief of Surgical Oncology
Cedars-Sinai Medical Center
Los Angeles, CA

3:15 pm

Break

3:30 pm

Margins and Re-Excision in Breast Cancer in 2015

Monica Morrow, MD
Chief, Breast Service; Anne Burnett Windfohr Chair in Clinical Oncology
Memorial Sloan Kettering Cancer Center
New York, NY
4 pm  Nipple Sparing Mastectomy: How I Do It  
Barbara Lynn Smith, MD, PhD  
Director, Breast Program  
Massachusetts General Hospital  
Boston, MA

4:30 pm  Management of Thin and Intermediate  
Thickness Melanoma of the Trunk/Extremities: How I Do It  
Merrick I. Ross, MD  
Professor of Surgery and Chief, Melanoma  
The University of Texas MD Anderson Cancer Center  
Houston, TX

5 pm  Minimally Invasive Approaches to  
Colorectal Cancer  
José G. Guillem, MD, MPH  
Professor of Surgery  
Memorial Sloan Kettering Cancer Center  
New York, NY

5:30 pm  Global Disparities in Cancer Care  
Harald Hoekstra, MD, PhD  
Professor of Surgical Oncology  
The University Medical Center  
Groningen, Netherlands

PRE-MEETING HANDS-ON WORKSHOP
Minimally Invasive Pancreas Surgery Workshop (AM and PM sessions)  
(Ticket Required, Limited Capacity)  
1, 2, 6  
(See page 38 for listing of ACGME Core Competencies)  
6:30 am-1 pm OR 12-6:30 pm, Wednesday, March 25  
The Surgical Innovation & Robotics Institute  
at Memorial Hermann Hospital

Faculty:  
Herbert Zeh, III, MD  
Chief, Division of GI Surgical Oncology  
University of Pittsburgh Medical Center  
Pittsburgh, PA

Melissa Hogg, MD  
Assistant Professor  
University of Pittsburgh Medical Center  
Pittsburgh, PA

Amer Zureikat, MD  
Assistant Professor of Surgery & Surgical Oncology  
University of Pittsburgh Medical Center  
Pittsburgh, PA
PRE-MEETING HANDS-ON WORKSHOP

Practical Aspects and Methodology to Minimally Invasive Groin Dissection
(Ticket Required, Limited Capacity)
1, 2, 6
(See page 38 for listing of ACGME Core Competencies)
6:30 am-6 pm, Wednesday, March 25
Methodist Institute for Technology Innovation & Education (MITIE)

Faculty:
Keith A. Delman, MD
Associate Professor of Surgery; Carlos Professor of Surgery
Emory University School of Medicine
Atlanta, GA

Karl Y. Bilimoria, MD, MS
Director, Surgical Outcomes and Quality Improvement Center (SOQIIC); Vice Chair for Quality
Northwestern University
Chicago, IL

James W. Jakub, MD
Assistant Professor of Surgery
Mayo Clinic
Rochester, MN

Viraj Master, MD, PhD
Associate Professor, Department of Urology
Emory University School of Medicine
Atlanta, GA

Maria C. Russell, MD
Assistant Professor of Surgery
Emory University School of Medicine
Atlanta, GA
SYMPOSIUM
Joint SSO/JSGS Symposium: Management of Bile Duct Tumors (MOC)

(See page 38 for listing of ACGME Core Competencies)
8-10 am, Thursday, March 26
GBCC-332
Moderators: Masaki Mori, MD, PhD and Richard D. Schulick, MD, MBA

Introductions and Welcome
8 am  Aggressive Surgical Resection after Pre-operative Chemotherapy for Locally Advanced Hepatobiliary Cancers
Masaru Miyazaki, MD, PhD
Professor and Chairman, Department of General Surgery
Graduate School of Medicine, Chiba University
Chiba, Japan

8:25 am  Aggressive Surgical Approach for Perihilar Cholangiocarcinoma
Masato Nagino, MD, PhD
Professor and Chairman, Department of Surgery
Nagoya University Graduate School of Medicine
Nagoya, Japan

8:50 am  Cholangiocarcinoma: What's New? From Prevention to Gene Therapies
Yuman Fong, MD
Professor of Surgery and Chair, Department of Surgery
City of Hope
Duarte, CA

9:15 am  A Modern Approach to Hilar Cholangiocarcinoma at the Mayo Clinic
David M. Nagorney, MD
Professor of Surgery
Mayo Clinic College of Medicine
Rochester, MN

9:40 am  Panel Discussion with Q&A

REFRESHMENT BREAK
10-10:15 am, Thursday, March 2
GBCC Grand Ballroom Foyer
SYMPOSIUM

Soft Tissue Sarcoma Tumor Board: A Case-Based Discussion of Ongoing Controversies (MOC)

(See page 38 for listing of ACGME Core Competencies)

8-10 am, Thursday, March 26

GBCC-320

Moderators: Aimee M. Crago, MD, PhD and Fritz C. Eilber, MD

Tumor Board Panelists:

Barry W. Feig, MD
Professor of Surgical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX

Alessandro Gronchi, MD
Chair, Sarcoma Service, Department of Surgery
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy

John M. Kane, III, MD
Chief, Melanoma/Sarcoma Service
Roswell Park Cancer Institute
Buffalo, NY

Carol J. Swallow, MD, PhD
Professor, Department of Surgery and Institute of Medical Science
University of Toronto
Toronto, Canada

For full session details, please utilize the Mobile App or SSO 2015 website. For details, see page 22.

REFRESHMENT BREAK

10-10:15 am, Thursday, March 26

GBCC Grand Ballroom Foyer
SYMPOSIUM

Neoadjuvant Therapy in the Modern Era (MOC)  
1, 2, 5, 6  
(See page 38 for listing of ACGME Core Competencies)  
8-10 am, Thursday, March 26  
GBCC-310  
Moderators: Nora M. Hansen, MD and  
E. Shelly Hwang, MD, MPH

Introductions and Welcome

8 am  
Selection Criteria for Neoadjuvant Therapy:  
How do you Decide?  
Elizabeth A. Mittendorf, MD, PhD  
Associate Professor  
The University of Texas MD Anderson Cancer Center  
Houston, TX

8:20 am  
Neoadjuvant Endocrine Therapy for Invasive Breast Cancer  
A. Marilyn Leitch, MD  
Professor of Surgery  
University of Texas Southwestern Medical Center  
Dallas, TX

8:40 am  
New Systemic Options in Neoadjuvant Therapy for Her2+ and Triple Negative Breast Cancers  
Jenny C. Chang, MD  
Director  
Houston Methodist Hospital  
Houston, TX

9 am  
Pre-Operative and Intra-Operative Decision Making in the Neoadjuvant Setting  
Henry M. Kuerer, MD, PhD  
Professor of Surgery, Department of Surgical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, TX

9:20 am  
Radiation and Reconstructive Issues in Neoadjuvant Patients  
E. Shelly Hwang, MD, MPH  
Professor and Chief Breast Surgery  
Duke University Medical Center  
Durham, NC

9:40 am  
Panel Discussion and Case Presentations

REFRESHMENT BREAK

10-10:15 am, Thursday, March 26  
GBCC Grand Ballroom Foyer
PARALLEL SESSION
Colorectal Parallel Session

(See page 38 for listing of ACGME Core Competencies)
10:15 am-12:15 pm, Thursday, March 26

GBCC-332

Moderators: Susan Galandiuk, MD and Rabih M. Salloum, MD, MPH

10:15 AM ................................................................. 8
Organ Preservation in Rectal Cancer Patients with Clinical Complete Response After Neoadjuvant Therapy
Jesse Joshua Smith, Memorial Sloan Kettering Cancer Center, New York, NY

10:27 AM ................................................................. 9
Is Pelvic Radiation Necessary for the Curative Treatment of Stage IV Rectal Cancer with Resectable Metastases?
Y. Nancy You, University of Texas MD Anderson Cancer Center, Houston, TX

10:39 AM ................................................................. 10
Comparative Effectiveness of Primary Tumor Resection in Metastatic Colon Cancer: An Instrumental Variable Analysis
Zeinab Alawadi, The University of Texas Health Science Center, Houston, TX

10:51 AM ................................................................. 11
Intraperitoneal Delivery of Anti-CEA Chimeric Antigen Receptor T Cells in a Murine Model of Peritoneal Carcinomatosis
Gary Point, Department of Surgery - Roger Williams Medical Center, Providence, RI

11:03 AM ................................................................. 12
Association of Surgical Site Infection with Survival and Receipt of Adjuvant Chemotherapy Following Curative Resection for Non-metastatic Colon Cancer
Gala Barden, Baylor College of Medicine, Houston, TX

11:15 AM ................................................................. 13
Neoadjuvant Pelvic Perfusion Provides Symptom Control and May Facilitate Resection of Pelvic Recurrent Rectal Cancer
Harold Wanebo, Landmark Medical Center, Bristol, Puerto Rico

11:27 AM ................................................................. 14
Factors associated with 60-day Readmission Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy
Kaitlyn Kelly, UCSD, La Jolla, CA

11:39 AM ................................................................. 15
Modern Era Adjuvant Chemotherapy is Associated with Improved Survival in Patients with Stage II Colon Cancer
Leigh Casadaban, University of Illinois at Chicago, Chicago, IL
A Novel Inhibitor of the β-catenin Pathway in Colorectal Cancers that Targets Colorectal Stem Cells to Prevent Endothelial-to-Mesenchymal Transition (EMT) and Migration
Peter White, Department of Surgery, University of Michigan, Ann Arbor, MI

Serious Postoperative Complications Affect Early Recurrence After Cytoreductive Surgery and HIPEC for Colorectal Peritoneal Carcinomatosis
Geert Simkens, Catharina Hospital, Eindhoven, Noord Brabant, Netherlands

PRESENTATION OF THE COLORECTAL CANCER RESEARCH SCHOLAR AWARD
See page 28 for more information.

PARALLEL SESSION
Sarcoma and Thoracic/Esophageal Parallel Session
(See page 38 for listing of ACGME Core Competencies)
10:15 am-12:15 pm, Thursday, March 26
GBCC-320
Moderators: Steven N. Hochwald, MD and Sam S. Yoon, MD

A Phase I Clinical Trial of LUM015: A Protease-Activated Fluorescent Imaging Agent to Detect Cancer during Surgery
Melodi Whitley, Duke University Medical Center, Apex, NC

Variations in Protein Expression are Associated with Survival Outcomes in Patients with Undifferentiated Pleomorphic Sarcomas
Christina Roland, MD Anderson Cancer Center, Houston, TX

The Use of Human Acellular Dermal Matrix (ADM) Seeded with Patient-Autologous Fibroblasts to Cover Soft Tissue Defects in Irradiated Areas
Peter Hohenberger, Div. of Surgical Oncology and Thoracic Surgery, Mannheim, Germany

Is Less Really More for Retroperitoneal Sarcoma? A NSQIP Analysis of 1,018 Patients
Jennifer Harris, University of Kentucky, Lexington, KY
11:03 AM .............................................................. 22
A Meta-Analysis of the Association Between Radiation Therapy and Survival for Surgically Resected Extremity and Trunk Soft Tissue Sarcoma
Melody Xuan Lu Qu, Queen’s University, Kingston, ON, Canada

11:15 AM ............................................................ 23
The Effect of Neoadjuvant Therapy on Lymph Node Harvest for Patients undergoing Transhiatal Esophagectomy for Cancer
Gregory Tiesi, Miami Miller School of Medicine, Miami, FL

11:27 AM ............................................................ 24
The Relationship Between a Total Psoas Muscle Area and Surgical Outcomes in Patients with Esophageal Cancer
Yuji Kikuchi, Keio University, Tokyo, Japan

11:39 AM ............................................................ 25
Complete Pathologic Response is Independent of the Timing of Esophagectomy and is Predictive of Improved Survival Following Neoadjuvant Chemoradiation for Esophageal Cancer
Smit Singla, Roswell Park Cancer Institute, Buffalo, NY

11:51 AM ............................................................ 26
Fluid Administration is Associated with Morbidity in Patients Undergoing Transhiatal Esophagectomy for Esophageal Carcinoma
Oliver Eng, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ

12:03 PM ............................................................ 27
Identical MicroRNA Signatures of Adenocarcinoma and Squamous Cell Carcinoma Subtypes of Cancers of Different Organs
Reema Mallick, University of Minnesota, St. Paul, MN

PARALLEL SESSION
Breast Parallel Session 1

(See page 38 for listing of ACGME Core Competencies)
10:15 am-12:15 pm, Thursday, March 26
GBCC-310
Moderators: David N. Danforth, Jr., MS, MD and Sarah A. McLaughlin, MD

10:15 AM ............................................................ 28
Prognostic Value of Combined Clinical and Pathologic Staging Variables in Predicting Local-regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer
Mediget Teshome, University of Texas MD Anderson Cancer Center, Houston, TX

PRESENTATION OF THE SUSAN G. KOMEN® BREAST CANCER RESEARCH AWARD
See page 27 for more information.
10:27 AM Anti-HER2 CD4 T-Cell Immunity Strongly Correlates with Pathologic Complete Response to Neoadjuvant Therapy in HER2+ Breast Cancer
Jashodeep Datta, University of Pennsylvania, Philadelphia, PA

10:39 AM TFAP2C Regulates Luminal Breast Cancer Growth through EGFR and is a Target for Vandetanib
James De Andrade, University of Iowa Hospitals and Clinics, Iowa City, IA

10:51 AM HER-2 Pulsed Dendritic Cell Vaccination Augments HER-2 Immunity and Clinical Response Regardless of Injection Route in DCIS
Megan Fracol, University of Pennsylvania, Philadelphia, PA

Stephanie Valente, The Cleveland Clinic, Cleveland, OH

11:15 AM Sexual Function in Breast Cancer Survivors: What Does Surgery Have to Do With It?
Jennifer Gass, Women & Infants Hospital, Providence, RI

11:27 AM The Incidence of Adjacent Synchronous Invasive Carcinoma and/or DCIS in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-institutional Registry (TBCRC 020)
Faina Nakhli, Brigham and Women’s Hospital, Boston, MA

11:39 AM Circulating Tumor Cells after Neoadjuvant Therapy in Stage I-III Triple-Negative Breast Cancer
Anthony Lucci, The University of Texas MD Anderson Cancer Center, Houston, TX

11:51 AM Complete Axillary Response in Breast Cancer Patients After Neoadjuvant Treatment Correlates with Overall Survival
Sebastian Diaz-Botero, Breast Surgical Oncology Unit - Hospital Universitario Vall d’Hebron - Universidad Autonoma de Barcelona, Barcelona, Spain

12:03 PM Results of a Phase Ib Trial of Combination Immunotherapy with HER2-derived Peptide Vaccine GP2+GM-CSF and Trastuzumab in Breast Cancer Patients
Guy Clifton, University of Texas MD Anderson Cancer Center, Houston, TX
EXHIBIT HALL OPENING LUNCH
12:15-1:15 pm, Thursday, March 26
(See page 20 for details.)
View Exhibits & Posters
Exhibit Hall B3

NEW MEMBER LUNCHEON
(By invitation only)
12:15-1:15 pm, Thursday, March 26
Hilton, Ballroom of the Americas D (Level 2)

POSTER GRAND ROUNDS
12:30-1 pm, Thursday, March 26
(See page 23 for details)
Exhibit Hall B3

FELLOW & RESIDENTS LOUNGE
12:15-6 pm, Thursday, March 26
(See page 19 for details)
Exhibit Hall B3
Introductions and Welcome

1:15 pm  Selective Internal Radiotherapy: What is the Role for Unresectable Hepatic Colorectal Metastases?  
**Roderich E. Schwarz, MD, PhD**  
Medical Director; Professor of Surgery  
*IU Health Goshen Center for Cancer Care*  
Goshen, IN

1:33 pm  Extending the Role of Liver Resection for Extensive CR Metastases: PVE Versus ALPPS. What is the Reality?  
**Thomas A. Aloia, MD**  
Associate Professor, Department of Surgical Oncology  
*The University of Texas MD Anderson Cancer Center*  
Houston, TX

1:51 pm  Ablation of Liver Tumors: RFA, Microwave or Laser? Percutaneous, Laparoscopic or Open?  
**Clifford S. Cho, MD**  
Associate Professor; Chief, Section of Surgical Oncology  
*University of Wisconsin School of Medicine and Public Health*  
Madison, WI

2:09 pm  Irreversible Electroporation: What is the Role for Locally Advanced and Borderline Resectable Pancreas Cancer?  
**Robert C.G. Martin, II, MD, PhD**  
Sam and Lolita Weakley Endowed Chair in Surgical Oncology  
*University of Louisville School of Medicine*  
Louisville, KY

2:27 pm  The Role of Mesenteric Shunt for Borderline Resectable Pancreas Cancer: When Should this Technique be Utilized?  
**Jeffrey E. Lee, MD**  
Professor and Chair, Department of Surgical Oncology  
*The University of Texas MD Anderson Cancer Center*  
Houston, TX

2:45 pm  Panel Discussion with Q&A
SYMPOSIUM
Cost Effective and Quality Care of the Melanoma Patient (MOC)
1, 2, 5, 6
(See page 38 for listing of ACGME Core Competencies)
1:15-3:15 pm, Thursday, March 26
GBCC-320
Moderators: Mary S. Brady, MD and Keith A. Delman, MD

Introductions and Welcome
1:15 pm  Quality Metrics in Melanoma: What is the Data and are We Following our Own Recommendations?
Sandra L. Wong, MD, MS
Associate Professor of Surgery
University of Michigan Health System
Ann Arbor, MI

1:35 pm  Effective Surveillance Strategies for Melanoma Patients
David W. Ollila, MD
Professor of Surgery
University of North Carolina at Chapel Hill
Chapel Hill, NC

1:55 pm  Vaccine Therapy for Melanoma: Relevance for Present and Future Patients
Craig L. Slingluff, Jr., MD
Professor of Surgery
University of Virginia
Charlottesville, VA

2:15 pm  What's New in Systemic Immunotherapy for Melanoma: The Roles of Anti-CTLA4 and Anti-PD-1 Therapies
Patrick Hwu, MD
Professor & Chair, Department of Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX

2:35 pm  Panel Discussion with Q&A

REFRESHMENT BREAK IN EXHIBIT HALL
3:15-4:15 pm, Thursday, March 26
View Exhibits & Posters
Exhibit Hall B3
SYMPOSIUM
Susan G. Komen® Symposium: Personalized Care for Early Stage Breast Cancer (MOC) 1, 2, 5
(See page 38 for listing of ACGME Core Competencies)
1:15-3:15 pm, Thursday, March 26
GBCC-310
Moderators: Lee G. Wilke, MD and David J. Winchester, MD

Introductions and Welcome
1:25 pm  Predicting Cancer Behavior with Imaging Studies and Biomarkers
Laura J. Esserman, MD
Director, Carol Franc Buck Breast Care Center
UCSF Medical Center
San Francisco, CA

1:45 pm  Individualizing Extent of Resection According to Recurrence Risk
E. Shelly Hwang, MD, MPH
Professor and Chief Breast Surgery
Duke University Medical Center
Durham, NC

2:05 pm  Personalizing Systemic Therapy for Patients with Limited Surgery
Debu Tripathy, MD
Professor and Chair, Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX

2:25 pm  Predictors and Prognosticators for Precision Radiotherapy
Wendy A. Woodward, MD, PhD
Associate Professor, Department of Radiation Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX

2:45 pm  Panel Discussion with Q&A

REFRESHMENT BREAK IN EXHIBIT HALL
3:15-4:15 pm, Thursday, March 26
View Exhibits & Posters
Exhibit Hall B3

POSTER GRAND ROUNDS
3:30-4 pm, Thursday, March 26
(See page 23 for details)
Exhibit Hall B3
### VIDEO SESSION

Late Breaking Videos  
3:30-4:10 pm, Thursday, March 26  
*Exhibit Hall Theater, Exhibit Hall B3*  
**Moderator:** John M. Kane, III, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Code</th>
<th>Title</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30 PM</td>
<td>LBV1</td>
<td>A Minimally Invasive Technique to Obtain Optimal Tumor Margins in Anatomically Confined Locations Using a Contoured Stapler</td>
<td>Ajay Maker</td>
<td>University of Illinois at Chicago, Chicago, IL</td>
</tr>
<tr>
<td>3:40 PM</td>
<td>LBV2</td>
<td>Approach to the Porta Hepatis During Cytoreductive Surgery: Technical Considerations</td>
<td>Nail Aydin</td>
<td>Mercy Medical Center, Ellicott City, MD</td>
</tr>
<tr>
<td>3:50 PM</td>
<td>LBV3</td>
<td>A Role for Minimally Invasive Approaches to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Super Morbidly Obese Patients</td>
<td>David Luyimbazi</td>
<td>Carilion Clinic, Roanoke, VA</td>
</tr>
<tr>
<td>4 PM</td>
<td>LBV4</td>
<td>Minimally Invasive Total Gastrectomy in the Setting of CDH-1 Mutation</td>
<td>Mihir Shah</td>
<td>Cleveland Clinic Foundation, Cleveland, OH</td>
</tr>
</tbody>
</table>
SYMPOSIUM

Microsatellite Instability: Understanding Biology and Optimizing Treatment of Colorectal Cancer (MOC)

1, 2, 6

(See page 38 for listing of ACGME Core Competencies)
4:15-5:45 pm, Thursday, March 26
GBCC-332

Moderators: Glen C. Balch, MD and Martin R. Weiser, MD

Introductions and Welcome

4:15 pm  Identifying Microsatellite Unstable Colorectal Cancer
Matthew F. Kalady, MD
Associate Professor of Surgery
Cleveland Clinic
Cleveland, OH

4:35 pm  Surgery for Microsatellite Unstable Colorectal Cancer
Daniel O. Herzig, MD
Associate Professor of Surgery
Oregon Health & Science University
Portland, OR

4:55 pm  Chemotherapy and Follow-Up of Microsatellite Unstable Colorectal Cancer Patients
Eduardo Vilar-Sanchez, MD, PhD
Assistant Professor, Department of Clinical Cancer Prevention
The University of Texas MD Anderson Cancer Center
Houston, TX

5:15 pm  Case Presentations and Q&A
SYMPOSIUM

Issues of Cost and Value in Surgical Oncology Care (MOC)
1, 5, 6
(See page 38 for listing of ACGME Core Competencies)
4:15-5:45 pm, Thursday, March 26
GBCC-320
Moderators: Timothy J. Eberlein, MD and Karyn B. Stitzenberg, MD, MPH

Introductions and Welcome

4:15 pm  Overview: Costs of Perioperative Cancer Care
Thomas A. Aloia, MD
Associate Professor, Department of Surgical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX

4:25 pm  Financial Distress and the Patient Perspective
Karyn B. Stitzenberg, MD, MPH
Assistant Professor
University of North Carolina
Chapel Hill, NC

4:35 pm  The Growing Incidence and Cost of Thyroid Cancer
Cord Sturgeon, MD, MS
Director of Endocrine Surgery
Northwestern University Feinberg School of Medicine
Chicago, IL

4:45 pm  Locoregional Treatment Costs of Early-Stage Breast Cancer
Rachel A. Greenup, MD, MPH
Assistant Professor, Breast Surgery
Duke University Medical Center
Durham, NC

4:55 pm  Cost Implications of Newer Systemic Therapies in Melanoma
Jeffrey E. Gershenwald, MD
Professor, Surgical Oncology; Professor, Cancer Biology
The University of Texas MD Anderson Cancer Center
Houston, TX

5:05 pm  Cost and Value From the Payer and Policy Maker Perspective
Sandra L. Wong, MD, MS
Associate Professor of Surgery
University of Michigan Health System
Ann Arbor, MI

5:15 pm  Panel Discussion with Q&A
Controversies in the Management of Thyroid Cancer (MOC)

4:15-5:45 pm, Thursday, March 26

GBCC-310

Moderators: Electron Kebebew, MD and Carmen C. Solorzano, MD

Molecular Testing of Thyroid Nodules: Use and Abuse

Pro: Sally E. Carty, MD
Professor of Surgery
University of Pittsburgh School of Medicine
Pittsburgh, PA

Con: Martha A. Zeiger, MD
Professor of Surgery, Oncology, Cellular and Molecular Medicine
The Johns Hopkins University School of Medicine
Baltimore, MD

Small Thyroid Cancers (<1cm): Surveillance or Surgery?

Pro Surveillance: Ashok R. Shaha, MD
Professor of Surgery
Memorial Sloan Kettering Cancer Center, New York, NY

Pro Surgery: Julie Ann Sosa, MD, MA
Professor of Surgery & Medicine
Duke University, Durham, NC

Prophylactic Central Neck Dissection for Papillary Thyroid Cancer Header

Pro: Gerard M. Doherty, MD
Utley Professor and Chair of Surgery
Boston University, Boston, MA

Con: Christopher R. McHenry, MD
Vice Chairman, Department of Surgery
Metro Health Medical Center, Cleveland, OH

WELCOME RECEPTION

6-7:30 pm, Thursday, March 26
Exhibit Hall B3

Join us in the Exhibit Hall for hors d’oeuvres, refreshments and networking as you visit exhibitors and view posters. Participate in the Exhibit Hall Passport to Prizes game and win prizes by visiting with the exhibitors. (See page 18 for full details.) Stop by the SSO Membership Booth 419 to purchase 75th Anniversary apparel.

This complimentary event is open to all registrants. One drink ticket is located in your attendee registration materials. The event will have a cash bar.
MEET THE PROFESSOR BREAKFASTS

6:45-7:45 am, Friday, March 27
Registration Required — Fee $60 Each
Limit 30 per session. Breakfast is included.

- **Are We Appropriately Using Sentinel Lymph Node Biopsy in Breast Cancer?**
  Merrick I. Ross, MD
  Hilton, Room 335B (Level 3)

- **Balancing Science and Clinical Practice in Surgery**
  David C. Linehan, MD
  Hilton, Room 328 (Level 3)

- **HIPEC: How to Select the Right Patients and the Right Therapy**
  David L. Bartlett, MD
  Hilton, Room 330 (Level 3)

- **Melanoma Therapy: What Have We Learned Lately?**
  Vernon K. Sondak, MD
  Hilton, Room 335C (Level 3)

- **NSQIP-ONNCC: How Patients and Surgeons Benefit From Databases**
  Sharon M. Weber, MD
  Hilton, Room 327 (Level 3)

- **The Management of Borderline Resectable Pancreatic Cancer**
  Douglas B. Evans, MD
  Hilton, Room 329 (Level 3)

**BREAKFAST IN THE EXHIBIT HALL**
7-8 am, Friday, March 27
View Exhibits & Posters
**Exhibit Hall B3**

**POSTER GRAND ROUNDS**
7-7:55 am, Friday, March 27
*Exhibit Hall Theater, Exhibit Hall B3*

**CLINICAL POSTER AWARD NOMINEES**
7-7:25 am

**RESEARCH POSTER AWARD NOMINEES**
7:25-7:55 am

**Welcome and Announcements**
8-8:15 am, Friday, March 27
**GBCC Grand Ballroom**

Ronald J. Weigel, MD, PhD — President
James R. Howe, MD — Scientific Program Committee Chair

SSO expresses its appreciation to the members of the SSO 2015 Local Arrangements Team: Daniel Albo, MD, PhD, Barbara Lee Bass, MD and Jeffrey Lee, MD.
PLENARY I
8:15-8:55 am, Friday, March 27
GBCC Grand Ballroom
Moderator: Ronald J. Weigel, MD, PhD

8:19 AM.................................................................1
Risk after Local Excision Alone for DCIS Patients
Eileen Rakovitch, Sunnybrook Health Sciences Centre,
Toronto, ON, Canada

8:31 AM.................................................................2
Targeted Axillary Dissection Improves Axillary
Evaluation Following Neoadjuvant Chemotherapy in
Node Positive Patients
Abigail Caudle, University of Texas MD Anderson Cancer
Center, Houston, TX

8:43 AM.................................................................3
The Impact of Health Insurance on Cancer Care
in Disadvantaged Communities
Zaid Abdelsattar, University of Michigan, Ann Arbor, MI

PLENARY II
8:55-9:45 am, Friday, March 27
GBCC Grand Ballroom
Moderator: Jeffrey A. Drebin, MD, PhD

8:57 AM.................................................................4
An Externally Validated Prognostic Multigene
Expression Assay for Survival in Resected Colorectal
Liver Metastases
Vinod Balachandran, Memorial Sloan Kettering Cancer
Center, New York, NY

2015 Harvey Baker Traveling Fellow Award
The Society congratulates Vinod P. Balachandran, MD
who is attending SSO 2015 as the recipient of the
2015 Harvey Baker Traveling Fellow Award for the
above abstract. See page 28 for full details.

Supported by an independent grant from
The SSO Foundation.
9:09 AM ............................................................................ 5
Blockade of Inflammatory Monocytes is Effective in Pancreas Cancer: Results of a Phase Ib/II Trial in Borderline Resectable and Locally Advanced Disease
Timothy Nywening, Washington University in St. Louis, St Louis, MO

9:21 AM ............................................................................. 6
Proteomic Features of Colorectal Cancer Predict Relapse-Free Survival and Identify Tumor Subgroups Independent of Oncogenic Mutations
Callisia Clarke, MD Anderson Cancer Center, Houston, TX

9:33 AM ............................................................................. 7
Comprehensive Multiplatform Biomarker Analysis of 313 Hepatocellular Carcinoma Identifies Potential Therapeutic Options
Celina Ang, Icahn School of Medicine at Mt. Sinai, New York, NY

REFRESHMENT BREAK IN EXHIBIT HALL
9:45-10:15 am, Friday, March 27
View Exhibits & Posters
Exhibit Hall B3
JAMES EWING LECTURE
SSO Highlights over 75 Years:
From Ewing to Weigel
10:15-11 am, Friday, March 27
GBCC Grand Ballroom

Charles M. Balch, MD
Professor of Surgery, Division of Surgical Oncology
UT Southwestern Medical Center
Dallas, TX

Dr. Charles Balch has led a distinguished career as a clinical and academic surgical oncologist for the past 35 years, serving as a leading authority in both melanoma and breast cancer. He has published extensively on the conduct and methodology of clinical research, including authoring more than 700 publications, which have been cited over 20,000 times in biomedical literature. He also has lectured in more than 35 different countries and most of the major academic centers in the U.S.

Dr. Balch’s leadership roles have involved SSO (President, 1992), where he currently serves as Editor-in-Chief for the Annals of Surgical Oncology, American Board of Surgery (Board of Directors), Association of Academic Surgeons (President), Commission on Cancer (Chair, Board of Directors) and American Joint Committee on Cancer (Executive Committee).

He has held major leadership roles involving clinical research in four comprehensive cancer centers and involving clinical research in cancer cooperative groups, NIH study sections and professional organizations. In past years, Dr. Balch has served as Executive Vice President and CEO of the American Society of Clinical Oncology, and as President and CEO of the City of Hope National Medical Center.

Supported by an independent grant from The SSO Foundation.
SSO PRESIDENTIAL ADDRESS
11-11:45 am, Friday, March 27
GBCC Grand Ballroom

SSO PRESIDENTIAL ADDRESS:
SSO: The Next 75 Years
Ronald J. Weigel, MD, PhD
Associate Vice President, UI Health Alliance; EA Crowell Jr. Professor and Chairman, Department of Surgery
University of Iowa
Iowa City, IA

LUNCH IN THE EXHIBIT HALL
11:45 am-1:15 pm, Friday, March 27
(See page 20 for details)
View Exhibits & Posters
Exhibit Hall B3

VIDEO SESSION
Late Breaking Videos
12:30-1 pm, Friday, March 27
Exhibit Hall Theater, Exhibit Hall B3
Moderator: Hong Jin Kim, MD

12:30 PM.............................................................LBV5
Robotic-Assisted Laparoscopic Marsupialization of Esophageal Duplication Cyst
Robert Crum, NJMS - Rutgers University, Newark, NJ

12:40 PM.............................................................LBV6
Laparoscopic Total Gastrectomy
Akhil Chawla, Case Western Reserve University, Cleveland, OH

12:50 PM.............................................................LBV7
Surgical Placement of Novel 3D Tissue Marker During Lumpectomy
Cary Kaufman, University of Washington, Bellingham, WA

POSTER GRAND ROUNDS
12:30-1 pm
(See page 23 for details)
Exhibit Hall B3
DISTINGUISHED SERVICE AWARD
1:15-1:25 pm, Friday, March 27
GBCC Grand Ballroom
Presented by: Monica Morrow, MD

Honoring: Leslie H. Blumgart, MD
Professor of Surgery
Memorial Sloan Kettering Cancer Center
New York, NY

For outstanding contributions to surgical oncology Leslie H. Blumgart graduated MBChB in 1962, MD in 1969, and was awarded DSc (Hon), at Sheffield University. In 1972, he assumed the St. Mungo Chair of Surgery at the University of Glasgow, Royal Infirmary. In 1979, he was named the Chair of Surgery at the Royal Postgraduate Medical School, Hammersmith Hospital, London. In 1986, Dr. Blumgart left the UK and joined the University of Bern, Inselspital, Switzerland, as Professor of Visceral and Transplantation Surgery.

In 1991, Dr. Blumgart was selected as the Enid A. Haupt Chair of Surgery at Memorial Sloan Kettering Cancer Center and Professor of Surgery at Cornell University Medical College, in New York City. He established and was the first Chief of both the Hepato-Pancreato-Biliary Surgical Division and the Disease Management Team at Memorial Sloan Kettering, where a Chair of Surgery was named recently in his honor.

Dr. Blumgart has made significant contributions to general surgery, surgical oncology, and particularly to Hepato-Pancreato-Biliary surgery. He was a founding member and subsequently President of the International Biliary Association, which has evolved into the International Hepato-Pancreato-Biliary Association.

Dr. Blumgart has authored more than 600 peer-reviewed papers and more than 150 book chapters. He also has authored a number of books including Blumgart’s Surgery of the Liver, Biliary Tract, and Pancreas, currently in its 5th edition, and the Video Atlas: Liver, Biliary & Pancreatic Surgery. As a visiting professor, he has lectured worldwide.

Of the many accolades received are honorary fellowships of a range of surgical colleges including the French Surgical Association, Royal College of Surgeons in Ireland, Austrian Society of Surgery and Italian Society of Surgery. He was awarded the Swedish Society of Surgery’s Acral Medal.

Today, Dr. Blumgart continues to contribute generously of his time to the training of surgical fellows at Memorial Sloan Kettering, and they may be found practicing on all five continents.
JAMES EWING LAYPERSON’S AWARD
1:25-1:30 am, Friday, March 27
GBCC Grand Ballroom

Presented by: Ronald J. Weigel, MD, PhD

Kristen Olewine Milke spent much of her career in the food service industry serving as Senior Vice President and Chief Financial Officer of Olewine’s, Inc. and Sysco Food Services of Central Pennsylvania in Harrisburg, Pennsylvania. After her retirement at the end of 2005, Milke served as interim president and CEO of Whitaker Center for Science and the Arts, the region’s premier center for educational, cultural and artistic activities.

Milke serves on numerous non-profit boards and committees, leading initiatives to raise awareness and funds for causes close to her heart. A cause very close to her heart is cancer research. At the age of 11, she was diagnosed with Ewing’s sarcoma in her left clavicle. In 2003, she was diagnosed with breast cancer and has been fortunate enough over the years to be able to support research efforts for the prevention and cure of cancer at several medical institutions.

Giving back to the community has been a priority for Milke. She is an emeritus board member of Whitaker Center for Science and the Arts and the Harrisburg Area Community College Foundation. She currently serves on the boards of Central Pennsylvania Youth Ballet, Harristown Development Corporation and Tres Bonne Annee. Previously, she held board positions with the Central Pennsylvania Food Bank, Friends of Wildwood Lake Sanctuary, The Cultural Enrichment Fund and many others.

Among Milke’s honors include recognition as a YWCA Woman of Excellence in 2001 and the 2013 Foundation for Enhancing Communities Women’s Fund Award, which celebrates women in philanthropy. She resides in Harrisburg, Pennsylvania with her husband Denis J. Milke, MD.

Supported by an independent grant from The SSO Foundation.
AMERICAN CANCER SOCIETY/SSO BASIC SCIENCE LECTURE
Clinical Implications of Cancer Stem Cells
1:30-2:15 pm, Friday, March 27
GBCC Grand Ballroom
Moderator: Ronald J. Weigel, MD, PhD

Max S. Wicha, MD
Distinguished Professor of Oncology
Director, University of Michigan
Comprehensive Cancer Center
Ann Arbor, MI

Max S. Wicha, MD is the founding and current director of the University of Michigan Comprehensive Cancer Center (UMCCC), which he has helped establish as a national leader. It currently receives more funding from the National Cancer Institute than any other university-based center. Dr. Wicha also is a leader in breast cancer research and has been a pioneer in the field of cancer stem cells.

Dr. Wicha’s group was part of the team that first identified cancer stem cells in human breast cancers, the first in any solid tumor. His laboratory has developed many of the techniques and assays used to study these cells and to elucidate the pathways which regulate their behavior. These pathways have provided targets for the development of drugs aimed at targeting cancer stem cells. The UMCCC has established itself as a world leader in cancer stem cell biology and therapeutics and is currently conducting nine early phase clinical trials aimed at targeting cancer stem cells, the most of any center in the world.

A co-founder of OncoMed Pharmaceuticals, a biotech technology company focused on developing cancer stem cell therapeutics, Dr. Wicha also is a practicing clinician whose practice is focused on women with breast cancer.

Supported by an independent educational grant from the American Cancer Society.
THE GREAT DEBATES

1, 6
(See page 38 for listing of ACGME Core Competencies)
2:45-4:15 pm, Friday, March 27
GBCC Grand Ballroom
Moderator: Mitchell C. Posner, MD

Breast MRI Used in the Preoperative Evaluation of Breast Cancer

Pro: Laura J. Esserman, MD
Director, Carol Franc Buck Breast Care Center
UCSF Medical Center
San Francisco, CA

Con: Monica Morrow, MD
Chief, Breast Service; Anne Burnett Windfohr
Chair in Clinical Oncology
Memorial Sloan Kettering Cancer Center
New York, NY

Minimally Invasive Versus Open Whipple for Pancreatic Adenocarcinoma

Pro: Herbert Zeh, III, MD
Chief, Division of GI Surgical Oncology
University of Pittsburgh Medical Center
Pittsburgh, PA

Con: Jeffrey A. Drebin, MD, PhD
The John Rhea Barton Professor and Chair,
Department of Surgery
University of Pennsylvania
Philadelphia, PA

Sentinel Lymph Node Biopsy Should be Performed on All Patients with Cutaneous Melanoma ≥ 1 mm Thick

Pro: Daniel G. Coit, MD
Professor of Surgery, Weill Cornell Medical College;
Attending Surgeon
Memorial Sloan Kettering Cancer Center
New York, NY

Con: Jeffrey E. Gershenwald, MD
Professor, Surgical Oncology; Professor, Cancer Biology
The University of Texas MD Anderson Cancer Center
Houston, TX

BREAK
4:15-4:30 pm, Friday, March 27
PARALLEL SESSION
Upper Gastrointestinal Parallel Session
(See page 38 for listing of ACGME Core Competencies)
4:30-6:30 pm, Friday, March 27
GBCC-332
Moderators: Brian D. Badgwell, MD, MS and Ryan C. Fields, MD

4:30 PM
Adjuvant Sequential Gemcitabine Followed by Trametinib Inhibits Outgrowth of Occult Liver Metastases and Prolongs Survival After Pancreatic Cancer Resection: Results from a Randomized Preclinical Trial with Patient-Derived Tumors
Timothy Newhook, University of Virginia, Charlottesville, VA

4:42 PM
The Optimal Length of the Proximal Resection Margin in Patients with Proximal Gastric Adenocarcinoma: A Multi-Institutional Study of the U.S. Gastric Cancer Collaborative
Lauren Postlewait, Division of Surgical Oncology, Emory University, Decatur, GA

4:54 PM
Minimally Invasive Pancreatectoduodenectomy does not Improve Use or Time to Initiation of Adjuvant Chemotherapy in Patients with Pancreatic Adenocarcinoma
Daniel Nussbaum, Duke University Medical Center, Durham, NC

5:06 PM
Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer
Omar Rashid, H. Lee Moffitt Cancer Center, Tampa, FL

5:18 PM
Sentinel Node Concept in Early Gastric Cancer: The Present State and the Future Prospect
Ayako Shimada, Keio University School of Medicine, Tokyo, Japan

5:30 PM
New Circulating Biomarker for Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Raoud Marayati, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC

5:42 PM
Desmoplastic Stroma Differences in Metastatic Pancreatic Cancer
Robert Torphy, University of North Carolina School of Medicine, Chapel Hill, NC
Importance of Preoperative CA 19-9 Levels in Patients with Localized Pancreatic Cancer Treated with Neoadjuvant Therapy
Ashley Krepline, Medical College of Wisconsin, Milwaukee, WI

Prediction of Stage II/III Gastric Cancer Patients Rescued by Postoperative Adjuvant Chemotherapy by CDO1 Gene Promoter Hypermethylation
Keishi Yamashita, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan

PARALLEL SESSION
Melanoma Parallel Session

CALM Study: A Phase II Study of a Novel Oncolytic Immunotherapeutic Agent, CVA21, Delivered Intratumorally in Patients with Advanced Malignant Melanoma
Robert Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

Safety and Feasibility of Minimally Invasive Inguinal Lymph Node Dissection in Patients with Melanoma (SAFE-MILND)
James Jakub, Mayo Clinic, Rochester, MN

Pilot Trial of Ipilimumab and Adoptive Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy
Sangeetha Prabhakaran, Moffitt Cancer Center, Tampa, FL

A Phase I/Ila Clinical Trial of an Autologous Tumor/Dendritic Cell Fusion (Dendritoma) Vaccine with Low Dose Interleukin-2 in Stage IV Melanoma
Julia Greene, San Antonio Military Medical Center, San Antonio, TX

Lower Risk of Visceral/Bone Metastasis (VM) in Patients with Stage IIIB/C/IVM1a Melanoma Treated with Talimogene Laherparepvec (T-VEC) Versus GM-CSF in OPTiM (NCT00769704)
Robert Andtbacka, University of Utah Huntsman Cancer Institute, Salt Lake City, UT
5:30 PM Predictors and Survival Impact of False-Negative Sentinel Nodes in Melanoma
David Lee, John Wayne Cancer Institute, Santa Monica, CA

5:42 PM Molecular Characterization of the Immune Profile in the Sentinel Lymph Node in Melanoma
Alexandra Gangi, Cedars Sinai Medical Center, Los Angeles, CA

5:54 PM Elevated Blood Neutrophil-to-Lymphocyte Ratio is Associated with Poor Survival in Melanoma
Jeremy Davis, Memorial Sloan Kettering Cancer Center, New York, NY

6:06 PM Molecular Characterization of Cutaneous Melanoma for the Surgical Oncologist: Insights from the Cancer Genome Atlas Program
William Burns, The University of Texas MD Anderson Cancer Center, Houston, TX

6:18 PM Risk Factors for Positive Deep Pelvic Nodal Involvement in Patients with Palpable Groin Melanoma Metastases: Can Extent of Surgery be Minimized?
Charlotte Oude Ophuis, Erasmus MC Cancer Institute - University Medical Center Rotterdam, Rotterdam, Zuid-Holland, Netherlands

PARALLEL SESSION
Breast Parallel Session 2

(See page 38 for listing of ACGME Core Competencies)
4:30-6:30 pm, Friday, March 27
GBCC-310

Moderators: Swati Kulkarni, MD and Jane E. Mendez, MD

4:30 PM Repeat Sentinel Node Biopsy in Recurrent Breast Cancer: Staging Information and Technical Success
Guusje Vugts, Catharina Hospital, Eindhoven, Netherlands

4:42 PM Effect of Genomic Heterogeneity on Breast Cancer Progression and Metastatic Spread
Rachel Ellsworth, Murtha Cancer Center, Windber, PA

4:54 PM Skin Flap Necrosis (SFN) After Mastectomy with Reconstruction (M+R): A Prospective Study
Cindy Matsen, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT
The Protrusion Protein Polo-Like Kinase 4 (PLK4) Enhances Cancer Invasion
Karineh Kazazian, University of Toronto, Toronto, ON, Canada

Total Skin-Sparing Mastectomy for Locally Advanced Breast Cancer
Anne Peled, University of California, San Francisco, San Francisco, CA

A Prospective Validation Study of Bioimpedance with Volume Displacement in Early Stage Breast Cancer Patients at Risk for Lymphedema
Andrea Barrio, Memorial Sloan Kettering Cancer Center, New York, NY

Is Preoperative Axillary Imaging Beneficial in Identifying Clinically Node-Negative Patients Requiring Axillary Lymph Node Dissection?
Melissa Pilewskie, Memorial Sloan Kettering Cancer Center, New York, NY

Validation of the ACOSOG Z11 Trial Criteria: A Matched Cohort Analysis on 637 Women
Nicolas Ajkay, University of Louisville, Louisville, KY

Peace of Mind After Contralateral Prophylactic Mastectomy: Does It Really Happen?
Sarah McLaughlin, Mayo Clinic, Jacksonville, FL

Breast Cancer Detection by Biomarkers in Exhaled Air
Schlomo Schneebaum, Breast Health Center Division of Surgery Tel-Aviv Sourasky Medical Center Sackler School of Medicine, Tel-Aviv, Israel

INDUSTRY SATELLITE SYMPOSIA:
ADVANCES IN IMMUNOTHERAPY FOR ADVANCED MELANOMA:
INTEGRATING INTRALESIONAL AND ANTI-PD-1 IMMUNOTHERAPIES INTO CURRENT PRACTICE
6:45-8 pm, Friday, March 27
Hilton, Ballroom of the Americas D (Level 2)
Dinner Provided
See page 139 for full information.
FRIDAY
HAPPY HOUR
6:45-9:30 pm, Friday, March 27
Sambuca, 909 Texas Avenue, Houston, TX

Socialize with colleagues in your disease track at a casual Happy Hour at Sambuca on Friday evening from 6:45-9:30 pm. Wear your badge to receive Happy Hour specials on drinks and appetizers.

BREAST:  
Bar
GASTROINTESTINAL/COLORECTAL:  
Stage Left
MELANOMA/SARCOMA/ENDOCRINE:  
Main Dining Area
MEET THE PROFESSOR BREAKFASTS
6:45-7:45 am, Saturday, March 28
Registration Required – Fee $60 Each
Limit 30 per session. Breakfast is included.

Adrenal Masses: Pearls for Surgeons
Jeffrey E. Lee, MD
Hilton, Room 327 (Level 3)

Gastrectomy: Shouldn’t Most be Done with
MIS Techniques?
Vivian E. Strong, MD
Hilton, Room 329 (Level 3)

Management of Recurrent and Primary
Retroperitoneal Sarcoma
Raphael E. Pollock, MD, PhD
Hilton, Room 335C (Level 3)

Recurrent Rectal Cancer: How Can We Help
the Patient?
Elin R. Sigurdson, MD, PhD
Hilton, Room 335B (Level 3)

Reducing Readmissions Following
Cancer Surgery
Syed A. Ahmad, MD
Hilton, Room 328 (Level 3)

What is the State of the Art in Personalized
Therapy for Breast Cancer?
V. Suzanne Klimberg, MD
Hilton, Room 330 (Level 3)
SYMPOSIUM
The Challenges of Defining and Treating Borderline Resectable Pancreatic Cancer
1, 2
(See page 38 for listing of ACGME Core Competencies)
8-10 am, Saturday, March 28
GBCC-332
Moderators: Peter J. Allen, MD and Nipun B. Merchant, MD

Introductions and Welcome
8 am
How Best to Define Borderline Resectable PDAC Radiographically
Eric P. Tamm, MD
Professor, Department of Diagnostic Radiology
The University of Texas MD Anderson Cancer Center
Houston, TX

8:25 am
Multimodality Therapy: Which Approach is Best?
Matthew H.G. Katz, MD
Assistant Professor, Department of Surgical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX

8:50 am
Surgical Challenges in the Management of Borderline Resectable Pancreas Cancer
Nipun B. Merchant, MD
Professor of Surgery and Cancer Biology
Vanderbilt University Medical Center
Nashville, TN

9:15 am
Case Presentations and Q&A
Peter J. Allen, MD
Associate Director for Clinical Programs, David M. Rubenstein Center for Pancreatic Cancer Research
Memorial Sloan Kettering Cancer Center
New York, NY

REFRESHMENT BREAK
10-10:15 am, Saturday, March 28
GBCC Grand Ballroom Foyer
SYMPOSIUM

Challenges of Gene Testing for Clinical Management (MOC) 1, 2
(See page 38 for listing of ACGME Core Competencies)
8-10 am, Saturday, March 28
GBCC-320

Moderators: David M. Euhus, MD and James R. Howe, MD

Introductions and Welcome

8 am When to Perform Genetic Testing and for What Diseases
Kevin S. Hughes, MD
Associate Professor of Surgery
Harvard Medical School
Boston, MA

8:20 am Technology Behind Genetic Testing
David M. Euhus, MD
Director, Breast Surgery; Professor of Surgery
Johns Hopkins Hospital
Baltimore, MD

8:40 am How to Make Sense of Variants of Uncertain Significance, Rare Polymorphisms, Low Penetrance Alleles and the Common Rare Syndromes
Mark E. Robson, MD
Clinic Director, Clinical Genetics Service
Memorial Sloan Kettering Cancer Center
New York, NY

9 am Ethical Issues in Genetic Testing
Sara M. Pirzadeh-Miller, MS, CGC
Manager, Clinical Cancer Genetics
Moncrief Cancer Institute/UT Southwestern
Ft. Worth, TX

9:20 am Can Surgeons Provide Cancer Genetic Testing for Patients?
Deanna J. Attai, MD
Assistant Clinical Professor of Surgery
David Geffen School of Medicine at UCLA
Burbank, CA

9:40 am Panel Discussion with Q&A

REFRESHEMENT BREAK
10-10:15 am, Saturday, March 28
GBCC Grand Ballroom Foyer
Symposium
Metastatic/Recurrent Colorectal Cancer in 2015, Where Are We Now? (MOC)
1, 2, 6
(See page 38 for listing of ACGME Core Competencies)
8-10 am, Saturday, March 28
GBCC-310
Moderators: Kelli M. Bullard Dunn, MD and George J. Chang, MD, MS

Introduction and Welcome
8 am Moving the Needle Forward in Carcinomatosis of Colorectal Origin
Laura A. Lambert, MD
Director, Peritoneal Surface Malignancy Program
UMass Memorial Medical Center
Worcester, MA

8:20 am Gotta Get It Right: Surgical Treatment of Recurrent Rectal Cancer
Phillip B. Paty, MD
Professor of Surgery
Memorial Sloan Kettering Cancer Center
New York, NY

8:40 am Resecting the Unresectable Colorectal Hepatic Metastasis
Jean-Nicolas Vauthey, MD
Professor of Surgery
The University of Texas MD Anderson Cancer Center
Houston, TX

9 am Primary Tumor Resection in the Setting of Synchronous Stage IV Colorectal Cancer
Johannes H.W. De Wilt, MD, PhD
Professor of Surgical Oncology
Radboud University Medical Center
Nijmegen, Netherlands

9:20 am Case Presentations and Q&A

Refreshment Break
10-10:15 am, Saturday, March 28
GBCC Grand Ballroom Foyer
JOHN WAYNE CLINICAL RESEARCH LECTURE

Challenging Paradigms in Cancer Research
10:15-11 am, Saturday, March 28
GBCC Grand Ballroom
Moderator: Ronald J. Weigel, MD, PhD

Lee M. Ellis, MD
Professor of Surgery, and Molecular & Cellular Oncology; The William C. Liedke, Jr. Chair in Cancer Research
The University of Texas MD Anderson Cancer Center
Houston, TX

Dr. Lee Ellis graduated from the University of Virginia School of Medicine in 1983 and completed his residency in surgery at the University of Florida in 1990. He went on to complete a surgical oncology fellowship at the MD Anderson Cancer Center (MDACC), where he has been on the faculty since 1993.

Dr. Ellis has a clinical practice focused on patients with colorectal cancer. Academically, Dr. Ellis has established a reputation for expertise in the area of angiogenesis and cell signaling in gastrointestinal malignancies and is funded by NIH and DOD grants. He has served on numerous NIH study sections and is currently Vice Chair of the National Cancer Institute Colon Cancer Task Force. In 2000, Dr. Ellis was awarded the Faculty Scholar Award from the MDACC, and he was also the inaugural recipient of the George and Barbara Bush Endowment for Innovative Cancer Research. In 2013, Dr. Ellis became SWOG’s Vice Chair for Translational Medicine and one of three PIs on the NIH grant supporting SWOG. In 2014, Dr. Ellis was inducted as a Fellow of ASCO.

Among the eight editorial boards Dr. Ellis serves on include the Journal of Clinical Oncology, Cancer Research, and Clinical Cancer Research (Senior Editor). He also has authored more than 230 peer-reviewed publications, 110 invited reviews and editorials, three books and 30 book chapters.

Supported by an independent grant from the John Wayne Cancer Foundation.
The Clinical Investigator Awards were established in 2007 by SSO to promote post-fellowship, patient-oriented research through the training of surgical oncologists in clinical and translational science. Each Award consists of $100,000, disbursed in two yearly installments of $50,000. To date, 27 Clinical Investigator Awards totaling more than $2.7 million dollars have been granted to researchers.

Beginning with the 2013-2015 awards cycle, the administration and management of the CIA program has moved under the auspices of The SSO Foundation.

**Introductions and Welcome**

11:05 am  Synergistic Action of Carboplatin/Eribulin in Combination with CDK Inhibitor Therapy for the Treatment of Triple Negative Cancer
Jacqueline S. Jeruss, MD, PhD
Associate Professor of Surgery
University of Michigan
Ann Arbor, MI

11:15 am  A Phase 1-2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients with Bladder Cancer
Jonathan L. Wright, MD, MS
Assistant Professor of Urology
University of Washington School of Medicine
Seattle, WA

11:25 am  A Population-Based Study of Sentinel Lymph Node Biopsy Adoption among Breast Cancer Patients: Does Efficacy Translate to Effectiveness?
Tina W.F. Yen, MD, MS
Associate Professor, Division of Surgical Oncology
Medical College of Wisconsin
Milwaukee, WI

11:35 am  Final Remarks and Announcement of the 2015 Award Recipient
Mitchell C. Posner, MD
President, The SSO Foundation

**LUNCH ON OWN**
11:45 am-12:45 pm, Saturday, March 28
(See page 20 for full details)
Exhibit Hall B3
PARALLEL SESSION

Endocrine and Head & Neck Parallel Session

(See page 38 for listing of ACGME Core Competencies)
12:45-2:15 pm, Saturday, March 28

GBCC-332

Moderators: Lawrence T. Kim, MD and Jeffrey F. Moley, MD

12:45 PM
Quantitative High Throughput Screening Identifies Carfilzomib as an Effective Anticancer Agent for Adrenocortical Carcinoma
Rachel Aufforth, National Cancer Institute, Washington, DC

12:56 PM
Wide Inter-Institutional Variation in Performance of a Molecular Classifier for Indeterminate Thyroid Nodules
Jennifer Marti, Mount Sinai Beth Israel, New York, NY

1:07 PM
Role of Adrenal Vein Sampling in Primary Hyperaldosteronism with Non-Localizing Imaging
Heather Wachtel, Hospital of the University of Pennsylvania, Dept. of Surgery, Philadelphia, PA

1:18 PM
Role of Octreotide Scan in Localization of Intra-Abdominal Neuroendocrine Tumors
Salman Zaheer, University of Pennsylvania, Philadelphia, PA

1:29 PM
Does the Addition of Adjuvant Intraoperative Post-Dissection Tumor Bed Chemotherapy During GI Neuroendocrine Tumor Debulking Benefit Patients?
Aman Chauhan, LSUHSC, Metairie, LA

1:40 PM
Impact of Multifocality in the Management of Small Bowel Neuroendocrine Tumors
Alexandra Gangi, Cedars-Sinai Medical Center, Los Angeles, CA

1:51 PM
Adrenal Imaging Features Predict Malignancy Better than Size
Jenny Yoo, University of Pittsburgh, Pittsburgh, PA

2:02 PM
Lymphoscintigraphy Concordance with Intraoperative Findings from Sentinel Lymph Node (SLN) Biopsy with [99mTc] Tilmanocept in Clinically Node-Negative (cN0) Head and Neck Squamous Cell Carcinoma Patients (HNSCC)
Douglas Chepeha, Univeristy of Toronto - Princess Margaret Hospital, Toronto, ON, Canada
PARALLEL SESSION
Quality Improvements/Clinical Outcomes Parallel Session
(See page 38 for listing of ACGME Core Competencies)
12:45-2:15 pm, Saturday, March 28
GBCC-320
Moderators: Christiana M. Shaw, MD, MS
and Larissa K.F. Temple, MD

12:45 PM ................................................................. 76
Assessing Post-Surgical Cancer Risk Using Time-Dependent Survival Curves
Amanda Goldin, UCSD, San Diego, CA

12:57 PM ................................................................. 77
A Simple Preoperative Risk Scale Accurately Predicts Perioperative Mortality Following Gastric Resection for Malignancy
Cristina Harnsberger, University of California, San Diego, Department of Surgery, Center for the Future of Surgery, La Jolla, CA

1:09 PM ................................................................. 78
Oncology-Led Clinical Documentation Improvement Program Beneficial for Physicians and Hospital
Keith Gray, University of Tennessee Medical Center Cancer Institute, Knoxville, TN

1:21 PM ................................................................. 79
Prolonged Venous Thromboprophylaxis Following Major Abdominal and Pelvic Cancer Surgery: A Meta-Analysis and Systematic Review
Varun Chakravorty, St. Barnabas Medical Center, Livingston, NJ

1:33 PM ................................................................. 80
Attributes and Outcomes of Older Adults in Surgical Oncology Trials: Results from ACOSOG Z901101 (Alliance)
Waddah Al-Refaie, Georgetown University Hospital, Washington, DC

1:45 PM ................................................................. 81
Improving Timeliness in the Diagnosis and Management of Breast Abnormalities: The Impact of a Rapid Diagnostic Unit
Jennifer Racz, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

1:57 PM ................................................................. 83
Does Surgical Palliation Improve Quality of Life Outcomes at the End of Life?
Ann Falor, City of Hope, Los Angeles, CA
PARALLEL SESSION

Hepatobiliary Parallel Session

(See page 38 for listing of ACGME Core Competencies)
12:45-2:15 pm, Saturday, March 28

GBCC-310

Moderators: Marcovalerio Melis, MD and Nicholas J. Petrelli, MD

12:45 PM
Summary of Outcomes from Consensus Conference on Training in HPB Surgery
D. Rohan Jeyarajah, MD, Methodist Dallas Medical Center, Dallas, TX

12:55 PM
Optimal Surgical Strategy for Pancreatic Neuroendocrine Tumor Based on a Review of the National Cancer Database: How Important is Extent of Resection and Lymphadenectomy?
Zeljka Jutric, Providence Cancer Center, Portland, OR

1:05 PM
Results from a Prospective Hepatocellular Cancer (HCC) Screening Program in 7,120 Chronic Hepatitis C Virus (HCV)-infected Patients
Steven Curley, Baylor College of Medicine, Houston, TX

1:15 PM
A Phase II Study of Bavituximab and Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
Adam Yopp, UT Southwestern Medical Center, Dallas, TX

1:25 PM
Comparing Perioperative Processes of Care in High- and Low-Mortality Centers Performing Pancreatic Surgery
Christopher Scally, University of Michigan, Ann Arbor, MI

1:35 PM
Adjuvant Chemotherapy and Radiation Therapy Improves Survival for Patients with Extrahepatic Cholangiocarcinoma
Audrey Ertel, University of Cincinnati, Cincinnati, OH

1:45 PM
National Trends in Resection of Cystic Lesions of the Pancreas
Bradley Reames, University of Michigan, Ann Arbor, MI

1:55 PM
Adaption of “Reversed” Treatment Sequencing Approach Contributes to Improved Survival in Patients with Rectal Cancer and Resectable Synchronous Liver Metastasis
Claudius Conrad, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Chemotherapy for Surgically Resected Intrahepatic Cholangiocarcinoma: Lymph Node Status Influences Treatment Efficacy
John Miura, Medical College of Wisconsin, Milwaukee, WI

REFRESHMENT BREAK
2:15-2:30 pm, Saturday, March 28
GBCC Grand Ballroom Foyer
Symposium
Great Debates in Breast Cancer
1, 2, 6
(See page 38 for listing of ACGME Core Competencies)
2:30-4 pm, Saturday, March 28
GBCC-332
Moderators: Kelly K. Hunt, MD and Kimberly J. Van Zee, MS, MD

Introductions and Welcome

Management of DCIS: Are We Overtreating?
Yes: Murray F. Brennan, MD
Vice President for International Programs
Memorial Sloan Kettering Cancer Center
New York, NY
No: Eleftherios P. Mamounas, MD, MPH
Medical Director, Comprehensive Breast Care Program
UF Health Cancer Center
Orlando, FL

Margin Width in Breast Conserving Surgery: No Ink on Tumor?
Yes: Lee G. Wilke, MD
Professor of Surgery; Director, UW Health Breast Center
University of Wisconsin School of Medicine and Public Health
Madison, WI
No: Alastair M. Thompson, BSc(Hons), MB ChB, MD
Professor of Surgery
The University of Texas MD Anderson Cancer Center
Houston, TX

Is Sentinel Lymph Node Biopsy Accurate for Staging After Chemotherapy in Patients with Initial Node Positive Disease?
Yes: Judy C. Boughey, MD
Professor of Surgery
Mayo Clinic
Rochester, MN
No: David W. Ollila, MD
Professor of Surgery
University of North Carolina at Chapel Hill
Chapel Hill, NC

Break
4-4:15 pm, Saturday, March 28
VIDEO SESSION

Top Rated Videos

(See page 38 for listing of ACGME Core Competencies)

2:30 PM, Saturday, March 28, 2015

GBCC-320

Moderators: Hisakazu Hoshi, MD and Yuman Fong, MD

2:30 PM ................................................................. V1
The Modified Keystone Flap
Samantha White, Norfolk and Norwich University Hospital, Bury St Edmunds, United Kingdom

2:41 PM ................................................................. V2
Radical Resection of Abdominal Wall Desmoid Tumor with Reconstruction Using Posterior Component Separation and Mesh Implantation
Kevin Choong, University Hospitals Case Medical Center, Cleveland, OH

2:52 PM ................................................................. V3
Total Laparoscopic Pancreatoduodenectomy: A Single Institutional Experience
Alessandro Paniccia, University of Colorado, Anschutz Medical Campus, Aurora, CO

3:03 PM ................................................................. V4
Use of Pedicled Omental Flap in Minimally Invasive Robotic-Assisted Ivor-Lewis Esophagogastrectomy
Geena Wu, City of Hope National Medical Center, Duarte, CA

3:14 PM ................................................................. V5
Total Laparoscopic Splenic Vessel Preserving Distal Pancreatectomy for pNETs in a Young Patient with MEN1 Claudius Conrad, Department of Surgical Oncology, UT MD Anderson Cancer Center, Houston, TX

3:25 PM ................................................................. V6
Robotic Prophylactic Total Gastrectomy
Patrick Lorimer, Levine Cancer Institute, Charlotte, NC

3:36 PM ................................................................. V7
Robotic-assisted Low Anterior Resection with Use of Fluorescence Imaging to Assess Proximal Bowel Transection Site and Anastomosis Perfusion
Tarek El Amadieh, University of Texas Southwestern Medical Center, Dallas, TX

3:47 PM ................................................................. V8
Laparoscopic Resection of a Proximal Jejunal Adenocarcinoma
Usmaan Hameed, University of Toronto, Toronto, ON, Canada

BREAK

4-4:15 pm, Saturday, March 28
SYMPOSIUM
Novel Paradigms for Lifelong Learning in Surgery (MOC)

6
(See page 38 for listing of ACGME Core Competencies)
2:30-4 pm, Saturday, March 28
GBCC-310
Moderators: Glenda G. Callender, MD and William G. Cance, MD

Introductions and Welcome
2:30 pm Coaching for Performance Improvement
Justin B. Dimick, MD, MPH
The Henry King Ransom Associate Professor of Surgery
University of Michigan Health Systems
Ann Arbor, MI

2:45 pm Simulation as a Tool for Lifelong Learning
Carlos A. Pellegrini, MD
The Henry N. Harkins Professor and Chair
University of Washington
Seattle, WA

3 pm The Ethics of Introducing New Technology and Procedures
Peter Angelos, MD, PhD
Linda Kohler Anderson Professor of Surgery and Surgical Ethics
University of Chicago Medicine and Biological Sciences
Chicago, IL

3:15 pm Remote Telementoring
Nancy D. Perrier, MD
Professor of Surgery, Department of Surgical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX

3:30 pm The Role of Social Media in Continuous Professional Development
Niraj J. Gusani, MD, MS
Associate Professor of Surgery, Medicine & Public Health Sciences
Penn State Hershey Medical Center & College of Medicine
Hershey, PA

3:45 pm Panel Discussion with Q&A

BREAK
4-4:15 pm, Saturday, March 28
SYMPOSIUM

Melanoma Multidisciplinary Tumor Board
1, 2, 5, 6
(See page 38 for listing of ACGME Core Competencies)
4:15-5:45 pm, Saturday, March 28

GBCC-332

Moderators: Douglas S. Tyler, MD and Jonathan S. Zager, MD

Tumor Board Panel:

B. Ashleigh Guadagnolo, MD, MPH
Associate Professor, Departments of Radiation Oncology and Health Services Research
The University of Texas MD Anderson Cancer Center
Houston, TX

Patrick Hwu, MD
Professor and Chair, Department of Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX

Kelly M. McMasters, MD, PhD
Ben A. Reid, Sr., Professor and Chair, The Hiram C. Polk, Jr., MD Department of Surgery
University of Louisville School of Medicine
Louisville, KY

Marc Moncrieff, MD
Consultant Plastic and Reconstructive Surgeon
Norfolk & Norwich University Hospital
Norwich, United Kingdom

Merrick I. Ross, MD
Professor of Surgery and Chief, Melanoma Section
The University of Texas MD Anderson Cancer Center
Houston, TX

Introductions and Welcome

4:15 pm  A Case in Management of Locally Advanced Melanoma
Jessica A. Cintolo, MD
General Surgery Resident
Hospital of the University of Pennsylvania
Philadelphia, PA

4:30 pm  Timing of Surgery, Targeted Therapy and Immunotherapy in a Patient with Recurrent Metastatic Melanoma
Ryan C. Fields, MD
Assistant Professor of Surgery
Washington University School of Medicine - St. Louis
St. Louis, MO
4:45 pm  Pelvic Lymphadenopathy: Regional or Systemic Approach?  
Travis E. Grotz, MD  
Chief Resident  
Mayo Clinic  
Rochester, MN

5 pm  Immunotherapy and Surgery for Metastatic Melanoma  
Vitor Moutinho, MD  
Surgical Oncology Fellow  
Memorial Sloan Kettering Cancer Center  
New York, NY

5:15 pm  Melanocytic Tumor of Uncertain Malignant Potential  
Andrea Porpiglia, MD  
Complex General Surgical Oncology Fellow  
Fox Chase Cancer Center  
Philadelphia, PA

5:30 pm  Controversial Pigmented Lesions in Children  
Douglas Reingten, MD  
Professor of Surgery  
University of South Florida  
Tampa, FL
SYMPOSIUM
Case Presentations with Professors and Fellows
2, 3, 4
(See page 38 for listing of ACGME Core Competencies)
4:15-5:45 pm, Saturday, March 28
GBCC-320
Moderators: Murray F. Brennan, MD and Douglas B. Evans, MD

For full session details, please utilize the SSO 2015 website or mobile app. For details, see page 22.

Fellows:
Mashaal Dhir, MBBS
University of Pittsburgh
Pittsburgh, PA

Miral Sadaria Grandhi, MD
The Johns Hopkins Hospital
Baltimore, MD

John B. Hamner, MD
City of Hope
Duarte, CA

J. Spencer Liles, MD
The University of Texas MD Anderson Cancer Center
Houston, TX

Nicole Lopez, MD
University of North Carolina Health Care
Chapel Hill, NC

Harveshp D. Mogal, MD
Wake Forest University School of Medicine
Winston Salem, NC

Jukes P. Namm, MD
The University of Chicago Medicine
Chicago, IL

Kelly Olino, MD
Memorial Sloan Kettering Cancer Center
New York, NY
SYMPOSIUM
What’s New in Gastric and Esophageal Cancers?
(See page 38 for listing of ACGME Core Competencies)
4:15-5:45 pm, Saturday, March 28
GBCC-310
Moderators: Kenneth Cardona, MD and Jennifer F. Tseng, MD, MPH

Introductions and Welcome
4:15 pm  Advances in Imaging, Endoscopic and Endoluminal Therapies
Mandeep S. Sawhney, MD, MS
Assistant Professor of Medicine
Harvard Medical School/Beth Israel Deaconess Medical Center
Boston, MA

4:30 pm  Minimally Invasive Gastroesophageal Surgery: Worth the Hype?
Vivian E. Strong, MD
Associate Professor of Surgery
Memorial Sloan Kettering Cancer Center
New York, NY

4:45 pm  Molecules, Genes, Druggable Targets for Gastric and Esophageal Cancers
Jaffer A. Ajani, MD
Professor, Department of Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX

5 pm  What’s the Best Way to Treat GE Junction Tumors? Approach Like Gastric Cancer
Paul F. Mansfield, MD
VP, Acute Care Services, Ofc/EVP Physician-in-Chief
The University of Texas MD Anderson Cancer Center
Houston, TX

What’s the Best Way to Treat GE Junction Tumors? Approach Like Distal Esophageal Cancer
Nabil P. Rizk, MD
Associate Attending
Memorial Sloan Kettering Cancer Center
New York, NY

5:35 pm  Panel Discussion with Q&A
Annual SSO Business Meeting Agenda

I. Call to Order
   Ronald J. Weigel, MD, PhD

II. Announcement of Annual Resident/Fellow Essay Award Winners
    Ronald J. Weigel, MD, PhD

III. President’s Report
     Ronald J. Weigel, MD, PhD
     • Recognition of Program Chair

IV. Secretary’s Report
    Armando Giuliano, MD
    • In Memoriam
    • Introduction of New Members
    • Consideration of Proposed Bylaw Amendments

V. Treasurer’s Report
   David Bartlett, MD

VI. Annals of Surgical Oncology Report
    Charles M. Balch, MD

VII. Membership Open Forum
     Ronald J. Weigel, MD, PhD

VIII. Award Recipients Announced
      Ronald J. Weigel, MD, PhD

IX. Recognition of Outgoing Councilors
    Ronald J. Weigel, MD, PhD

X. Nominating Committee Report
   James S. Economou, MD, PhD

XI. Introduction of New President
    Ronald J. Weigel, MD, PhD

XII. New Business
     Jeffrey A. Drebin, MD, PhD
     • SSO 2016 – Boston, MA

XIII. Adjourn
All Scientific Posters will be displayed from 12:15 pm on Thursday to 2:45 pm on Friday. Presenters are requested to be available during the times below, as their schedules permit, to answer questions about their posters. Any posters withdrawn as of February 26, 2015 are not included in the following listing.

**THURSDAY, MARCH 26**
- 12:15-1:15 pm
- 3:15-4:15 pm
- 6-7:30 pm

**FRIDAY, MARCH 27**
- 7-8 am
- 9:45-10:15 am
- 11:45 am-1:15 pm
- 2:15-2:45 pm

New this year! Poster signage is color-coded by track.

- **Pink**: Breast Track
- **Dark Blue**: Colorectal Track
- **Light Blue**: Gastrointestinal Track (Hepatobiliary; Upper Gastrointestinal)
- **Green**: General Education Track (Quality Improvement/Clinical Outcomes)
- **Yellow**: Melanoma and Sarcoma Track
- **Orange**: Other Surgical Oncology Track (Endocrine; Head & Neck; Thoracic/Esophageal)

Disease Site Poster Grand Rounds participants will all be marked with a star on in the Program Guide and in the Exhibit Hall. Please see page 23 of the Program Guide for Poster Grand Round details.

**BREAST CANCER PostERS**

**P1** Early Postoperative Complications of Breast Conservation Surgery Versus Simple Mastectomy with Implant Reconstruction: A NSQIP Analysis of 11,645 Patients
Abhishek Chatterjee, University of Pennsylvania, Drexel Hill, PA

**P2** Avoidance of Sentinel Lymph Node Biopsy: Can Molecular Profiling of Primary Breast Tumors Predict Lymph Node Status?
Rachel Ellsworth, Murtha Cancer Center, Windber, PA
P3 Impact of Consensus Guidelines by Society of Surgical Oncology/American Society for Radiation Oncology on Margins for Breast Conserving Surgery in Stages I and II Invasive Breast Cancer
Alice Chung, Cedars Sinai Medical Center, Los Angeles, CA

P4 Features of Local-Regional Recurrences after 21-Gene Breast Cancer Assay-Directed Treatment
Dorian Korz, Moffitt Cancer Center, Tampa, FL

P5 Interaction between CD47 and SIRPA in BM and in PB Predicts Poor Prognosis in Breast Cancer Subtypes
Makoto Nagahara, Tokyo Medical and Dental University, Tokyo, Japan

P6 The Effect of HER2 Amplification in HER2+ Breast Cancer
Minna Lee, UCLA, Los Angeles, CA

P7 Rehabilitation Needs in the Breast Cancer (BC) Survivorship Population: A Prospective Observational Study
Veronica Jones, Emory University, Decatur, GA

P9 Immunohistochemical (IHC) Marker Discordance Between Primary Breast Cancer Biopsy and Recurrent Cancer: Should Surgical Breast and Lymph Node Specimens be Tested?
Michele Gage, Walter Reed National Military Medical Center, Bethesda, MD

P11 Factors associated with Increasing Mastectomy Rates in Early Stage Breast Cancer Patients: Report from a Single Institution and Population-Based Database
Min Yi, UT MD Anderson Cancer Center, Houston, TX

P12 Health Disparity or Bad Biology? An Analysis of Triple-negative Breast Cancer Patients in an Urban Academic Hospital
Lindsay Petersen, Rush University Medical Center, Chicago, IL

P13 Anti-HER2 CD4+ Th1 Responses can be Restored in DC1 Vaccinated Breast Cancer Patients
Lea Lowenfeld, University of Pennsylvania, Philadelphia, PA

P14 Excising Additional Margins at Initial Breast-Conserving Surgery (BCS) Reduces the Need for Re-Excision: A Report of a Randomized Prospective Study in a Public Hospital
Veronica Jones, Emory University, Decatur, GA

P15 National Utilization of Post-Mastectomy Radiation after Neoadjuvant Chemotherapy
Olga Kantor, Department of Surgery, The University of Chicago Medicine, Chicago, IL
P17  Trends in Tumor Characteristics Among DCIS Patients: A Population-Based Analysis of 130,229 Patients
Mathias Worni, Duke University Medical Center, Durham, NC

P18  Who is Ordering Breast MRIs in Newly Diagnosed Breast Cancer Patients?
Hank Schmidt, Mount Sinai Hospital, New York, NY

P19  Axillary Ultrasound Predicts Lymph Node Metastatic Burden in Invasive Ductal Carcinoma
Rubie Sue Jackson, Anne Arundel Medical Center, Annapolis, MD

P20  LCIS, Race and Age: 10-year Cancer Specific Survival after a Diagnosis of Lobular in Situ Disease
Ingrid Lizarraga, University of Iowa Hospitals and Clinics, Iowa City, IA

P21  Metaplastic Breast Cancer is Resistant to Standard Breast Cancer Treatment Modalities
Starr Mautner, Memorial Sloan Kettering Cancer Center, New York, NY

P22  Timing of Breast Cancer Surgery: How Much Does it Matter?
Sara Mansfield, Department of General Surgery, The Ohio State University, Columbus, OH

P23  Trends in Income, Race and Ethnicity Disparities in Guidelines for Breast Conserving Therapy
Jilma Patrick, Northwestern University, Chicago, IL

P24  Contralateral Lymph Node Recurrence in Breast Cancer Patients: Regional or Distant Disease?
Martine Moossdorff, Maastricht University Medical Center, Maastricht, Limburg, Netherlands

P25  Predictors of 30-day Readmission After Mastectomy: A Multi-Institutional Analysis of 21,271 Patients
Ian Chow, Northwestern University, Chicago, IL

P26  Importance of Hospital Volume and Treatment Facility on Early-Stage Breast Cancer
Rachel Greenup, Duke University Medical Center, Durham, NC

P27  Is Lymph Node Ratio Prognostic after Neoadjuvant Therapy for Breast Cancer?
Danielle Bertoni, Stanford, Stanford, CA

P28  Influence of preoperative Magnetic Resonance Imaging on the Surgical Management of Breast Cancer Patients
Armen Parsyan, McGill University, Montreal, QC, Canada
P29 Survival Post-Neoadjuvant Chemotherapy in Breast Cancer: Validation of the MD Anderson Cancer Center Nomogram
Jacquelyn Palmer, Carolinas Medical Center, Charlotte, NC

P30 Disparities in the Use of Post-Mastectomy Radiation Therapy for Inflammatory Breast Cancer
Catherine Loveland-Jones, MD Anderson, Houston, TX

P31 Comprehensive Exploration of Phenylbutyrate (PB) Sensitivity Identified Epigenetic Methylation Genes that Play Critical Roles in Drug Resistance in Breast Cancer
Mariko Kikuchi, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan

P32 Impact of Postmastectomy Radiation Therapy in Overall Survival and Disease-Free Survival in Metastatic Breast Cancer
Antonio Maffuz-Aziz, Breast Disease Institute. FUCAM, Mexico, D.F., Mexico

P33 Effect of Topical Microporous Polysaccharide Hemosphere on Wound Drainage Following Mastectomy: A Prospective Randomized Trial
Lorena Suarez-Kelly, Memorial Health-University Medical Center, Savannah, GA

P34 Radioactive Seed Localization in Breast Cancer Patients Treated with Neoadjuvant Therapy: A Safe and Effective Alternative to Wires
Tara Grahovac, Magee Women’s Hospital of UPMC, Pittsburgh, PA

P35 Are We Failing to Treat? Trends in the Omission of XRT after Lumpectomy for Breast Cancer in the United States
Christina Minami, Northwestern Memorial Hospital, Chicago, IL

P36 The Impact of Socioeconomic and Geographic Factors on Ductal Carcinoma in Situ Treatment
Deba Sarma, Duke University Medical Center, Raleigh, NC

P37 Post-mastectomy Radiation: Should Subtype Factor into the Decision?
Adena Scheer, St. Michael’s Hospital, Toronto, ON, Canada

P38 Baseline MRI for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy Leads to Additional Biopsies and Unnecessary Cost
Mikki Seagren, USCF, San Francisco, CA
A Prospective Study of Preoperative BRCA Status Determination and Surgical Choice
Marissa Howard-McNatt, Wake Forest School of Medicine, Winston-Salem, NC

Complication Rates in Early Stage Breast Cancer Patients Treated with Single Lumen versus Multi-Lumen Brachytherapy Catheters
Jillian Lloyd, Bryn Mawr Hospital, Bryn Mawr, PA

A Simple Intervention to Relieve Chest Wall Pain Due to Post-Mastectomy Pain Syndrome
Mikki Seagren, USCF, San Francisco, CA

Left-Sided Breast Radiation does not Result in Increased Long-Term Cardiac-Related Mortality Among Women Undergoing Breast Conserving Surgery
G. Paul Wright, GRMEP/Michigan State University, Grand Rapids, MI

FOXC1 Mediates the Basal Phenotype in BRCA1-Mutant Breast Cancer
Jeffrey Johnson, Cedars-Sinai Medical Center, Los Angeles, CA

Implications of New Lumpectomy Margin Guidelines for Breast-Conserving Surgery: Changes in Re-Excision Rates and Predicted Rates of Residual Tumor
Andrea Merrill, Massachusetts General Hospital, Boston, MA

Pleomorphic Invasive Lobular Carcinoma: An Aggressive Variant?
B. Marie Ward, UmassMemorial, Worcester, MA

Acceptance of Adjuvant Chemotherapy in Patients with Early Stage Breast Cancer
Emily Marcinkowski, City of Hope, Azusa, CA

Features of Triple-Negative Breast Cancer (TNBC): Analysis of 38,813 Cases from the National Cancer Data Base (NCDB)
Magdalena Plasilova, Yale University School of Medicine, The Breast Center-Smilow Cancer Hospital at Yale New Haven, New Haven, CT

Failure of a Breast Density Notification Law to Impact the Screening of Women with Dense Breasts
Bharti Jasra, University of Texas Southwestern, Dallas, TX

The Influence of Breast Cancer Subtype on the Prognosis of Young Breast Cancer Patients in China
Lichen Tang, Shanghai Cancer Center, Fudan University, Shanghai, China
P52  Factors Affecting Completion of Adjuvant Chemotherapy in Early Stage Breast Cancer
Sylvia Reyes, Memorial Sloan-Kettering Cancer Center, New York, NY

P53  Severity of Acute Pain After Axillary Lymphadenectomy and Primary Reconstruction with a Tissue Expander in Breast Cancer Patients
Nikola Besic, Institute of Oncology, Ljubljana, Slovenia

P54  The Feasibility of Performing a Preference-Tolerant Randomized Controlled Trial of Personalized versus Annual Breast Cancer Screening
Carlie Thompson, University of California San Francisco, San Francisco, CA

P55  Concordance of Clinical and Pathologic Staging in Breast Cancer: Report from the National Cancer Data Base
Puneet Singh, Department of Surgery, The University of Chicago, Chicago, IL

P56  Axillary Staging after Neoadjuvant Chemotherapy (NAC) for Breast Cancer (BC): A Pilot Study Combining Sentinel Lymph Node Biopsy (SLB) with Radioactive Seed Localization (RSL) of Pre-Treatment Positive Axillary Lymph Nodes (LN+)
Emilia Diego, Magee Womens Hospital of UPMC, Monroeville, PA

P57  Knowledge Deficits and Concern About Contralateral Breast Cancer Risk: A Prospective Study
Katharine Yao, NorthShore University HealthSystem, Evanston, IL

P58  Using Quantitative ER to Predict the Likelihood and Timing of Distant Recurrence of Breast Cancer
Michele Gage, Walter Reed National Military Medical Center, Bethesda, MD

P59  Reoperative Sentinel Lymph Node Biopsy (SLNB) is Feasible for the Treatment of Locally Recurrent Invasive Breast Cancer, but is it Necessary?
Stacy Ugras, Memorial Sloan Kettering Cancer Center, New York, NY

P60  Sentinel Node Biopsy in Patients with Ductal Carcinoma in Situ on Core Biopsy: Standard Care or Overtreatment?
Lori van Roozendaal, Maastricht University Medical Center, Maastricht, Netherlands
P61 Long-Term Outcomes of Multiple Wire Localization for Breast Cancer: Multiple Wires Do Not Increase Recurrence, Unplanned Imaging or Biopsies
Maureen McEvoy, Massachusetts General Hospital, Boston, NY

P62 Healthcare Costs Reduced After Incorporating the Results of the American College of Surgeons Oncology Group (ACOSOG) Z11 Trial into Clinical Practice
Michelle Fillion, The Ohio State University Wexner Medical Center, Wilmington, NC

P63 Outcomes with Contralateral Axillary Nodal Metastases in Breast Cancer
Candice Sauder, M.D. Anderson Cancer Center, Houston, TX

P64 Effect of Young Age on Aggressive Subtypes of Breast Cancer (BC)
Raquel Prati, UCLA, Los Angeles, CA

P65 Over-utilization of Chest Computed Tomography in Stage I and II Breast Cancer Patients
Barbara Dull, Washington University, St. Louis, MO

P66 Contralateral Prophylactic Mastectomy in Young Women with Breast Cancer: A Population-Based Analysis of Predictive Factors and Clinical Impact
Antoine Bouchard-Fortier, University of Calgary, Calgary, AB, Canada

P67 Do the ACOSOG Z11 Criteria Affect Number of Sentinel Lymph Nodes Removed?
Preeti Subhedar, Memorial Sloan Kettering Cancer Center, New York, NY

P68 Factors Associated with DCIS Diagnosis: A Population-based Review of the National Cancer Database
Alfred Colfry, MD Anderson Cancer Center, Houston, TX

P69 Quality of Life for Long-Term Breast Cancer Survivors: A Population-Based Study of 937 Patients
Shuja Ahmed, Wake Forest Baptist Health, Winston Salem, NC

P70 MICA Expression is Decreased in Benign Breast Lobules with Fibrocystic Changes
Daniel Kerekes, University of Notre Dame, South Bend, IN

P71 Limited Efficacy of Preoperative Magnetic Resonance Imaging in Breast Cancer Patients
David Strauss, Geisinger Medical Center, Orefield, PA
P72  **Contralateral Breast Cancer: Is the Second Cancer Worse?**
Lindsey Karavites, UIC/Mt. Sinai Hospital, Chicago, IL

P73  **Pilot Study of a Passive Non-Radioactive Infrared-Activated and Radar-Detected Marker to Localize Non-Palpable Breast Lesions**
Charles Cox, University of South Florida Morsani College of Medicine, Tampa, FL

P74  **Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer**
Maria Gunthner-Biller, Memorial Sloan Kettering Cancer Center, New York, NY

P75  **Breast MRI and Pathologic Tumor Size: Examining the Effect of Radiopathologic Discordance on Positive Margins and Rates of Re-Excision**
Stephanie Wong, McGill University Health Centre, Boston, MA

P76  **False Negative Rate (FNR) and Negative Predictive Value (NPV) from 3-Year Outcome Study After Sentinel Lymph Node Biopsy (SLNB) with [99mTc] Tilmanocept in Clinically Node-Negative (cNO) Breast Cancer and Melanoma Patients**
Julian Kim, Case Western Reserve University, Cleveland, OH

P77  **Lumpectomy Margins: Is “No Ink on Tumor” Enough?**
Simon Fitzgerald, Mount Sinai Medical Center, New York, NY

P78  **Augmentation of Adoptive Cellular Immunotherapy for Breast Cancer with Decitabine**
Krista Terracina, Department of Surgery, Virginia Commonwealth University and Massey Cancer Center, Richmond, VA

P79  **Changes in Practice Patterns for Completion Axillary Node Dissection in a Population-Based Breast Cancer Cohort Before and After the Dissemination of ACOSOC Z11 Results**
Sylvie Cornacchi, McMaster University, Hamilton, ON, Canada

P80  **The Impact of Obesity on Costs for Mastectomy**
Susie Sun, Penn State Hershey Medical Center, Hershey, PA

Maureen McEvoy, Massachusetts General Hospital, Boston, NY
P82 PD-L1 Gene Amplification in Triple-Negative Breast Cancer: Implications for Immunotherapy
Kate Peng, Mayo Clinic, Phoenix, AZ

P83 The Impact of BRCA Mutations in a Young, Predominantly Hispanic Breast Cancer Population
Jessica Ryan, University of Southern California, Los Angeles, CA

P84 A Comparison of the Mammographic Findings Between Oncoplastic Mammoplasty Patients and Lumpectomy Patients
Merisa Piper, University of California, San Francisco, San Francisco, CA

P85 Histopathologic Axillary Staging Prior to Neoadjuvant Chemotherapy can Impact Treatment in Breast Cancer
Kara Friend, University of Michigan, Whitmore Lake, MI

P86 Comparison of Intraoperative Specimen Mammography to Standard Specimen Mammography: A Randomized Trial
Cynthia Miller, Massachusetts General Hospital, Boston, MA

P87 Presence of Circulating Tumor Cells and Disseminated Tumor Cells Does Not Predict Site of Recurrent or Metastatic Disease
Sarah DeSnyder, The University of Texas MD Anderson Cancer Center, Houston, TX

P88 Combined Chemotherapy and Radiation are Associated with Improved Overall Survival for Metaplastic Breast Cancer
Susan Sharpe, University of Chicago, Chicago, IL

P89 A Comparison of Treatment Outcomes for Patients with Close or Positive DCIS Margins After Mastectomy for Early Stage Breast Cancer
Mary Freyvogel, University Hospitals Case Medical Center, Westlake, OH

P90 Expression of HER-2 Receptor is Not Associated with Worse Outcomes in Breast Cancer: An 18-Year Prospective Follow-Up
Kelly Rosso, Henry Ford Hospital, Grosse Pointe Woods, MI

P91 Overall Survival in Patients with a Re-Excision Following Breast Conserving Surgery Compared to Those Without in a Large Population-Based Cohort
Elvira Vos, Erasmus MC Cancer Institute, Rotterdam, Zuid-Holland, Netherlands

P92 The Impact of Neoadjuvant Chemotherapy on Anxiety in Breast Cancer Patients
Cory Donovan, Oregon Health & Sciences University, Portland, OR
Predictors of Tamoxifen Use in Women with Estrogen-Receptor Positive DCIS
Rondi Kauffmann, City of Hope Comprehensive Cancer Center, Claremont, CA

Local Recurrence and Metachronous Contralateral Breast Cancers Diagnosed at a Community-Based Regional Cancer Program Over a 10-Year Period: Patterns and Practice
Perry Soriano, The Everett Clinic and Providence Cancer Partnership, Everett, WA

Is Preoperative Imaging Predictive of Histopathology in BRCA Mutation Carriers Undergoing Prophylactic Mastectomy?
Michael Choi, Cedars-Sinai Medical Center, Los Angeles, CA

Can Twitter Social Media be an Effective Tool for Breast Cancer Survivor Support and Education?
Deanna Attai, David Geffen School of Medicine at UCLA, Burbank, CA

Implementing a Radioactive Seed Localization Program in Breast Cancer Surgery: A Multidisciplinary Approach
Dalliah Black, MD Anderson Cancer Center, Houston, TX

Prospective Trial of Breast MRI versus Ultrasound (US) for Evaluation of Response to Neoadjuvant Chemotherapy
Segundo Gonzalez, H. Lee Moffitt Cancer Center, Tampa, FL

Upstaging of Breast Lobular Intraepithelial Neoplasia and Its Implications for Surgical Management
Alexandra Allard-Coutu, McGill University, Montreal, QC, Canada

Use of Twitter during the Society of Surgical Oncology and American Society of Breast Surgeons 2014 Annual Meetings
Michael Cowher, Allegheny Health Network, Pittsburg, PA

Clinical Significance of Para-Aortic Lymph Node Dissection for Advanced or Metastatic Colorectal Cancer in the Current Era of Modern Chemotherapy
Keisuke Uehara, Nagoya University Graduated School of Medicine, Nagoya, Aichi, Japan
P103 Peritoneal Metastases from Small Bowel Cancer: Results of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Netherlands
Thijs Van Oudheusden, Catharina Hospital, Eindhoven, Netherlands

P104 Clinical Cancer Staging at Initial Presentation: Are We Improving?
Sanjay Reddy, Fox Chase Cancer Center, Philadelphia, PA

P105 Oligometastatic Micro-RNAs are Regulated by DNA Methylation
Go Oshima, Department of Surgery, The University of Chicago, Chicago, IL

P106 In vitro Functional Study of RhoA in Colorectal Cancer Cell Line and the Significance of Its Expression in Colorectal Cancer Patients
Moo-Jun Baek, Soonchunhyang University Hospital, Cheonan, Korea (the Republic of)

P107 Association of Nuclear Karyopherin Alpha2 with Poor Prognosis in Colorectal Cancer Patients
Moo-Jun Baek, Soonchunhyang University Hospital, Cheonan, Korea (the Republic of)

P109 National Disparities in Minimally Invasive Surgery for Colorectal Cancer
Emmanuel Gabriel, Roswell Park Cancer Institute, Buffalo, NY

P110 Safety and Efficacy of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion in Elderly Patients
Patricio Polanco, University of Texas Southwestern Medical Center, Dallas, TX

P111 Assessment of Clinical Complete Response After Chemoradiation for Rectal Cancer with Digital Rectal Exam, Endoscopy and MRI
Geerard Beets, MUMC, Maastricht, Limburg, Netherlands

P112 Global Transcriptional Signature of Peripheral Blood Immature Myeloid Cells as a Marker for Abdominal Tumor Progression in Mouse
Niv Pencovich, Laboratory of Molecular Surgical Oncology, Department of General Surgery, Tel-aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

P113 Long-term Outcome of Rectal Cancer with Clinically Metastatic Mesorectal Lymph Nodes (cN+) Treated by Neoadjuvant Chemoradiation: Implications for Surgical Strategies in Relation to Pathological Response
Claudio Belluco, National Cancer Institute, CRO-IRCCS, Aviano, Italy
P114  **Delay to Colectomy and Survival for Patients Diagnosed with Colon Cancer**  
Sanjay Bagaria, Mayo Clinic, Jacksonville, FL

P115  **Predictors of Circumferential Resection Margin Involvement After Curative Surgery for Rectal Cancer**  
Eisar Al-Sukhni, Roswell Park Cancer Institute, Buffalo, NY

P116  **Conditional Survival After Cytoreductive Surgery with Heated Intraperitoneal Chemotherapy for Low- and High-Grade Appendiceal Primaries**  
Harveshp Mogal, Wake Forest School of Medicine, Winston-Salem, NC

P117  **MiR-29b is a Novel Potential Prognostic Marker and Regulates Tumor Progression in Colorectal Cancer**  
Akira Inoue, Gastroenterological Surgery, Osaka University, Suita City, Osaka, Japan

P118  **Is Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy More Cost-Effective than Palliative Chemotherapy in the Management of Colorectal Peritoneal Metastases?**  
Zhen Jin Lee, Singhealth, Singapore

P119  **A Longer Time Interval to Surgery After Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer Increases the Chance of a Complete Response**  
Niek Hugen, Radboud University Medical Center, Nijmegen, Netherlands

P120  **Is Patient Derived Xenograft Model Appropriate for Colon Cancer Preclinical Drug Development?**  
Leopoldo Fernandez, Virginia Commonwealth University, Richmond, VA

P121  **The Role of Inflammatory Monocytes in Human Metastatic Colorectal Cancer**  
Julie Grossman, Washington University School of Medicine, St. Louis, MO

P122  **Identification of the Genetic Interaction Between the Oncogenic SNP and Environmental Factors in Diabetic Colorectal Cancer Patients**  
Keishi Sugimachi, Kyushu University Beppu Hospital, Beppu, Japan

P123  **Tumor Derived Hypoxia Inducible Factor-1α Modulates Peritoneal Macrophage Activation in a Metastatic Model of Murine Colon Adenocarcinoma**  
Brooke Bredbeck, University of Colorado, Denver, CO
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors, Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>P124</td>
<td>Safety and Efficacy of Concurrent Surgical Therapy for Peritoneal Carcinomatosis and Synchronous Hepatic Metastases in Patients with Disseminated Colorectal Cancer</td>
<td>Haroon Choudry, University of Pittsburgh Medical Center, Pittsburgh, PA</td>
</tr>
<tr>
<td>P125</td>
<td>Time to Chemotherapy After Abdominoperineal Resection: Comparison Between Primary Closure Versus Perineal Flap Reconstruction</td>
<td>Azah Althumairi, Johns Hopkins Hospital, Baltimore, MD</td>
</tr>
<tr>
<td>P126</td>
<td>Optimal Timing of Surgical Resection After Radiation Therapy in Locally Advanced Rectal Adenocarcinoma: An Analysis of the National Cancer Database (NCDB)</td>
<td>Ciara Huntington, Carolinas Medical Center, Charlotte, NC</td>
</tr>
<tr>
<td>P127</td>
<td>Tumor Size as a Prognostic Factor in Colon Cancer: A Comparison of National Cancer Data Base versus Surveillance, Epidemiology and End-Results Analysis</td>
<td>Sukamal Saha, McLaren Regional Medical Center, Flint, MI</td>
</tr>
<tr>
<td>P128</td>
<td>An Investigation of the Role of Irinotecan and Oxaliplatin in Liver Toxicity During First-Line Chemotherapy</td>
<td>Gregoire Desolneux, Institut Bergonie, Bordeaux, France</td>
</tr>
<tr>
<td>P129</td>
<td>Pelvic Exenteration and Composite Sacral Resection in the Surgical Management of Locally Recurrent Rectal Cancer</td>
<td>Wael Gawad, National Cancer Institute, Cairo, Egypt</td>
</tr>
<tr>
<td>P130</td>
<td>Preoperative Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios are Prognostic in Patients Undergoing Resection for Non-Metastatic Colorectal Cancer</td>
<td>Woo Jin Choi, University of Toronto, Toronto, ON, Canada</td>
</tr>
<tr>
<td>P131</td>
<td>Transanal Local Excision of Rectal Cancer: Social Disparities and Impact on Outcome</td>
<td>Emmanuel Gabriel, Roswell Park Cancer Institute, Buffalo, NY</td>
</tr>
<tr>
<td>P132</td>
<td>Feeding Tube Placement During CRS/HIPEC for Colorectal Cancer Does Not Improve Postoperative Nutrition and is Associated with Higher Readmission Rates</td>
<td>Sean Dineen, MD Anderson Cancer Center, Houston, TX</td>
</tr>
<tr>
<td>P133</td>
<td>Selective Loss of MicroRNA 145 in Therapeutic Resistant Colorectal Cancer Cells</td>
<td>Ernest Camp, Medical University of South Carolina, Charleston, SC</td>
</tr>
</tbody>
</table>
Intralesional Injection of Rose Bengal Induces an Anti-Tumor Immune Response and Potent Tumor Regressions in a Murine Model of Colon Cancer
Krunal Pardiwala, University of Illinois at Chicago, Chicago, IL

Tumorigenesis and Stage Progression in Rectal Cancer is Paralleled by Progressive Differential Expression in a Subset of Genes and miRNAs
Oliver Chow, Memorial Sloan Kettering Cancer Center, New York, NY

The Impact of Radiotherapy on Rates of Surgical Site Infection in Patients with Rectal Cancer: Benchmarks for Comparison
Noah Yuen, UC Davis Medical Center, Sacramento, CA

Postoperative Morbidity and Mortality After Resection of the Primary Tumor in Patients with Stage IV Colorectal Cancer
Jorine ‘t Lam-Boer, Radboud University Medical Center, Nijmegen, Netherlands

The Impact of Nodal Metastasis on Survival in Stage IV Colon Cancer: Analysis of National Cancer Data Base versus Surveillance, Epidemiology and End Results
Sukamal Saha, McLaren Regional Medical Center, Flint, MI

Quantifying the Contribution of Stage to Race-Related Colorectal Cancer Survival Disparity: A Texas Cancer Registry Analysis
Uma Phatak, University of Texas Houston, Houston, TX

Neutrophil-to-Lymphocyte Ratio Predicts Major Perioperative Complications in Patients with Colorectal Cancer
Jonathan Josse, University of Toronto, Toronto, ON, Canada

Biologic Factors Associated with Survival in Patients with Pseudomyxoma Peritonei
Sean Judge, Creighton University School of Medicine, Omaha, NE

Identifying Preoperative and Perioperative Variables that Predict Poor Outcomes in Cytoreduction/HIPEC Patients
Smit Singla, Roswell Park Cancer Institute, Buffalo, NY

Genetic Analysis of Colorectal Cancers in Young Patients
Andrea Abbott, H. Lee Moffitt Cancer Center, Tampa, FL
P144 Oncologic Outcomes Following Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemoperfusion for Disseminated Peritoneal Carcinomatosis
Filip Bednar, University of Pittsburgh, Pittsburgh, PA

P145 Predictors of Postoperative Mortality in Stage IV Colorectal Cancer After Resection of the Primary Tumor
Jurian Rooks, Radboud University Medical Center, Nijmegen, Netherlands

P146 Tumor-Penetrating iRGD Peptide Potentiates Intraperitoneal Chemotherapy and Facilitates Peritoneal Tumor Detection
Kazuki Sugahara, Columbia University, New York, NY

P147 Usefulness of Carcinoembryonic Antigen (CEA) as Prognosis Factor in Patients with Stage III Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy (CRT)
Pedro Luna-Perez, Hospital de Oncologia CMN SXXI, Mexico D.F, Mexico

P148 Real-World Treatment Patterns and the Uptake of Biologics in Elderly Medicare Patients with Metastatic Colon Cancer
Nader Hanna, University of Maryland School of Medicine, Baltimore, MD

P149 Intermedin (IMD) Stimulates Cell Growth, Migration and Angiogenesis in Human Colorectal Adenocarcinoma
Lindsay Hollander, Yale University, West Hartford, CT

P150 Robotic versus Laparoscopic Colectomy for Colonic Adenocarcinoma: A Nationwide Analysis of Surgical Outcomes
Pragattheeshwar Thirunavukarasu, Roswell Park Cancer Institute, Buffalo, NY

P151 Modified Orthotopic Murine Colon Cancer Cell Implantation Method that Mimics Clinical Cancer Progression
Krista Terracina, Virginia Commonwealth University, Richmond, VA

P152 Premalignant Anal HPV Tumors are Not More Likely to Recur than Benign HPV Tumors
Anjali Kumar, MedStar Washington Hospital Center, Washington, DC

P153 Disparities in the Treatment and Outcome of Rectal Cancer Patients: A Health Insurance Perspective
Colleen Kiernan, Vanderbilt University, Nashville, TN
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P154</td>
<td>Changing Pattern of Locally Recurrent Rectal Adenocarcinoma in Post-Total Mesorectal Excision (TME) Era</td>
<td>Joe Liles, UT MD Anderson Cancer Center, Houston, TX</td>
</tr>
<tr>
<td>P155</td>
<td>A Retrospective Single-Center Analysis of Robotic Abdominoperineal Resection</td>
<td>James Ouellette, Wright State University, Dayton, OH</td>
</tr>
<tr>
<td>P156</td>
<td>Lymph Node Ratio is a More Accurate Prognostic Factor in Stage III Colon Cancer Compared to Standard Nodal Staging</td>
<td>Andrea MacNeill, University of Toronto, Toronto, ON, Canada</td>
</tr>
</tbody>
</table>

**ENDOCRINE CANCER POSTERS**

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P157</td>
<td>Total Thyroidectomy versus Lobectomy as Initial Operation for Small Unilateral Papillary Thyroid Carcinoma: A Meta-Analysis</td>
<td>Francisco Macedo, Providence Hospital and Medical Centers, Troy, MI</td>
</tr>
<tr>
<td>P158</td>
<td>Rural-urban Disparities in Incidence and Outcomes of Neuroendocrine Tumors: A 15-Year Population-Based Analysis of 6,271 Cases</td>
<td>Julie Hallet, Odette Cancer Centre - Sunnybrook Health Sciences Centre, Toronto, ON, Canada</td>
</tr>
<tr>
<td>P159</td>
<td>Sociodemographic Disparities in Treatment of Anaplastic Thyroid Carcinoma</td>
<td>Michael Dacey, University of Southern California Keck SOM, Los Angeles, CA</td>
</tr>
<tr>
<td>P160</td>
<td>Vanishing Tumors of Thyroid: Histological Variations After Fine Needle Aspiration</td>
<td>Parisha Bhatia, Tulane University, School of Medicine, New Orleans, LA</td>
</tr>
<tr>
<td>P161</td>
<td>Comparison of Secondary and Primary Thyroid Cancers: Patient Characteristics and Postoperative Outcomes</td>
<td>Zaid Al-Qurayshi, Tulane University School of Medicine, Department of Surgery, New Orleans, LA</td>
</tr>
<tr>
<td>P162</td>
<td>Outcomes Following Parathyroidectomy for Primary Hyperparathyroidism: Availability and Impact of Surgeon Experience</td>
<td>Zaid Al-Qurayshi, Tulane University School of Medicine, Department of Surgery, New Orleans, LA</td>
</tr>
<tr>
<td>P163</td>
<td>Long-term Operative Outcomes of Thyroid Cancer: A Comparison of Adults and Children</td>
<td>Zaid Al-Qurayshi, Tulane University School of Medicine, Department of Surgery, New Orleans, LA</td>
</tr>
</tbody>
</table>
P164  Safety of Outpatient Thyroidectomy
Jonathan Black, UNC, Chapel Hill, NC

P165  Implications of Delayed Normalization of Serum Calcium Levels After Presumed Curative Parathyroidectomy
Victoria Lai, Virginia Hospital Center, Arlington, VA

P166  The Risk of Thyroid Cancer in Patients with Metabolic Diseases: Demographic Disparities at the National Level
Zaid Al-Qurayshi, Tulane University School of Medicine, Department of Surgery, New Orleans, LA

P167  Incidental Thyroid Malignancy Found in Thyroidectomy Performed for Benign Diagnoses
Rebekah Campbell, Geisinger Medical Center, Danville, PA

P168  Long-Term Outcomes and Risk of Endocrine Cancer Surgery: The Role of Surgeon Experience
Zaid Al-Qurayshi, Tulane University School of Medicine, Department of Surgery, New Orleans, LA

P169  Does Marital Status Impact Survival in Patients with Carcinoid Tumors?
Erin Kenning, Penn State Hershey Medical Center, Hershey, PA

P170  Surgeon Volume Impact on the Outcomes of Thyroidectomy and Related Hospital Charges: A National Forecast
Zaid Al-Qurayshi, Tulane University School of Medicine, Department of Surgery, New Orleans, LA

P171  Neoadjuvant Chemotherapy in 13 Patients with Locally Advanced Poorly Differentiated Thyroid Carcinoma: A Phase I/II Study
Nikola Besic, Institute of Oncology, Ljubljana, Slovenia

P172  Long-Term Hypercalcemia Recurrence Risk Following Successful Minimal Invasive Parathyroidectomy
Amanda Nijhuis, Diakonessehuis Utrecht, Utrecht, Netherlands

P173  Factors that Contribute to Inadvertent Parathyroidectomy During Thyroid Surgery: Does the Presence of Lymphocytic Thyroiditis, Concomitant Primary Hyperparathyroidism or Hyperthyroidism Have an Impact?
Natalie Calcatera, Baylor University Medical Center, Dallas, TX

P174  Implications of Gene Express Classifier Testing in Evaluation of Indeterminate Thyroid Nodules: A Single Institutional Experience
Zaid Al-Qurayshi, Tulane University School of Medicine, New Orleans, LA
P175  Can Suspicious Surgeon's Performed Ultrasound Features Predict BRAFV600E Status in Papillary Thyroid Carcinoma?  
Zaid Al-Qurayshi, Tulane University School of Medicine, New Orleans, LA

HEAD & NECK CANCER POSTERS

P176  When Would We Advocate a Total Thyroidectomy in Cases of Hypopharyngeal Carcinoma?  
Abdelmaksoud Ali, National Cancer Institute, Cairo, Egypt

P177  Spectrum of Enteral Access Procedures for Perioperative Nutritional Management of Oral Cancer Patients  
Ashish Jakhetiya, All India Institute of Medical Sciences, New Delhi, India

HEPATOBILIARY CANCER POSTERS

P178  Changing Treatment Patterns of Early Hepatocellular Carcinoma  
Sanjay Mohanty, Department of Surgery, Henry Ford Hospital, Detroit, MI

P179  The Impact of Perioperative Red Blood Cell Transfusion on Long-Term Survival After Hepatectomy for Colorectal Liver Metastases  
Julie Hallet, Odette Cancer Centre - Sunnybrook Health Sciences Centre, Toronto, ON, Canada

P180  Non-Invasive Radiofrequency-Induced Hyperthermia Selectively Increases Tumor Vascular Permeability  
Jason Ho, Baylor College of Medicine, Houston, TX

P181  Analysis of Nodal Status and Survival in Early T-Stage Gallbladder Cancers in the Modern Era  
Michael White, City of Hope, Arcadia, CA

P182  Can Contrast-Enhanced MRI using Gadoxetate Disodium (Eovist) Replace Triphasic CT to Derive Future Liver Remnant?  
Viet Le, Greenville Health System, Piedmont, SC

P183  Addition of Hepatic Arterial Infusional Floxuridine to Adjuvant Chemotherapy After Colorectal Liver Metastasis Resection is Associated with Altered Patterns of Disease Progression, Cause of Death and Prolonged Survival  
Matthew Porembka, UT Southwestern Medical Center, Dallas, TX
P184 Effect of Epidural Compared to Patient-Controlled Intravenous Analgesia on Outcomes for Patients Undergoing Hepatectomy
Shelby Allen, Wake Forest School of Medicine, Winston Salem, NC

P185 Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases
Georgios A. Margonis, Johns Hopkins Hospital, Baltimore, MD

P186 Neutrophil-lymphocyte and Platelet-Lymphocyte Ratio in Patients After Resection for Hepato-Pancreato-Biliary Malignancies
Timothy Pawlik, Johns Hopkins Hospital, Baltimore, MD

P188 Management and Outcomes of Patients with Recurrent Intrahepatic Cholangiocarcinoma Following Previous Curative Intent Surgical Resection
Gaya Spolverato, Johns Hopkins Hospital, Baltimore, MD

P190 Short-Term and Long-Term Results of Patients with Colorectal Liver Metastases Undergoing Surgery With or Without RFA
Martinus Amerongen, Radboud University Medical Center, Nijmegen, Netherlands

P191 HBV and HCC Screening Practices in Immigrant-Rich Neighborhoods of New York City
Simon Fitzgerald, Icahn School of Medicine at Mount Sinai, New York, NY

P192 Hepatic Artery Infusion for Recurrent or Chemo-Resistant Hepatic Malignancy
Harold Wanebo, Landmark Medical Center, Bristol, Puerto Rico

P193 AST to Platelet Ratio Index Improves Prediction of Hepatocellular Carcinoma Mortality
Kelvin Allenson, UTHealth, Houston, TX

P194 A Retrospective Review of the University Health Network (UHN) Multimodal Treatment Experience with Extended Resection of Pancreatic Ductal Adenocarcinoma (PDAC) in Patients with Arterial Involvement
Amélie Tremblay St-G., Department of Surgery, Toronto General Hospital, University of Toronto, Toronto, ON, Canada
P196 Survival of Patients with Colorectal Liver Metastases Treated with Electrochemotherapy
Ibrahim Edhemovic, Institute of Oncology Ljubljana, Ljubljana, Slovenia

P197 Regional Disparities in the Surgical Treatment of Gallbladder Cancer
Michael White, City of Hope, Arcadia, CA

P198 Biologic Mesh Spacer Placement Facilitates Safe Delivery of Dose-Intense Radiation Therapy: A Novel Treatment Option for Unresectable Liver Tumors
Hishaam Ismael, University of Texas MD Anderson Cancer Center, Houston, TX

P199 Initial Experience with a Surgeon-Led Hepatic Arterial Pump Program
Neil Saunders, The Ohio State University, Wexner Medical Center, Columbus, OH

P200 Ki67 Score can Predict Benefit for Different Transarterial Liver-Directed Therapies in Patients with Metastatic Neuroendocrine Tumors
Smit Singla, Roswell Park Cancer Institute, Buffalo, NY

P201 Multimodality Adjuvant Therapy is Associated with Improved Overall Survival Following Resection for Extrahepatic Cholangiocarcinoma in Patients with Positive Margins or Lymph Node Metastases
Susan Sharpe, University of Chicago, Chicago, IL

P202 Colorectal Cancer Liver Metastases: Does TACE, Radioembolization Add a Survival Benefit to Resection?
Aaron Lewis, City of Hope, Duarte, CA

P203 Major Liver Resections Followed by Radioembolization: Is It Safe?
Aaron Lewis, City of Hope, Duarte, CA

P205 A Comparative Analysis of Transarterial Therapy for Unresectable Hepatocellular Carcinoma with Portal Vein Thrombosis: Radioembolization (90Y) versus Doxorubicin Drug Eluting Beads (DEBDOX)
Prejesh Philips, University of Louisville, Louisville, KY

P206 Outcomes of Liver-Directed Therapy for Metastatic Carcinoid Tumors
John Hamner, City of Hope National Medical Center, Duarte, CA

P207 Treatment of Metastatic Neuroendocrine Tumors (NET) with Transarterial Chemoembolization Using Doxorubicin-Eluting Beads (DEBDOX)
Murwarid Assifi, University of Pittsburgh Medical Center, Pittsburgh, PA
P208 Delayed Gastric Emptying Following Classic and Pylorus Preserving Pancreaticoduodenectomy: A Meta-Analysis and Systematic Review
Krishnaraj Mahendraraj, St Barnabas Medical Center, West Orange, NJ

P209 Hepatocellular Carcinoma in the Pediatric Population: A Population-Based Clinical Outcomes Study Involving 257 Patients
Christine Lau, St. Barnabas Medical Center, West Orange, NJ

MELANOMA CANCER POSTERS

P210 Validation of a Nomogram to Predict Sentinel Lymph Node Metastases in Melanoma in Israeli Population
Helena Moshe, Radioguided Surgery Unit Division of Surgery Tel-Aviv Sourasky Medical Center, Sackler School of Medicine, Tel-Aviv, Israel

P211 Melanoma Outcomes based on Histologic Subtype: A Review of the National Cancer Database
Halle Ellison, Geisinger Medical Center, Danville, PA

P212 The Long-Term Risk of Upper Extremity Lymphedema is Two-Fold Higher in Breast Cancer Compared to Melanoma Patients
Rachel Voss, The University of Texas MD Anderson Cancer Center, Houston, TX

P214 Increased Visceral to Subcutaneous Fat Ratio is Associated with Decreased Overall Survival in Patients with Metastatic Melanoma Receiving Antiangiogenic Therapy
Valerie Grignol, Ohio State University, Hilliard, OH

P215 Management of Melanoma in the Elderly: The Impact of Increasing Age
Matthew Rees, Division of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

P216 Anti-tumor Immunity and Improved Survival with Combination of Immune Checkpoint Blockade and Local Chemotherapy
Jamie Green, Memorial Sloan Kettering Cancer Center, New York, NY

P217 In vivo Tracking of Site-Directed, Heat-Inducible Nanodelivery Vectors: Implications for Cancer ImmunoTherapy
Christopher Loo, University of Hawaii, Honolulu, HI
P218  The Impact of Sun-Avoidance Advice and Vitamin D Levels at a Tertiary Referral Melanoma Service
Marc Moncrieff, Norfolk & Norwich University Hospital, Norwich, United Kingdom

P219  Suppression of CXCL10 Affects Migration, Invasion and Apoptosis in the Polymetastatic PheNotype of a Melanoma Mouse Model
Sean Wightman, University of Chicago, Chicago, IL

P220  Adverse Events Following Lymph Node Dissection for Melanoma: A Systematic Review and Meta-analysis
Haytham Alabbas, McGill University, Montreal, QC, Canada

P221  The Contemporary Role of Major Amputation in the Management of Advanced Limb Melanoma
John Thompson, Melanoma Institute Australia, Sydney, NSW, Australia

P222  External Iliac Sentinel Nodes in Lower Extremity Melanoma are Frequent but Rarely Impact Staging
Jennifer Tseng, Oregon Health and Science University, Portland, OR

P223  Outcome for Melanoma Patients Whose Sentinel Node Biopsy was Cancelled After Preoperative Lymphoscintigraphy
Norbertus Ipenburg, Melanoma Institute Australia, Sydney, NSW, Australia

P224  Patient Outcome and Detailed Pathologic Examination of Negative Completion Lymph Node Dissection Specimens in Melanoma Patients with Minimal (<0.1mm) Sentinel Node Metastases
Lodewijka Holtkamp, Melanoma Institute Australia, North Sydney, NSW, Australia

P225  A High Rate of TP53 Mutation Identified in Patients with Advanced Melanoma using Next Generation Sequencing
Edmund Bartlett, University of Pennsylvania, Philadelphia, PA

P226  Cutaneous Head and Neck Melanoma (CHNM) in OPTIM: A Randomized Phase 3 Trial of Talamogene Laherparepvec (T-VEC) versus GM-CSF for the Treatment of Unresected Stage IIIIB/C and IV Melanoma
Robert Andtbacka, University of Utah Huntsman Cancer Institute, Salt Lake City, UT
<table>
<thead>
<tr>
<th>Posters</th>
<th>Title</th>
<th>Authors</th>
<th>Institution/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>P227</td>
<td>Outcomes Following Lymphoscintigraphy Without Sentinel Node Biopsy in Patients Who are Elderly or Have Medical Comorbidities</td>
<td>Norbertus Ipenburg, Melanoma Institute Australia, Amsterdam, Netherlands</td>
<td></td>
</tr>
<tr>
<td>P228</td>
<td>Scalp Melanoma: Role for Enhanced Detection Through Professional Training</td>
<td>Maria Russell, Emory University, Atlanta, GA</td>
<td></td>
</tr>
<tr>
<td>P229</td>
<td>Pediatric Melanoma: An Age-Based Analysis of the National Cancer Database</td>
<td>Patrick Lorimer, Levine Cancer Institute, Charlotte, NC</td>
<td></td>
</tr>
<tr>
<td>P230</td>
<td>Nodal Positivity Does Not Affect Survival in Pediatric Patients with Melanoma</td>
<td>Patrick Lorimer, Levine Cancer Institute, Charlotte, NC</td>
<td></td>
</tr>
<tr>
<td>P231</td>
<td>Intraoperative Real-Time Visualization of Sentinel Lymph Nodes Through a Novel Binocular Goggle-Assisted Imaging Navigation in Surgery System</td>
<td>Matthew Strand, Washington University in St. Louis, Department of Surgery, St. Louis, MO</td>
<td></td>
</tr>
<tr>
<td>P232</td>
<td>Oligometastatic Disease in AJCC Stage IV Melanoma: Incidence and Outcomes of Primary Surgical Resection</td>
<td>Marc Moncrieff, Norfolk &amp; Norwich University Hospital, Norwich, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>P233</td>
<td>T3JAM is a Novel Regulator of Tumor Growth</td>
<td>Jennifer Samples, Department of General Surgery, University of North Carolina, Durham, NC</td>
<td></td>
</tr>
<tr>
<td>P234</td>
<td>Gene Expression Profile Test Adds Prognostic Information in Management of Primary Melanoma</td>
<td>Eddy Hsueh, Saint Louis University, St. Louis, MO</td>
<td></td>
</tr>
<tr>
<td>P235</td>
<td>Risk of Second Primary Malignancies Increases with Melanoma Breslow Thickness</td>
<td>Alex Varey, Melanoma Institute Australia, North Sydney, NSW, Australia</td>
<td></td>
</tr>
<tr>
<td>P236</td>
<td>Outcomes After Lymphadenectomy in Obese and Non-Obese Patients with Melanoma: An Analysis of ACS-NSQIP Data</td>
<td>Tasha Hughes, Rush University Medical University, Chicago, IL</td>
<td></td>
</tr>
<tr>
<td>P237</td>
<td>Is Skin Graft for Melanoma Associated with Increased Risk of Local and In-Transit Recurrence?</td>
<td>Charles Kimbrough, Department of Surgery, University of Louisville, Louisville, KY</td>
<td></td>
</tr>
<tr>
<td>P238</td>
<td>Topical Diphencyprone for the Treatment of In-Transit Melanoma Metastases of the Skin</td>
<td>Jennifer Garioch, Norfolk &amp; Norwich University Hospital, Norwich, Norfolk, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>ID</td>
<td>Title</td>
<td>Authors</td>
<td></td>
</tr>
<tr>
<td>-----</td>
<td>-------------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>P239</td>
<td>Gene Expression Profile (GEP) Enhances Prognostic Value of Sentinel Lymph Node Biopsy (SLNB) in a Cohort of Patients with Head and Neck Melanoma</td>
<td>Maggie Diller, <em>Winship Cancer Institute of Emory University</em>, Atlanta, GA</td>
<td></td>
</tr>
<tr>
<td>P240</td>
<td>Incidence of Neuropathic Pain and Quality of Life in Melanoma Patients After Primary Surgery: A Multicenter Study</td>
<td>Marc Moncrieff, <em>Norfolk &amp; Norwich University Hospital</em>, Norwich, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>P241</td>
<td>A UK Feasibility and Validation Study of the VE1 Monoclonal Antibody Immunohistochemistry Stain for BRAF V600 Mutations in Metastatic Melanoma Patients</td>
<td>Marc Moncrieff, <em>Norfolk &amp; Norwich University Hospital</em>, Norwich, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>P242</td>
<td>Risk of Sentinel Lymph Node Metastasis in “Truly” Thin Melanoma</td>
<td>Garth Herbert, <em>Memorial Sloan Kettering Cancer Center</em>, New York, NY</td>
<td></td>
</tr>
<tr>
<td>P243</td>
<td>Completion Lymph Node Dissection or Observation for Melanoma Sentinel Lymph Node Metastases: A Decision Analysis</td>
<td>Erin Burke, <em>University of Minnesota</em>, Minneapolis, MN</td>
<td></td>
</tr>
<tr>
<td>P244</td>
<td>Breslow Thickness and Ulceration Do Not Predict Melanoma-Specific Survival in Patients with Melanoma &gt;4mm Thick Undergoing Sentinel Lymph Node Biopsy</td>
<td>David Gyorki, <em>Peter MacCallum Cancer Centre</em>, Melbourne, VIC, Australia</td>
<td></td>
</tr>
<tr>
<td>P245</td>
<td>Surgical Treatment of Melanoma in Elderly: Do We Follow NCCN Guidelines?</td>
<td>Saad Ajmal, <em>Brown University</em>, Providence, RI</td>
<td></td>
</tr>
<tr>
<td>P246</td>
<td>Association Between Durable Response (DR) and Overall Survival (OS) in Patients (pts) with Unresected Stage IIIB-IV Melanoma Treated with Talimogene Laherparepvec (T-VEC) in the Phase 3 OPTIM Trial</td>
<td>Howard Kaufman, <em>Rutgers Cancer Institute of New Jersey</em>, New Brunswick, NJ</td>
<td></td>
</tr>
<tr>
<td>P247</td>
<td>Demographic and Socioeconomic Disparities in the Presentation and Management of Melanoma: A National Perspective</td>
<td>Zaid Al-Qurayshi, <em>Tulane University School of Medicine</em>, Department of Surgery, New Orleans, LA</td>
<td></td>
</tr>
<tr>
<td>P248</td>
<td>Sentinel Lymph Node Biopsy in Thin Melanoma: A Systematic Review and Meta-Analysis</td>
<td>Erin Cordeiro, <em>The Ottawa Hospital</em>, Ottawa, ON, Canada</td>
<td></td>
</tr>
</tbody>
</table>
**P249** Pediatric Melanoma: Staging, Surgery and Mortality in the Surveillance, Epidemiology and End Results (SEER) Database
Patrick Lam, Howard University College of Medicine, Silver Spring, MD

**P250** Prognostic Factors Vary After Conditional Survival in a Large Cohort of Stage III Melanoma Patients (n=4586)
Lauren Haydu, The University of Sydney, Houston, TX

**P252** Molecular Profiling in Malignant Melanoma: Initial Experience at an NCI-designated Cancer Center
Nandini Kulkarni, Fox Chase Cancer Center, Philadelphia, PA

**P253** Is a Wider Margin (2 cm versus 1cm) for a 1.0-2.0 mm Thick Melanoma Necessary?
Matthew Doepker, Moffitt Cancer Center, Tampa, FL

**P254** Robotic Pelvic Lymphadenectomy for Metastatic Melanoma
Andrea Abbott, Moffitt Cancer Center, Tampa, FL

**P255** Hepatic Progression Free and Overall Survival After Regional Therapy to the Liver for Metastatic Melanoma
Andrea Abbott, Moffitt Cancer Center, Tampa, FL

**P256** Primary Overall Survival (OS) from OPTIM, a Randomized Phase 3 Trial of Talimogene Laherparepvec (T-VEC) Versus Subcutaneous (SC) Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for the Treatment of Unresected Stage IIIB/C/IV Melanoma
Howard Kaufman, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

**P257** Utility of Sentinel Node Biopsy in Patients with T4 Melanoma
Katherine Shoush, University of North Carolina at Chapel Hill, Chapel Hill, NC

**P258** NanoString Analysis Prediction of Outcome in a Prospective Trial of Tumor Infiltrating Lymphocytes (TIL) Therapy
Sangeetha Prabhakaran, Moffitt Cancer Center, Tampa, FL

**P259** Neurotropic Melanomas: Clinical Behavior and Radiotherapy Responsiveness
Alex Varey, Melanoma Institute Australia, North Sydney, NSW, Australia

**P260** Does Serum Vitamin D Level Show a Durable Correlation with Outcome of Locoregional Melanoma?
Simon Lavotshkin, John Wayne Cancer Institute at Saint John’s Health Center, Santa Monica, CA
P261  Is it Time for a Shift in the Treatment of Advanced Resectable Stage III and Stage IV Oligometastatic Melanoma? Results of a Pilot Trial and Plans for a Randomized Trial of Neoadjuvant Therapy Versus Upfront Surgery
Jennifer Wargo, UT MD Anderson, Houston, TX

QUALITY IMPROVEMENT/CLINICAL OUTCOMES POSTERS

P262  The Impact of Neoadjuvant Chemotherapy and Extended Lymphadenectomy on Outcomes of Gastrectomy Performed for Malignancy
David Lee, John Wayne Cancer Institute, Santa Monica, CA

P263  Structural Characteristics of Cancer Programs are Associated with increased Mortality After Cancer Surgery
Bradley Reames, University of Michigan, Ann Arbor, MI

P264  Development of Effective Prophylaxis Against Intraoperative Carcinoid Crisis
Eugene Woltering, Louisiana State University Health Sciences Center New Orleans, Kenner, LA

P265  An Outcomes Analysis Using Cost-Utility Comparing the Sartorius Flap versus VAC Therapy for the Definitive Treatment of the Postoperative Infected Groin Wound
Abhishek Chatterjee, University of Pennsylvania, Drexel Hill, PA

P266  Preoperative Leukopenia is Not Associated with Postoperative Outcomes in Cancer Patients Undergoing Abdominal Surgery: A Retrospective Cohort Study
Lindy Davis, Baystate Medical Center/Tufts University School of Medicine, Springfield, MA

P267  Impact of Restricted Fluid Administration During Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion on Perioperative Outcomes
James Padussis, University of Pittsburgh Medical Center, Pittsburgh, PA

P268  Volume-Outcomes and Resource Utilization in Esophagus and Pancreas Cancers
Mark Healy, University of Michigan, Ann Arbor, MI

P269  ACGME Complex General Surgical Oncology Accreditation: Attitudes and Perceptions of Current and Future Fellows
David Lee, John Wayne Cancer Institute, Santa Monica, CA
P270  The Management of Small Asymptomatic Pancreatic Neuroendocrine Tumors: A Matched Case-Control Study
Eran Sadot, Memorial Sloan Kettering Cancer Center, New York, NY

P271  Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy Perfusion for Carcinomatosis: 100 Cases at a Single Institution
Gary Mann, University of Washington, Seattle, WA

P272  Quality Improvement in Mastectomy Processing: Routine Use of a Standardized Mastectomy Diagram by Surgeons Improves Accuracy and Timeliness of Final Pathology Report
Jennifer Bishop, Stamford Hospital, Stamford, CT

P273  Maastricht Delphi Consensus on Event Definitions for Classification of Recurrence in Breast Cancer Research
Martine Moossdorff, Maastricht University Medical Center, Maastricht, Netherlands

P274  Relative Incidence of Uterine Sarcoma and Surgical Treatments for Fibroids
Michaela Dinan, Duke Cancer Institute, Durham, NC

P275  Comparison of Observed to Predicted Outcomes Using the ACS NSQIP Universal Risk Calculator in Patients Undergoing Pancreatoduodenectomy
Harveshp Mogal, Wake Forest School of Medicine, Winston Salem, NC

P276  Cancer Care in Low- and Middle-Income Countries: Surgical Workforce Limitations
Andre Ilbawi, MD Anderson Cancer Center, Houston, TX

P277  Does the Axillary Approach for Robotic Thyroidectomy Affect Subsequent Breast Screening and/or Axillary Staging?
Angela Chen, University of Pittsburgh, Breast Surgery, Pittsburgh, PA

P278  Air-bubble Sign is Useful to Detect Anastomotic Leakage After Esophagectomy
Yoshiaki Shoji, Keio University, Tokyo, Japan

P279  Factors Associated with Mortality After Surgical Oncologic Emergencies
Marianne Bosscher, University Medical Center Groningen, Groningen, Netherlands

P280  The Impact of Epidural Analgesia on the Rate of Venous Thromboembolism Without Chemical Thromboprophylaxis in Major Oncology Surgery
Nicholas Manguso, Cedars-Sinai Medical Center, Los Angeles, CA
P281 Determinants of the Type of Oncologists Providing Breast Cancer Follow-Up
Heather Neuman, University of Wisconsin School of Medicine and Public Health, Madison, WI

P282 Are Clinical Guidelines for the Management of Intraductal Papillary Mucinous Neoplasms Followed? A Single Center Analysis
Parissa Tabrizian, Surgery, Mount Sinai Medical Center, New York, NY

P283 Inconsistent Selection and Definition of Local and Regional Endpoints in Breast Cancer Research
Martine Moossdorff, Maastricht University Medical Center, Maastricht, Netherlands

P284 The ACS-NSQIP Surgical Risk Calculator Lacks Enough Sensitivity to Risk Stratify Patients with Gastric Cancer at Academic Medical Centers
Neil Saunders, The Ohio State University, Wexner Medical Center, Columbus, OH

P285 Isolated Chemotherapeutic Perfusion as Neoadjuvant Therapy for Advanced/Unresectable Pelvic Malignancy
Harold Wanebo, Landmark Medical Center, Bristol, Puerto Rico

P286 Inability to Return Home and Hospital Readmission are Frequent Among Patients with Disseminated Malignancy Undergoing Surgical Intervention
Sarah Bateni, University of California, Davis, Sacramento, CA

P287 Should a Resident Participate in My Cancer Operation? Elucidating Trainee Level Effect on Oncologic Surgery Outcomes
Megan Sippey, East Carolina University, Greenville, NC

P288 Metabolic Complications of mTOR Inhibitors in Solid Tumor Patients: A Meta-Analysis and Systematic Review
Sungyub Lew, Saint Barnabas Medical Center, Millburn, NJ

P289 Long-Term Patient-Reported Symptoms and Quality of Life Outcomes are Favorable Following Resection of Pancreatic Neoplasms
Hop Tran Cao, U.T. MD Anderson Cancer Center, Bellaire, TX

P290 Palliative Care Training in Surgical Oncology and Hepatobiliary Fellowships: A National Survey of Program Directors
Gregory Larreix, Medical College of Wisconsin, Milwaukee, WI
P291 A Novel Prediction Tool for Major Complications After Cytoreductive Surgery and HIPEC
Joel Baumgartner, University of California, San Diego, La Jolla, CA

P292 Venous Thromboembolism Prophylaxis: Differences in Practice Patterns in Two Institutions Within a Single Health System
Nandini Kulkarni, Fox Chase Cancer Center, Philadelphia, PA

P293 Transitional Care Needs Predict Worse Survival After Cancer Surgery
Meredith Mason, Baylor College of Medicine, Houston, TX

P294 Preoperative Risk Assessment Tool to Predict Worse Outcomes in Patients with Serious Complications After Major Oncologic Surgery
Rebecca Tuttle, Roswell Park Cancer Institute, Lancaster, NY

P295 Barriers to Cancer Care at a District Hospital in Rural Cameroon
Andre Ilbawi, MD Anderson Cancer Center, Houston, TX

P296 Improving Quality Measure Adherence: Non-Compliance Timeline Analysis in Adjuvant Therapy Timing in Colorectal and Breast Cancer
Omar Rashid, H. Lee Moffitt Cancer Center, Tampa, FL

P297 Delayed Recovery After Surgery Does Not Impact Long-Term Health-Related Quality of Life in Cancer Patients
Meredith Mason, Baylor College of Medicine, Houston, TX

P298 Increasing Incidence Rates and Worse Outcome Measures in Patients with Hepatocellular Carcinoma Initially Diagnosed at Safety Net Hospitals
Ali El Mokdad, UT Southwestern Medical Center, Dallas, TX

P299 Chemotherapy Utilization among Patients with Metastatic Colon Cancer: The Relevance of Insurance Status
Meredith Mason, Baylor College of Medicine, Houston, TX

P300 Multidisciplinary Tumor Board Evaluation of Hepatocellular Carcinoma Leads to Increased Treatment Delivery and Improved Overall Survival
Daniel Anaya, Baylor College of Medicine, Houston, TX
**P301** Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy with and without Early Postoperative Intraperitoneal Chemotherapy (EPIC): Matched Pair Analysis of Survival Outcomes
Grace Tan, National Cancer Centre Singapore, Singapore

**SARCOMA CANCER POSTERS**

**P302** Association of Rosacea and Angiosarcoma/Lymphangiosarcoma (AS/LAS)
Frank Johnson, St. Louis University Medical Center, St. Louis, MO

**P303** The Changing Epidemiology of Gastrointestinal Stromal Tumors (1992-2011)
Iris Wei, University of Michigan, Ann Arbor, MI

**P305** Primary Retroperitoneal Sarcomas (RPS): Rationale for Organ Resection
Mark Fairweather, Brigham and Women’s Hospital/Harvard Medical School, Boston, MA

**P306** Regional Lymph Node Metastasis from Epithelioid Sarcoma is Not Associated with Disease-Specific Survival
Mary Dillhoff, Ohio State University, Columbus, OH

**P307** Neoadjuvant Imatinib for Primary GIST: Mutational Status and Timing of Resection
Danielle Bischof, Department of Surgery, Mount Sinai Hospital, Toronto, ON, Canada

**P308** Early Results of Tissue Ablation with Irreversible Electroporation in Soft Tissue Tumors
Caleb Mentzer, Georgia Regents University, Augusta, GA

**P309** Validation of a Sarcoma Nomogram using a Cancer Registry
Nabil Wasif, Mayo Clinic Arizona, Phoenix, AZ

**P310** Determinants of Recurrence and Survival in Myxofibrosarcoma (MFS)
Nicole de Rosa, UT MD Anderson Cancer Center, Houston, TX

**P311** Validation of the Memorial Sloan Kettering Cancer Center Sarcoma Nomogram (MSKCCSN) for Sarcoma-Specific Mortality in an Asian Population
Deanna Ng, National Cancer Centre Singapore, Singapore

**P312** Vascular Surgery in Soft Tissue Sarcoma: Long-Term Prognosis and Functional Outcome in a Large Series of Patients Treated at a Tertiary Center
Stefano Radaelli, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
P313  Soft Tissue Sarcomas in the United States: An Analysis of 56,479 Cases Using the Surveillance, Epidemiology and End Results Program (SEER) from 2002-2011
Neeraja Nagarajan, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD

P314  Patterns of Systemic Relapse in Curatively Treated Soft Tissue Sarcomas: Long-Term Results from a Tertiary Care Cancer Centre
Jyoti Sharma, All India Institute of Medical Sciences, New Delhi, Delhi NCR, India

P315  Is F-18 Fluoro-2-deoxy-D-glucose Positron Emission Tomography (FDG-PET/CT) of Value in Soft Tissue Sarcoma Management?
Wayne Orr, UT MD Anderson Cancer Center, Houston, TX

P316  Recurrent Retroperitoneal Liposarcoma: At Which Point is Surgery No Longer Useful?
Nita Thiruchelvam, National Cancer Centre Singapore, Singapore

P317  Neoadjuvant Radiation Therapy for Retroperitoneal Sarcoma: A Systematic Review
Hao Cheng, Medical College of Wisconsin, Milwaukee, WI

P318  Clinicopathologic Comparison of Retroperitoneal Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma
Naruhiko Ikoma, UT MD Anderson Cancer Center, Houston, TX

P319  Impact of Chemotherapy on Survival in Surgically Resected Retroperitoneal Sarcoma: A United States Population-Based Analysis
John Miura, Medical College of Wisconsin, Milwaukee, WI

P320  Predicting Radiosensitivity in Soft Tissue Sarcoma Utilizing a Novel Molecular Scoring System
Andrea Abbott, Moffitt Cancer Center, Tampa, FL

P321  Predictors of Outcome in Primary and Recurrent Epithelioid Sarcoma
Omar Rashid, H. Lee Moffitt Cancer Center, Tampa, FL

P414  The Contribution of Local Treatment Measures to Control Imatinib-Resistant Liver Metastases of Gastrointestinal Stromal Tumors (GIST)
Peter Hohenberger, Div.of Surgical Oncology and Thoracic Surgery, Mannheim, Germany
P322 Promoter DNA Hypermethylation of CD01 Gene Predicts Poor Prognosis in Clinical Stage II/III Esophageal Squamous Cell Carcinoma
Hideki Ushiku, Kitasato University, Sagamihara, Kanagawa, Japan

P323 A Population-Based Examination of the Surgical Outcomes of Esophageal Sarcoma
Geena Wu, City of Hope National Medical Center, Duarte, CA

P324 Poor Survival Rate in Patients with Postoperative Pneumonia After Radical Esophagectomy for Esophageal Cancer
Eisuke Booka, Keio University, School of Medicine, Tokyo, Japan

P325 Treatment of Diaphragmatic Hernia Occurring After Transhiatal Esophagectomy
Sumana Narayanan, Rutgers Robert Wood Johnson, New Brunswick, NJ

P326 Ex Vivo Analysis of Human Esophageal Adenocarcinoma Demonstrated the Selective Infectivity of a Conditionally Replicative Oncolytic Adenovirus
Christopher LaRocca, University of Minnesota, Minneapolis, MN

P329 A Study of Relationship Between Neutrophil Lymphocyte Ratio and Postoperative Complications and Prognosis for Esophageal Cancer Patients
Yu Kigawasa, Keio University, Tokyo, Japan

P330 Ferredoxin Reductase is Useful for Predicting the Effect of Chemoradiation Therapy on Esophageal Squamous Cell Carcinoma
Hiroshi Okumura, Kagoshima University, Kagoshima, Japan

P331 Impact of Surgical Care on Survival in Esophageal Cancer
Chase Campbell, Carolinas Medical Center, Charlotte, NC

P332 Hedgehog Pathway Regulates a Putative Cancer Stem Cell-Like Population in Esophageal Cancer
Da Wang, Dept. of Surgical Oncology, University Medical Center Groningen, Groningen, Netherlands

P333 Impact of Surgeon Volume on Outcomes with Esophagectomy
Kenneth Meredith, University of Wisconsin, Madison, WI
P334 Pulmonary Metastasectomy for Soft Tissue Sarcoma at the National Cancer Institute of Mexico: The Value of Repeated Metastasectomy and Other Factors Associated with Prolonged Survival
Jose Francisco Corona-Cruz, Instituto Nacional de Cancerología, Mexico City, Mexico

P335 The Prognostic Value of Residual Nodal Disease Following Neoadjuvant Chemoradiation for Esophageal Cancer in Patients with Complete Primary Tumor Response
Aaron Blackham, Moffitt Cancer Center, Lutz, FL

P336 Outcomes Associated with Varying Approaches to Minimally Invasive Esophageal Resection
Andrea Abbott, Moffitt Cancer Center, Tampa, FL

P337 Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Neoadjuvant Therapy: Do Thoracic and Abdominal Approaches Differ?
Peter Kneuertz, Department of Surgery, University of Texas Medical School at Houston, Houston, TX

P338 Laparoscopic Transhiatal Esophagectomy Improves Hospital Outcomes and Reduces Cost: A Single-Institution Cohort Analysis of Laparoscopic and Open Techniques
Brett Ecker, University of Pennsylvania Health System, Philadelphia, PA

P339 Tumor Differentiation and Lymph Node Ratio: Impact on Survival in Esophageal Cancer
Elizabeth Paulus, University of Miami Miller School of Medicine, Miami, FL

P340 Tumor Size Correlates with Mediastinal Lymph Node Metastasis After Robotic-Assisted Pulmonary Lobectomy for Non-small Cell Lung Cancer: Retrospective Analysis of 159 Consecutive Cases
Eric Toloza, Moffitt Cancer Center, Tampa, FL

UPPER GASTROINTESTINAL CANCER POSTERS

P341 Laparoscopic Gastrectomy with D2 Lymphadenectomy as a Standard Approach to Gastric Adenocarcinoma in a Community Setting
Vanessa Palter, University of Toronto, Toronto, ON, Canada

P342 Overexpression of Lysophosphatidylcholine Acyltransferase 1 and Concomitant Lipid Alterations in Gastric Cancer
Hirotoshi Kikuchi, Hamamatsu University School of Medicine, Hamamatsu, Japan
P343  Resource Utilization Following Total Gastrectomy: The Effect of Postoperative Adverse Events in 238 Patients
Luke Selby, Memorial Sloan Kettering Cancer Center, New York, NY

P344  The Impact of Adjuvant Therapy on Survival in Clinically Relevant Subsets of Patients with Pancreatic Head Cancer
Rebecca Snyder, Vanderbilt University, Nashville, TN

P345  Quality over Quantity: Psoas Muscle Density, Not Volume, Predicts NSQIP Serious Complications in a Prospective Study of Older Patients Undergoing Pancreatectoduodenectomy
Malini Sur, University of Chicago, Chicago, IL

P346  The Prognostic Value of Signet Ring Cell Histology in Resected Gastric Cancer
Lauren Postlewait, Division of Surgical Oncology, Emory University, Decatur, GA

P347  IDH1 Mutation in Small Bowel Adenocarcinoma
Carlos Chan, Massachusetts General Hospital, Boston, MA

P348  Preoperative Helicobacter Pylori Infection is Associated with Increased Survival After Resection of Gastric Adenocarcinoma
Lauren Postlewait, Division of Surgical Oncology, Emory University, Decatur, GA

P349  An Assessment of Feeding Jejunostomy Tube Placement at the Time of Resection for Gastric Adenocarcinoma: A 7-Institution Analysis of 837 Patients from the U.S. Gastric Cancer Collaborative
Lauren Postlewait, Division of Surgical Oncology, Emory University, Decatur, GA

P350  Exploration of Rural Disparities in Pancreas Cancer Staging and Mortality to Incidence Ratio in Illinois
Bridget Kistner, Southern Illinois University, Springfield, IL

P351  Value of Peritoneal Drain Placement After Total Gastrectomy for Gastric Adenocarcinoma: A Multi-Institutional Analysis from the U.S. Gastric Cancer Collaborative
Lauren Postlewait, Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Decatur, GA

P352  An Alarming Trend in the Incidence of Advanced Gastric Adenocarcinoma in Young Hispanic Males
Shaila Merchant, City of Hope National Medical Center, Duarte, CA
P353  A Novel Orthotopic Murine Model of Pancreatic Cancer: Recapitulation of Stromal and Immune Microenvironment  
Vikas Dudeja, University Of Minnesota, Minneapolis, MN

P354  Routine Feeding Jejunostomy Placement is Unnecessary Following Curative Resection for Gastric Cancer  
Andrew Blakely, Brown University/Rhode Island Hospital, Providence, RI

P355  Inhibition of Hypoxia Inducible Factor-1α in Pancreatic Adenocarcinoma Attenuates Phenotypic Polarization of Tumor-Associated Macrophages  
Jeniann Yi, University of Colorado, Aurora, CO

P356  Early Surgical Bypass versus Endoscopic Stent Placement in Pancreatic Cancer  
Lindsay Bliss, Beth Israel Deaconess Medical Center, Boston, MA

P357  What is the Accuracy of Preoperative Abdominal CT Staging for Gastric Cancer? A Population-based Analysis  
Daniel Kagedan, University of Toronto, Toronto, ON, Canada

P358  Effect of Complications After Pancreaticoduodenectomy on Adjuvant Therapy Utilization and Survival in Pancreatic Cancer  
Dima Hnoosh, University Of Kentucky, Lexington, KY

P359  Defining the Optimal Timing of Adjuvant Therapy for Resected Pancreatic Cancer: A Statewide Cancer Registry Analysis  
Hayder Saeed, University of Kentucky-Markey Cancer Center, Lexington, KY

P360  Vitamin E δ-Tocotrienol (VEDT) Transiently Activates PI3K/AKT Signaling in Pancreatic Cancer Cells: Rationale for Inhibiting AKT Pathway with VEDT Therapy  
Evan Glazer, Moffitt Cancer Center, Tampa, FL

P361  Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis  
Amanda Kirane, UT Southwestern, Dallas, TX

P362  The Diagnostic Utility of Pancreatic Cyst Fluid Analysis  
Halle Ellison, Geisinger Medical Center, Danville, PA

P363  Improved Survival with Adjuvant Chemoradiotherapy versus Chemotherapy Alone in Resected Gastric Cancer in the United States: A Propensity-Matched Analysis  
Jashodeep Datta, University of Pennsylvania, Philadelphia, PA
P364  **Nodal Involvement in Gastric Adenocarcinoma Decreases with Age: A Population-Based Analysis**  
Ali Ahmad, Roger Williams Medical Center, Warwick, RI

P365  **Optimal Extent of Lymphadenectomy in Gastric Adenocarcinoma: A Seven-Institution Study of the U.S. Gastric Cancer Collaborative**  
Reese Randle, Wake Forest University, Winston-Salem, NC

P366  **Tumor Regression Grade in Gastric Cancer: Predictors and Impact on Outcome**  
Joyce Wong, Penn State Hershey Medical Center, Harrisburg, PA

P367  **The Impact of Neoadjuvant Therapy for Gastroesophageal Adenocarcinoma on Postoperative Morbidity and Mortality**  
John Mullen, Massachusetts General Hospital, Boston, MA

P368  **Chemotherapy is Not Indicated for Early Stage Pancreatic Adenocarcinoma**  
Katherine Ostapoff, Roswell Park Cancer Institute, Buffalo, NY

P369  **Integrin-linked Kinase Over-expression in the Pancreatic Stellate Cells of Pancreatic Cancer Stroma Portends a Poor Prognosis**  
Lawrence Shirley, The Ohio State University Wexner Medical Center, Columbus, OH

P370  **Effect of Neoadjuvant Chemotherapy on 30-day Morbidity and Mortality Following Resection of Gastric Malignancy**  
Kate Dinh, University of Massachusetts, Worcester, MA

P371  **Hypoxia in Pancreatic Cancer Microenvironment Interacts with Metabolic and EMT Features to Define Prognostic Subtypes**  
Nicholas Borja, UT-Southwestern, Dallas, TX

P372  **Delayed Gastric Emptying (DGE) After Pylorus Preserving Pancreatoduodenectomy (PPPD): Does Gastrointestinal Reconstruction Technique Matter?**  
Mena Hanna, University of Miami-Miller School of Medicine, Miami, FL

P373  **Adherence to Expected Treatment for Pancreatic Cancer Improves Outcomes**  
Lee Ocuin, UPMC, Pittsburgh, PA

P374  **Clonal Composition and Selection During PanIN Progression**  
Kelly Lafaro, Memorial Sloan Kettering Cancer Center, New York, NY
<table>
<thead>
<tr>
<th>POSTERS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>P375</strong> Prognostic Value of the Circumferential Resection Margin After Neoadjuvant Treatment in Esophageal Cancer Patients</td>
</tr>
<tr>
<td><strong>P376</strong> Targeting Pancreatic Cancer with Sigma-2/Erastin Conjugate SW V-49s</td>
</tr>
<tr>
<td><strong>P377</strong> Age Bias and Under-Treatment in Octogenarians with Pancreatic Cancer</td>
</tr>
<tr>
<td><strong>P378</strong> Multimodality Management of Borderline Resectable Pancreatic Neuroendocrine Tumors; Sentinel Report of a Single Institutional Experience</td>
</tr>
<tr>
<td><strong>P380</strong> Single Cell Mutational Analysis of Isolated Circulating Tumor Cells in Pancreatic Cancer</td>
</tr>
<tr>
<td><strong>P381</strong> Myofibroblast Expression of Smooth Muscle Actin in Pancreatic Cancer Correlates with Changes in the Immune Infiltrate Following Neoadjuvant Therapy</td>
</tr>
<tr>
<td><strong>P382</strong> Implementation of a Surgical Oncology Robotics Program: Safe with Progressive Improvement, Expansion and Growth</td>
</tr>
<tr>
<td><strong>P383</strong> Profiling of Mucins in Pancreatic Juice</td>
</tr>
<tr>
<td><strong>P384</strong> Key Metabolic Pathways are Upregulated in Pancreatic Cancers from Obese Patients</td>
</tr>
<tr>
<td><strong>P385</strong> The Prognostic Added-Value of FDG-PET in the Staging of Gastric Adenocarcinoma</td>
</tr>
<tr>
<td><strong>P386</strong> Underreporting of Gastrointestinal Stromal Tumors to the National Cancer Registry: Is the True Incidence Being Captured?</td>
</tr>
</tbody>
</table>
P387  Number of Evaluated Lymph Nodes, Number of Positive Lymph Nodes, Lymph Node Ratio and Log Odds: Numerology or Valid Indicators of Pancreatic Ductal Adenocarcinoma (PDAC) Patient Outcome?  
Guy Lahat, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

P388  MicroRNA Profiling of Pancreatic Ductal Adenocarcinoma (PDAC) Reveals Signature Expression Related to Lymph Node Metastasis  
Guy Lahat, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

P389  Omental Spread of GI Malignancies: New Insights and Potential Therapeutic Strategies  
Guy Lahat, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

P390  Role of Multivisceral Resection in the Management of Gastrointestinal Stromal Tumor  
Jolene Wong, National Cancer Centre, Singapore, Singapore

P391  A Population-Based Analysis of Risk Factors for Positive Resection Margins in Gastric Adenocarcinoma  
Maryam Elmi, Sunnybrook Health Sciences Center, Richmond Hill, ON, Canada

P392  Clinical Outcome of Surgical and Endoscopic Resection for Gastric Remnant Cancer  
Masazumi Inoue, Department of Surgery, School of Medicine, Keio University, Shinjyuku, Tokyo, Japan

P393  Efficacy of Photoimmunotherapy After Surgical Resection on a Pancreatic Cancer Patient Derived Orthotopic Xenograft (PDOX) Nude Mouse Model  
Ali Maawy, University of California San Diego, San Diego, CA

P394  Predicting Delayed Gastric Emptying After Pancreaticoduodenectomy for Enhanced Recovery After Surgery  
Aaron Saunders, Loma Linda University Medical Center, Loma Linda, CA

P395  7th AJCC Staging Classification Correlates with Biological Behavior of Pseudomyxoma Peritonei (PMP) Tumors Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)  
Vladimir Milovanov, Mercy Medical Center, Baltimore, MD
P397 Preoperative Inflammatory and Tumor Markers Associated with Outcomes in Patients with Appendiceal Neoplasms Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Maria Nunez, Mercy Medical Center, Baltimore, MD

P398 Adaptive Response of Pancreatic Cancer to Single Agent Kinase Inhibitor Therapies
Christopher Tignanelli, UNC - Chapel Hill, Morrisville, NC

P399 Importance of Anastomotic Site (AS) Resection During Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) in Patients with Peritoneal Carcinomatosis (PC) of Appendiceal Origin
Nail Aydin, Mercy Medical Center, Ellicott City, MD

P400 Preoperative CA 19-9 Does Not Correlate with Loco-Regional Tumor Cell Burden in Resectable Pancreatic Adenocarcinoma
John Bergquist, Mayo Clinic, Rochester, MN

P401 A Matched Cohort Analysis of 192 Pancreatic Anaplastic Carcinomas and 960 Pancreatic Adenocarcinomas: A 13-year North American Experience Using the National Cancer Database
Alessandro Paniccia, University of Colorado, Anschutz Medical Campus, Aurora, CO

P402 Depletion of Contaminating Murine Stromal Cells using Flow Cytometric Sorting of Human Pancreatic Cancer Xenografts
Karthika Divakaran, Medical College of Wisconsin, Milwaukee, WI

P403 Novel GeNotype-PheNotype Correlations in Patients with Hereditary Diffuse Gastric Cancer
Joal Beane, Indiana University School of Medicine, Dept of Surgery, Indianapolis, IN

P404 Factors Associated with Failure to Reach Surgical Resection in Patients Undergoing Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma
Ana Luiza Gleisner, UPMC, Pittsburgh, PA

P405 Adjuvant Chemotherapy for Adenocarcinoma of the Small Intestine in a Veteran Population: Minimal Impact on Survival
Somala Mohammed, Baylor College of Medicine, Houston, TX

P406 Nationwide Trends and Outcomes Associated with Neoadjuvant Therapy in Pancreatic Cancer: An Analysis of 18,243 Patients
Linda Youngwirth, Duke University Hospital, Durham, NC
P407  **An Immunomodulating Peptide that Enhances Gemcitabine Inhibition of Pancreatic Growth in the KRAS / p16 Mouse Model of Pancreatic Cancer**

Nicholas Schaub, Thoracic and GI Oncology Branch, Surgery Branch, National Cancer Institute, National Institutes of Health, Durham, NC

P408  **Level of Adherence to Processes of Care in the Treatment of Gastric Cancer: A Population Level Assessment**

Matthew Dixon, Maimonides Medical Center, Brooklyn, NY

P409  **Role of Inflammatory Monocyte Mobilization in Growth of Liver Metastasis in a Murine Model of Metastatic Pancreatic Cancer**

Roheena Panni, Washington University in St. Louis, St. Louis, MO

P411  **Gemcitabine Cooperates with TGFβ Inhibition to Effectively Suppress Tumor Growth in Genetically Engineered Mouse Models of Pancreas Cancer**

Nicholas Schaub, Thoracic and GI Oncology Branch, Surgery Branch, National Cancer Institute, National Institutes of Health, Durham, NC

P412  **Reducing Transfusion Rates in Major Oncologic Surgery: Preliminary Results of a Randomized, Double-Blind, Placebo-Controlled Trial using Preoperative Tranexamic Acid**

G. Paul Wright, GRMEP/Michigan State University, Grand Rapids, MI

P413  **Clinical Characteristics of Familial Pancreatic Cancer Kindreds: Comparable Staging at Presentation to Sporadic Pancreatic Cancer**

Murwarid Assifi, University of Pittsburgh Medical Center, Pittsburgh, PA
DISCLOSURE POLICY AND DISCLOSURES

In accordance with the ACCME’s Accreditation Criteria and the Society of Surgical Oncology (SSO) policy, all educational planners, presenters, instructors, moderators, authors, reviewers and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. This includes the disclosure of financial relationships of a spouse or partner. The ACCME considers financial relationships to create conflicts of interest when individuals have both a financial relationship with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest. The ACCME defines a commercial interest as “any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients.” ACCME does not consider providers of clinical service directly to patients to be commercial interests.

All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the SSO.

All identified conflicts of interest have been resolved.

The following faculty, moderators, planners, reviewers and staff have disclosed financial relationships with commercial interests:

**Jaffer A. Ajani, MD**
Advisory Board: Amgen, Celgene, Lilly; Consultant: Amgen, Celgene, Lilly; Research: Amgen, Bristol-Myers Squibb, Celgene, Lilly, Roche, Genentech, DFP, Novartis, Taiho

**Charles M. Balch, MD**
Consultant: Amgen, Merck, Inc.; Speaker Honorarium: Merck, Inc., Novartis

* = Planners and Reviewers  § = Moderators
* § Andrea V. Barrio, MD  
Speaker Honorarium: Genentech

* § David R. Brenin, MD  
Consultant: Insightec; Research: Teraclion

§ Murray F. Brennan, MD  
Advisory Board: Ziopharm Oncology; Consultant: Ziopharm Oncology; Stocks: Ziopharm Oncology

§ William G. Cance, MD  
Co-Founder: CureFaktor Pharmaceuticals, LLC

Sally E. Carty, MD  
Consultant: Chapter Book Author - Jaypee Brothers Publishing, Section Editor - UpToDate

* § George J. Chang, MD, MS  
Advisory Board: Ethicon; Consultant: Ethicon; Grant: Agenda; Research: Agenda

* § Anees Chagpar, MD, MSc, MA, MPH  
Research: Faxitron

* § David N. Danforth, Jr., MS, MD  
Stocks: Pfizer

Johannes H.W. De Wilt, MD, PhD  
Grant: Roche; Research: Roche

Justin Dimick, MD, MPH  
Other: Co-Founder – ArborMetrix

Jeffrey A. Drebin, MD, PhD  
Other: Patent Royalty - Roche Pharmaceuticals, Employee (Spouse) - GlaxoSmithKline; Stocks: ISIS Pharmaceuticals

§ James S. Economou, MD, PhD  
Stocks: Kite Pharma

Lee M. Ellis, MD  
Advisory Board: Eli Lilly, Genentech/Roche

* § Richard Essner, MD  
Advisory Board: Amgen, Merck, Inc.; Consultant: Merck, Inc.; Stocks: Amgen, Celgene, Pfizer

Yuman Fong, MD  
Consultant: Amgen, Covidien, Genelux, Johnson and Johnson, Perfint; Stocks: Genelux

* § Susan Galandiuk, MD  
Research: AbbVie, Excited States

* § Jeffrey E. Gershenwald, MD  
Advisory Board: Merck, Inc.; Other: Licensing - Mercator Therapeutics

* § Stephen R. Grobmyer, MD  
Speaker Honorarium: Carl Zeiss Meditec, Inc.; Travel Expenses: Carl Zeiss Meditec, Inc., Seno Medical

* = Planners and Reviewers  § = Moderators
* § Nora M. Hansen, MD
  Speaker Honorarium: Genentech

§ Martin J. Heslin, MD
  Consultant: Best Doctors; Grant: Genentech; Research: Genentech

* § Steven N. Hochwald, MD
  Consultant: Ethicon Endo-Surgery

Harald Hoekstra, MD, PhD
  Advisory Board: Amgen

Kevin S. Hughes, MD
  Honorarium: Myraid Genetics Speaker Bureau; Other: HughesRiskApps Risk Assessment Software. Founder and Own Equity; Stock: 5 AM Solutions

Melissa Hogg, MD
  Grant: Intuitive

* § E. Shelly Hwang, MD, MPH
  Advisory Board: Genomic Health

D. Rohan Jeyarajah, MD
  Consultant: Ethicon

§ Hong Jin Kim, MD
  Advisory Board: Ethicon Endo-Surgery; Speaker Honorarium: Sanofi-Aventis

Matthew F. Kalady, MD
  Consultant: Precision Therapeutics; Speaker Honorarium: Precision Therapeutics

* § Joseph Kim, MD
  Advisory Board: Genentech; Speaker Honorarium: Genentech, Novartis

V. Suzanne Klimberg, MD
  Research: Ascendant Diagnostic; Stocks: Ascendant Diagnostics

Henry M. Kuerer, MD, PhD
  Advisory Board: Lightpoint Medical Inc.; Research Funding: Genomic Health, Inc.

A. Marilyn Leitch, MD
  Consultant: Celgene

David C. Linehan, MD
  Research: Pfizer Oncology

Eleftherios (Terry) P. Mamounas, MD, MPH
  Advisory Board: Celgene, Eisai, Genomic Health, GlaxoSmithKline, GE Healthcare, Pfizer; Speaker Honorarium: Genomic Health, Genentech/Roche

Robert C.G. Martin, II, MD, PhD
  Consultant: Angiodynamics

* = Planners and Reviewers  § = Moderators
* David R. McCready, MD  
Stocks: Johnson & Johnson

Kelly M. McMasters, MD, PhD  
Other: Board of Directors - Provectus Biopharmaceuticals

Elizabeth A. Mittendorf, MD, PhD  
Research: Antigen Express, Galena Biopharma

* § John A. Olson, Jr., MD, PhD  
Other: Founder and Principle Shareholder - Core Prognostex

Mark E. Robson, MD  
Advisory Board: Bayer Health, Pfizer; Research: AbbVie, Astra-Zeneca

Merrick I. Ross, MD  
Advisory Board: GlaxoSmithKline, Merck, Inc.; Neostem/Viralytics; Consultant: GlaxoSmithKline, Merck, Inc.; Research: GlaxoSmithKline, Vestan, Inc.; Speaker Honorarium: Genomic Health, GlaxoSmithKline, Merck, Inc.

* § Michael S. Sabel, MD  
Advisory Board: Merck, Inc., IceCure

Mandeep S. Sawheny, MD, MS  
Other: Principal Investigator on a Training Grant - Boston Scientific; Stocks: Allurion, Inc.

* § Richard D. Schulick, MD, MBA  
Other: Milestone and Royalty Payments from licensing patent to Aduro Biotech. Managed and distributed by Johns Hopkins University - Aduro Biotech

Roderich E. Schwarz, MD, PhD  
Speaker Honorarium: Genentech, Novartis

Craig L. Slingluff, Jr., MD  
Advisory Board: Immatics Biotechnologies, Polynoma; Consultant: Immatics Biotechnologies, Polynoma; Grant: GlaxoSmithKline; Other: Inventor of peptides patented at UVA and licensed for use in peptide vaccines - UVA Licensing and Ventures Group; Research: GlaxoSmithKline, Merck, Inc., 3M

Vernon K. Sondak, MD  
Consultant: Amgen, Merck, Inc., MabVax, Oncosec, Polynoma, Provectus; Other: Data Safety Monitoring Board - Bristol-Myers Squibb, GlaxoSmithKline, Novartis; Speaker Honorarium: Merck, Inc.

Debu Tripathy, MD  
Consultant: Merck, Inc.; Research: Genentech/Roche

* = Planners and Reviewers  § = Moderators
The following faculty, moderators, planners, reviewers and staff have no relevant financial relationships to disclose:

Syed Ahmad, MD
* § Peter Allen, MD
* Thomas A. Aloia, MD
* Peter Angelos, MD, PhD
* § Charlotte E. Ariyan, MD, PhD
Deanna J. Attai, MD
* § Brian D. Badgwell, MD, MS
* § Glen C. Balch, MD
David L. Bartlett, MD
* § Adam C. Berger, MD
Karl Y. Bilimoria, MD, MS
Judy C. Boughey, MD
Pam Bowerman (Staff)
* § Mary S. Brady, MD
* § Kelli M. Bullard Dunn, MD
* § Glenda G. Callender, MD
* § Kenneth Cardona, MD
Jenny C. Chang, MD
Clifford S. Cho, MD
Jessica A. Cintolo, MD

* § Thomas E. Clancy, MD
Daniel G. Coit, MD
* Carol S. Connor, MD
* § Aimee M. Crago, MD, PhD
Charmaine Cummings, PhD, RN, CHCP (Staff)
* Kimberly M. Dalal, MD
* § Keith A. Delman, MD
Mashaal Dhir, MBBS
Gerard M. Doherty, MD
* § Timothy J. Eberlein, MD
* Fritz C. Eilber, MD
Laura J. Esserman, MD
* § David M. Euhus, MD
* § Douglas B. Evans, MD
Barry W. Feig, MD
* § Ryan C. Fields, MD
* Douglas Fraker, MD
Armando E. Giuliano, MD
* § Melanie Goldfarb, MD
Miral S. Grandhi, MD

* = Planners and Reviewers  § = Moderators
* Caprice C. Greenberg, MD, MPH
Rachel A. Greenup, MD, MPH
Alessandro Gronchi, MD
Travis E. Grotz, MD
B. Ashleigh A. Guadagnolo, MD, MPH
JoseGuadagnolo, MD, MPH
Niraj J. Gusani, MD, MS
John B. Hamner, MD
Ronda S. Henry-Tillman, MD
Daniel O. Herzig, MD
Hisakazu Hoshi, MD
Marissa Howard-McNatt, MD
Kelly K. Hunt, MD
Karen Hurley (Staff)
Patrick Hwu, MD
James W. Jakub, MD
Jacqueline S. Jeruss, MD, PhD
John M. Kane, III, MD
Brian J. Kaplan, MD
Matthew H.G. Katz, MD
Electron Kebebew, MD
Mark C. Kelley, MD, MMHC
Lawrence T. Kim, MD
Tari King, MD
David Kooby, MD
Swati Kulkarni, MD
Scott Kurtzman, MD
Laura A. Lambert, MD
Jeffrey E. Lee, MD
Augusto Leon, MD
J. Spencer Liles, MD
Nico Lopez, MD
Ajay V. Maker, MD
Gary N. Mann, MD
Paul F. Mansfield, MD
John C. Mansour, MD
Viraj Master, MD
Christopher R. McHenry, MD
Daniel P. McKellar, MD
Sarah A. McLaughlin, MD
Marcovalerio Melis, MD
Jane E. Mendez, MD
Nipun Merchant, MD
Masaru Miyazaki, MD, PhD
Jeffrey F. Moley, MD
Marc Moncrieff, MD
Masaki Mori, MD, PhD
Monica Morrow, MD
Vitor Moutinho, MD
Masato Nagino, MD, PhD
David M. Nagorney, MD
Jukes P. Nam, MD
Kelly Oino, MD
Ana Oliveira (Staff)
David W. Oillia, MD
T. Salewa Oseni, MD
Kepal N. Patel, MD
Phillip B. Paty, MD
Carlos A. Pellegrini, MD
Nicholas J. Petrelli, MD
Nancy D. Perrier, MD
Christopher M. Pezzi, MD
Sara M. Pirzadeh-Miller, MS, CGC
Raphael E. Pollock, MD, PhD
Andrea Porporiglia, MD
Mitchell C. Posner, MD
Douglas Reintgen, MD
John A.D. Ridge, MD, PhD
Nabil P. Rizk, MD
Maria Russell, MD
Rabih M. Saloum, MD
Ashok R. Shaha, MD
Christian M. Shaw, MD, MS
David Shibata, MD
Elin R. Sigurdson, MD, PhD
Barbara Lynn Smith, MD, PhD
Carmen C. Solorzano, MD
Julie Ann Sosa, MD, MA
Patti Stella, CHCP (Staff)
John H. Stewart, IV, MD
Karyn B. Stitzenger, MD, MPH
Vivian E. Strong, MD
Cord Sturgeon, MD
Sonia L. Sugg, MD
Carol J. Swallow, MD, PhD
Danny M. Takanishi, Jr., MD
Eric P. Tamm, MD
Larissa K.F. Temple, MD
Edrea Tesiorna (Staff)
Alastair M. Thompson, BSc (Hons), MB ChB, MD
Jennifer F. Tseng, MD, MPH

* = Planners and Reviewers  § = Moderators
The following oral abstract presenters and video presenters have disclosed relevant financial relationships with commercial interests:

**Robert Andtbacka, MD**
Speaker Honorarium: Amgen

**Celina Ang, MD**
Advisory Board: Caris Life Science

**Leigh Casadaban, MD**
Stocks: Johnson & Johnson

**Steven Curley, MD**
Advisory Board: Polaris Pharmaceuticals

**Eileen Rakovitch, MD**
Grant: Genomic Health

**Melodi Whitley, BS, BA**
Other: Lumicell – Co-held pending patent application

The following oral abstract presenters and video presenters have reported that they have no relevant financial relationships with commercial interests to disclose:

Zaid Abdelsattar, MD
Nicolas Ajkay, MD
Zeinab Alawadi, MD
Waddah Al-Refaie, MD
Rachel Aufforth, MD
Nail Aydin, MD
Vinod
Balachandran, MD
Gala Barden, MD
Andrea Barrio, MD
William Burns, MD
Abigail Caudle, MD, MD
Varun Chakravorty, MD
Aman Chauhan, MD

Akhil Chawla, MD
Douglas Chepeha, MD
Kevin Choong, MD
Callisia Clarke, MD
Guy Clifton, MD
Claudius Conrad, MD, PhD
Robert Crum, MD
Jashodeep Datta, MD
Jeremy Davis, MD
James De Andrade, MD
Sebastian Diaz-Botero, MD
Tarek El Amadieh, MD

* = Planners and Reviewers  § = Moderators
| Rachel Ellsworth, PhD  |
| Oliver Eng, MD        |
| Audrey Ertel, MD      |
| Ann Falor, MD         |
| Megan Fracol, MD      |
| Alexandra Gangi, MD   |
| Jennifer Gass, MD     |
| Amanda Goldin, MD     |
| Keith Gray, MD        |
| Julia Greene, MD      |
| Usmaan Hameed, MD     |
| Cristina Harnsberger, MD |
| Jennifer Harris, MD   |
| Peter Hohenberger, MD |
| James Jakub, MD       |
| Zeilka Jutric, MD     |
| Cary Kaufman, MD      |
| Karineh Kazazian, MD  |
| Kaitlyn Kelly, MD     |
| Yuji Kikuchi, MD      |
| Ashley Krepline, MD   |
| David Lee, MD         |
| Patrick Lorimer, MD   |
| Anthony Lucci, MD     |
| David Luyimbazi, MD   |
| Ajay V. Maker, MD     |
| Reema Mallick, MD     |
| Raoud Marayati, MD    |
| Jennifer Marti, MD    |
| Cindy Matsen, MD      |
| Sarah A. McLaughlin, MD |
| John Miura, MD        |
| Faina Nakhlis, MD     |
| Timothy Newhook, MD   |
| Daniel Nussbaum, MD   |
| Timothy Nywening, MD  |
| Charlotte Oude Ophuis, MD |
| Alessandro Paniccilla, MD |
| Anne Peled, MD        |
| Melissa Pilewskie, MD |
| Gary Point, BS, BA    |
| Lauren Postlewait, MD |
| Sangeetha Prabhakaran, MD |
| Melody Xuan Lu Qu, MD |
| Jennifer Racz, MD     |
| Omar Rashid, MD, JD   |
| Bradley Reames, MD, MS|
| Christina Roland, MD  |
| Christopher Scally, MD|
| Schlomo Schneebaum, MD|
| Mihir Shah, MD        |
| Ayako Shimada, MD     |
| Geert Simkens, MD     |
| Smit Singla, MD       |
| Jesse Joshua Smith, MD |
| Smith, MD, PhD        |
| Mediget Teshome, MD, MPH|
| Gregory Tiesi, MD     |
| Robert Torphy, BS     |
| Stephanie Valente, DO |
| Guusje Vugts, MD      |
| Heather Wachtel, MD   |
| Harold Wanebo, MD     |
| Peter White, MD       |
| Samantha White, MbChB |
| Geena Wu, MD          |
| Keishi Yamashita, MD, PhD |
| Jenny Yoo, MD         |
| Adam Yopp, MD         |
| Y. Nancy You, MD, MHSc|
| Salman Zaheer, MD     |

* = Planners and Reviewers  § = Moderators
INDUSTRY SATELLITE SYMPOSIA

Advances in Immunotherapy for Advanced Melanoma: Integrating Intralesional and Anti-PD-1 Immunotherapies into Current Practice

6:45 pm, Friday, March 27
Hilton, Ballroom of the Americas D (Level 2)
Dinner Provided

Programming to take place from 7-8 pm. Please arrive by 6:45 pm for registration.

Sponsored by Paradigm Medical Communications. Supported by Provectus Biopharmaceuticals, Inc. and Amgen, Inc.

This program is CME certified. There is no charge to attend this symposium.

Robert Andtbacka, MD, CM
Associate Professor, Division of Surgical Oncology, Department of Surgery
University of Utah School of Medicine
Surgeon and Investigator
Intermountain Healthcare, Huntsman Cancer Institute
Salt Lake City, UT

Sanjiv Agarwala, MD
Chief of Medical Oncology and Hematology
St. Luke’s University Hospital & Health Network
Bethlehem, PA
Professor of Medicine
Temple University School of Medicine
Philadelphia, PA

Kenneth F. Grossmann, MD, PhD
Assistant Professor, Division of Oncology, Department of Medicine
University of Utah
Medical Oncologist and Investigator, Melanoma and Cutaneous Oncology Program
Huntsman Cancer Institute
Salt Lake City, UT

Merrick I. Ross, MD
Professor of Surgery, Chief Melanoma Section
Charles M. McBride Distinguished Professor, Department of Surgical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX
Executive Summary

I. The Cancer Immunity Cycle
   • The antitumor immune response is a multi-step process
   • Release of tumor-derived antigens

II. Immune Evasion and Dysregulation in Melanoma
   • A surgeon’s perspective
   • Unique features of melanoma

III. Future Research Directions in Melanoma
   • New therapeutic strategies under investigation
   • Immunotherapy classes targeting the cancer immunity cycle: oncolytic immunoNotherapy, cytokines and checkpoint inhibitors

EXHIBIT HALL THEATER DEMONSTRATION

Ethicon
6:15-7 pm, Thursday, March 26
Exhibit Hall Theater, Exhibit Hall B3
If there was an award, we’d win it.

The Acculis Microwave Tissue Ablation System is the only single applicator system to complete a spherical 5 cm ablation in six minutes.†

Watch an animation of the Acculis MTA System at www.angiodynamics.com

†Based on 140 W, 6 min. ex-vivo bovine study—liver, +/- 0.5 cm. Bench Test results may not necessarily be indicative of clinical performance.


Acculis Accu2i pMTA 510-245

AngioDynamics, the AngioDynamics logo, Acculis and the Acculis logo are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate or a subsidiary.

INDICATIONS FOR USE: The Accu2i pMTA Applicator with Sulis VpMTA Generator Software release 2.1.0 is indicated for intraoperative coagulation of soft tissue.

CONTRAINDICATIONS: The Accu2i pMTA Applicators are contraindicated in patients with heart pacemakers and other electronic device implants.

CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician. Refer to instructions provided with product for all contraindications, warnings and potential complications.

© 2015 AngioDynamics, Inc. MLC 641 Rev A
EXHIBITS

The Exhibit Hall is located in Exhibit Hall B3

Hours
Thursday, March 26  12:15-7:30 pm
Friday, March 27    7 am-2:45 pm

Exhibit Hall Passport to Prizes
Visit SSO 2015 exhibitors to earn a chance to win exciting prizes!
As you make your way through the exhibit hall talking with the companies and visiting their booths, collect signatures on your Passport game card and enter to win. View full details on page 18.

As of February 27, 2015

Exhibitors

Agendia Inc.  Booth 333
22 Morgan
Irvine, CA 92618
Phone: 949-540-6300; Fax: 888-811-3404
www.agendia.com

Agendia's Symphony™ Personalized Breast Cancer Genomic Profile provides a suite of genomic assays to address complex treatment decisions for all types of breast cancer. Convenient to order in paraffin embedded or fresh tissue, Symphony results will help provide clear direction for indeterminate cases and definitive results so a personalized treatment decision can be made for each of your breast cancer patients. For more information, visit www.agendia.com.

Ambry Genetics  Booth 404
15 Argonaut
Aliso Viejo, CA 92656
Phone: 866-262-7943; Fax: 949-900-5501
www.ambrygenetics.com

Ambry Genetics is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified commercial clinical laboratory with headquarters in Orange County, California. Ambry is a leader in providing genetic services focused on clinical diagnostics and genomic services, and has established a reputation for unparalleled customer satisfaction. To learn more, visit www.ambrygen.com.
For more than 100 years, the American College of Surgeons has taken the lead to improve the quality of patient care. Through the Commission on Cancer (CoC) and the National Accreditation Program for Breast Centers (NAPBC) voluntary accreditation programs, patients can look for their seals of approval to identify providers who are committed to providing high-quality, data-driven, comprehensive and multidisciplinary patient care.

The American Society of Clinical Oncology is the world’s leading professional society of multidisciplinary medical professionals who treat people with cancer. Join ASCO while at the meeting and receive a free personalized pen and immediate access to valuable member benefits. Already a member? Stop by our booth to pick up your commemorative ASCO pin and check your membership status!

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

The premier monthly journal of the Society of Surgical Oncology
AngioDynamics Inc.  
14 Plaza Drive  
Latham, NY 12110  
Phone: 518-795-1400; Fax: 518-798-1360  
www.angiodynamics.com

AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics’ diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products.

Automated Medical Products  
PO Box 2508  
Edison, NJ 08818  
Phone: 732-602-7717; Fax: 732-602-7706  
www.ironintern.com


Belmont Instrument Corporation  
780 Boston Rd.  
Billerica, MA 01821  
Phone: 978-663-0212-124; Fax: 978-663-0214  
www.belmontinstrument.com

The Belmont® Hyperthermia Pump is making hyperthermic therapy available for all patients. The affordable system uses patented electromagnetic induction technology to precisely warms fluids to target temperature in a single pass. It is a safe, simple, efficient portable system. Belmont also offers the Belmont® Rapid Infuser and the Belmont buddy series of blood warmers.

BK Medical  
8 Centennial Drive  
Peabody, MA 01960  
Phone: 978-326-1300; Fax: 978-326-1399  
www.analogicultrasound.com

BK Ultrasound systems are designed for the surgical suite. Our wide range of laparoscopic, intraoperative and percutaneous transducers provide one-button control, puncture guides and are compatible with modern disinfection and sterilization techniques. Compact and easy to maneuver, our Flex Focus premium ultrasound systems provide up to four hours of plug-free imaging.
BSD Medical
2188 West 2200 South
Salt Lake City, UT 84119
Phone: 801-972-5555; Fax: 801-972-5930
wwwbsdmedical.com

BSD Medical Corporation develops and markets systems for soft-tissue ablation using focused microwave energy. The MicroThermX® microwave ablation system has been developed to employ precision-guided microwave energy to target diseased soft-tissue (tumors). The innovative design is the first of its kind, allowing for fast and efficient delivery of energy through single or multiple antennas to create scalable zones of necrosis for planar coagulation or for ablation of diseased soft-tissue.

Cancer Treatment Centers of America
Booth 314
2610 Sheridan Road
Zion, IL 60099
Phone: 847-746-4441; Fax: 847-746-4380
wwwcancercenter.com

Cancer Treatment Centers of America is a national network of cancer treatment hospitals that offer a unique, whole-person approach to cancer treatment. Patients are surrounded by a care team that creates personalized treatment plans to specifically meet the needs of each individual patient. CTCA continuously updates treatment protocols to utilize the latest, best technology and the most recent, relevant clinical research on behalf of cancer patients.

Caris Life Sciences
Booth 332
6655 North MacArthur Boulevard
Irving, TX 75039
Phone: 972-689-6757; Fax: 214-276-7714
wwwcarisilifesciences.com

Caris Life Sciences® develops and delivers innovative molecular diagnostic, prognostic and theranostic services. Caris Molecular Intelligence™, is the world’s foremost evidence-guided tumor profiling service designed to provide oncologists with the most relevant, clinically-actionable and individualized treatment information to personalize cancer care for all solid tumors.

Carl Zeiss Meditec, Inc.
Booth 304
5160 Hacienda Drive
Dublin, CA 94568
Phone: 925-557-4854;
wwwmeditec.zeiss.com

Carl Zeiss Meditec AG’s extensive portfolio encompasses the unique INTRABEAM Radiotherapy System for intraoperative radiotherapy. Backed by years of clinical experience, INTRABEAM provides a unique alternative to traditional breast cancer treatment options.
Castle Biosciences, Inc.  
2014 San Miguel Drive  
Friendswood, TX 77546  
Phone: 866-788-9007; Fax: 866-431-2924  
www.castlebiosciences.com  

Castle Biosciences is a leading cancer molecular diagnostics company dedicated to helping patients and their physicians make the best possible decisions about treatment based on the individual molecular signature of their tumor. We offer tests for rare and underserved cancers including cutaneous melanoma, uveal melanoma, esophageal and thymic cancers, and mesothelioma. Based in Friendswood, Texas with laboratory facilities in Phoenix, Arizona, find more information at castlebiosciences.com.

Cianna Medical  
6 Journey, Suite 125  
Aliso Viejo, CA 92656  
Phone: 866-920-9444; Fax: 949-297-4527  
www.ciannamedical.com  

Cianna Medical, Inc. is a women’s health company dedicated to the innovative treatment of early-stage breast cancer. The company manufactures and markets the SAVI® breast brachytherapy applicator, as well as the new SAVI Scout®. The SAVI Scout® surgical guidance system is an FDA-cleared medical device that utilizes electromagnetic wave technology to provide tumor localization and real-time guidance during breast surgery.

Dilon Diagnostics  
12050 Jefferson Avenue, Suite 340  
Newport News, VA 23606  
Phone: 757-269-4910; Fax: 757-269-4912  
www.dilon.com  

SurgicEye GmbH is a pioneer in intra-operative 3-D imaging for surgical navigation. The declipseSPECT product is the world’s first FDA and CE certified product for intra-operative, three dimensional visualization of radio-labeled tissues and allows the detection, localization and guided biopsy of sentinel lymph nodes in breast cancer, melanoma and head and neck malignancies. Dilon Diagnostics, the leading company in molecular breast imaging, is the exclusive U.S. distributor of declipseSPECT.
Domain Surgical  
Booth 228  
1370 South 2100 East  
Salt Lake City, UT 84108  
Phone: 801-924-4950; Fax: 801-924-4951  
www.domain Surgical.com  

Domain Surgical has developed the FMX Ferromagnetic Surgical System, a surgical platform for precise cutting, coagulation and sealing of tissue and vessels. Domain Surgical’s patented technology produces surface-only tissue effects without passing electrical energy through the patient, and is designed to provide unparalleled safety and predictability in the most critical surgical applications. For more information, visit domainsurgical.com.

Dune Medical Devices  
Booth 123  
43 Leopard Road, Building 2, Suite 302  
Paoli, PA 19301  
Phone: 484-320-7536; Fax: 484-320-7537  
www.marginprobe.com  

The MarginProbe® System is a recently FDA-approved tissue assessment device that significantly improves the breast surgeon’s ability to intra-operatively identify cancer on the margin of excised tissue during lumpectomy, helping to reduce the positive margin rate following the initial lumpectomy procedure.

Eight Medical  
Booth 205  
345 S. College Avenue, Suite 2013  
Bloomington, IN 47403  
Phone: 812-822-0404; Fax: 812-645-3902  
www.eightmedical.com  

The Recirculator 8.0 and 8100 Lavage Procedure Kit. State-of-the-art technology. Elegant and simple in design and function. The Recirculator 8.0 is the latest and most straightforward device developed specifically for intraperitoneal and thoracic hyperthermia.

Elsevier  
Booth 201  
1600 JFK Boulevard, Suite 1800  
Philadelphia, PA 19103  
Phone: 215-239-3722; Fax: 215-239-3494  
www.elsevierhealth.com  

Elsevier is a leading publisher of health science publications, advancing medicine by delivering superior reference information and decision support tools to doctors, nurses, health practitioners and students. With an extensive media spectrum (print, online and handheld), we are able to supply the information you need in the most convenient format.
Enovative Technologies  
9748 Stephen Decatur Highway 
Ocean City, MD 21842

Enovative Technologies designs products that help improve people’s lives. Our brands focus on enhancing comfort, well-being and convenience for our consumers.

Ethicon  
4545 Creek Road 
Cincinnati, OH 45242 
Phone: 877-384-4266; 
www.ethicon.com

Ethicon US LLC, a Johnson & Johnson company, commercializes a broad range of innovative surgical products, solutions and technologies used to treat some of today’s most prevalent medical issues, such as: colorectal and thoracic conditions, women’s health conditions, hernias, cancer and obesity. Learn more at ethicon.com, or follow us on Twitter @Ethicon.

Faxitron  
3440 East Britannia Drive, Suite 150 
Tucson, AZ 85706 
Phone: 520-399-8180; Fax: 520-399-8182 
www.faxitron.com

As the specialist in specimen radiography, Faxitron continues to be the world’s most trusted brand in dedicated digital radiography systems for breast biopsy and lumpectomy specimens. Our new industry leading 21 lp/mm detector, featured in Faxitron’s BioVision+, delivers 3X the resolution of standard mammography/tomosynthesis. Raising the standard-of-care to new heights for patients undergoing surgical excision or core biopsy procedures.

Focal Therapeutics  
30 Enterprise, Suite 220 
Aliso Viejo, CA 92656 
Phone: 949-600-5050; Fax: 949-600-5060 
www.focalrx.com

Focal Therapeutics, located in Aliso Viejo, California, manufactures and distributes BioZorb, an implantable marker, placed by surgeons at the time of surgical tissue excision. BioZorb is a 3D, bioabsorbable implant that uniquely delineates the surgical site after tissue removal and helps visualize the area on clinical imaging. Clinicians using BioZorb have shown its clinical utility across many aspects of breast cancer care, including oncoplastic surgery, radiation therapy and long term follow-up.
Genentech
1 DNA Way
South San Francisco, CA 94080
Phone: 650-225-1000
www.gene.com

For more than 30 years, we’ve been following the science, seeking solutions to unmet medical needs. As a proud member of the Roche Group, we make medicines to treat patients with serious medical conditions. We are headquartered in South San Francisco, California.

Genomic Health, Inc.
301 Penobscot Drive
Redwood City, CA 94063
Phone: 866-662-6897; Fax: 866-444-0640
www.oncotypedx.com

Genomic Health’s Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. With half a million patients tested in more than 70 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about OncotypeDX tests, visit oncotypedx.com and mybreastcancertreatment.org.

Hitachi Aloka Medical
10 Fairfield Boulevard
Wallingford, CT 06492
Phone: 800-872-5652; Fax: 203-269-6075
www.hitachi-aloka.com

Hitachi Aloka Medical’s commitment to ultrasound for surgeons allows us to offer a wide range of consoles and specifically designed transducers to meet the needs of every surgeon. Recognized for our superior image quality, outstanding system reliability and intuitive use of cutting edge technology, we remain the standard in the field of ultrasound for surgeons.

Hologic
35 Crosby Drive
Bedford, MA 01730
Phone: 781-999-7300; Fax: 781-280-0667
www.hologic.com

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products. The Company’s core business units focus on diagnostics, breast health, GYN surgical, and skeletal health. With a unified suite of technologies and a robust research and development program, Hologic is dedicated to The Science of Sure.
ImpediMed, Inc.  
Booth 300  
5900 Pasteur Court, Suite 125  
Carlsbad, CA 92008  
Phone: 877-247-0111; Fax: 760-804-9245  
www.impedimed.com

ImpediMed’s FDA-cleared L-Dex® devices enable pre-emptive care of cancer-related lymphedema. L-Dex devices utilize bioimpedance spectroscopy (BIS) to detect extracellular fluid difference between limbs. Lymph is an extracellular fluid that can accumulate as a result of surgical removal or irradiation of lymph nodes. L-Dex provides a standardized and objective measure of fluid accumulation in the at-risk limb allowing lymphedema management and risk reduction (NAPBC Std 2.15).

IntraMedical Imaging LLC  
Booth: 207  
12569 Crenshaw Boulevard  
Hawthorne, CA 90250  
Phone: 844-426-6277; Fax: 844-426-6277  
www.GammaProbe.com

IMI markets a family of surgical probes, including Surgical Gamma Probes for sentinel lymph node biopsy in breast cancer and melanoma surgery, and PET Probes for intraoperative Gamma Probe and Beta Probe tumor detection and surgical margin evaluation. Our technology is based on the injection of radio-pharmaceuticals that emit gamma or beta rays. Surgeons use our probes to locate the sentinel lymph nodes or cancerous tissues that accumulate the radio-pharmaceuticals.

IntraOp Medical Corporation  
Booth 325  
570 Del Rey Avenue  
Sunnyvale, CA 94085  
Phone: 408-636-1020-128; Fax: 949-743-0570  
www.intraopmedical.com

IntraOp Medical provides innovative technology for the treatment and eradication of cancer through the safe and effective administration of intraoperative electron radiotherapy. Mobetron, the first fully portable, self-shielding intraoperative electron radiotherapy device is designed for use in any operating room. Founded in 1993, IntraOp continues to be encouraged by the positive clinical outcomes published in peer-reviewed journals by Mobetron users worldwide for all treated body sites.
Intuitive Surgical
Booth 112
1266 Kifer Rd., Bldg. 101
Sunnyvale, CA 94086-5304
Phone: 408-523-2100; Fax: 408-523-1390
www.intuitivesurgical.com

Intuitive Surgical is the global technology leader in robotic-assisted, minimally invasive surgery. The da Vinci® System enables general surgeons to offer a minimally invasive approach — even to patients with complex conditions. Da Vinci can be used across a wide array of surgical specialties, including bariatric, esophageal and colorectal surgery. Studies suggest that da Vinci Gastric Bypass may reduce risk of anastomotic leak and stricture and reduce procedure time for high-BMI patients.

Invuity
Booth 309
39 Stillman St.
San Francisco, CA 94107
Phone: 415-655-2100
www.invuity.com

Invuity develops advanced medical devices to dramatically improve access and visualization in minimally invasive and minimal access surgery. Invuity’s products incorporate its proprietary Eigr illumination technology into sophisticated handheld illumination devices and access systems for a variety of surgical specialties including spine, orthopedics, breast and thyroid oncologic, plastic and general surgery.

Lee Medical
Booth 120
30 Vreeland Drive, Suite #8
Skillman, NJ 08558
Phone: 609-285-2153; Fax: 609-285-2154
www.leemedicalnj.com

Lee Medical markets a full line of disposable needles for bone marrow aspiration, biopsy, harvest and transplantation. Our Lee-Lok® product line has been the trusted name in bone marrow needles for over 25 years. Since 1987 Lee Medical has established a reputation for delivering high quality products directly to hospitals and physicians. We are a certified woman-owned, family-operated small business that strives to guarantee efficiency and perfect customer service without sacrificing quality.
**Lightpoint Medical**  
Cardinal Point Park Road  
Rickmansworth, United Kingdom WD3 1RE  
Phone: 855 842-6708;  
www.lightpointmedical.com

Lightpoint Medical introduces an innovative molecular imaging technology designed to improve the detection of cancer during surgery, the evaluation of surgical margins, and the assessment of lymph nodes. Based on Cerenkov luminescence imaging, Lightpoint Medical’s products combine the benefits of optical imaging with commonly used PET radiopharmaceuticals. New products include the LightPath specimen analyzer and EnLight intraoperative scope (for investigational use only).

**Mammotome**  
300 E-Business Way, 5th Floor  
Cincinnati, OH 45241  
Phone: 513-864-9028; Fax: 513-864-9011  
www.mammotome.com

As the global market leader in vacuum-assisted breast biopsy, Mammotome offers a wide range of products to healthcare professionals specializing in breast diseases, including breast cancer. Our extensive product portfolio includes Mammotome revolve® (biopsy system), Mammotome elite® (tetherless), Mammotome MammoTestTM (stereotactic biopsy table), distribution of Faxitron’s CoreVision® (core specimen radiography), Neoprobe® Gamma Detection System and a wide range of biopsy site tissue markers.

**Memorial Healthcare System**  
4320 Sheridan St.  
Hollywood, FL 33021  
Phone: 954-265-0904; Fax: 954-989-7959  
www.memorialrehab.com

As the third-largest public healthcare system in the nation, Memorial Healthcare System includes six hospitals, a nursing home, home health services and a network of six community health centers in South Florida. Our utilization of advanced technology and a clinical informatics has enabled us to excel in the areas of patient safety, quality, customer service, business processes, workforce and disaster readiness. Our outstanding workplace and diversity of opportunities are matched by the quality of our exemplary team.
Today’s Merck is working to help the world be well. Through our medicines, vaccines, biologic therapies and consumer and animal products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. For more information, visit merck.com.

Mitaka USA is the distributor of the Hamamatsu PDE Neo. The Hamamatsu PDE Neo is used worldwide for the fluorescence of sentinel lymph nodes in oncology. In the U.S., the PDE Neo is FDA cleared for vascular fluorescence navigation and is not FDA cleared for lymph uses.

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patient’s lives through the discovery and commercialization of transformative tests to assess a person’s risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence.

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Lymphoseek® (technetium 99m tilmanocept) Injection, Navidea’s first commercial product, was approved by the FDA in March 2013. For more information, visit navidea.com.
NeuWave Medical, Inc.  
3529 Anderson Street  
Madison, WI 53704  
Phone: 608-512-1500; Fax: 608-512-1509  
www.neuwave.com

Powerful microwave energy delivered to the hand of the surgeon. The Certus 140 System maximizes the synchronized power delivered to soft tissue in laparoscopic/open procedures, providing rapid coagulation resulting in tissue hemostasis. Advanced features include Tissu-Loc Technology and Clic n’ Go connections. Now featuring the CertuSurg, a surgical tool used exclusively in open surgical applications. Don’t imagine the future; see it now. To learn more about this product visit neuwave.com.

New York Life Insurance Company  
39650 Liberty Street, Suite 200  
Fremont, CA 94538  
Phone: 916-847-6481;  
www.newyorklife.com

Maram Alaiwat, MA, is a licensed agent with New York Life Insurance Company and registered representative offering securities through NYLIFE Securities LLC (member FINRA/SIPC). Contact mkalaiwat@ft.newyorklife.com or 916-847-6481 for life insurance and financial services.

Novartis Oncology  
One Health Plaza  
East Hanover, NJ 07936  
Phone: 862-778-7358  
www.novartisoncology.com

Novartis Oncology has emerged as a global leader in oncology through targeted research and open partnership in the pursuit of new therapies capable of transforming outcomes for people with cancer. Our research is driven by a distinctive scientific and clinical strategy, focusing on unmet medical needs and disease pathways. For more information, visit novartisoncology.com.
Sirtex Medical Inc.  
300 Unicorn Park Drive  
Woburn, MA 01801  
Phone: 888-474-7839; Fax: 978-229-9585  
www.sirtex.com

SIR-Spheres microspheres is the first and only fully FDA PMA approved radiolabeled product for the treatment of colorectal liver metastases. With Selective Internal Radiation Therapy (SIRT), beta emitting Yttrium-90 bound resin microspheres are infused through the hepatic artery and lodge preferentially in liver tumors. SIR-Spheres microspheres are offered at more than 700 treatment centers worldwide. With over 45,000 doses supplied worldwide, Sirtex is the leading global provider of SIRT.

SIT USA  
2363 CR852  
McKinney, TX 75071  
Phone: 425-766-0890  
www.soior.com

Sordina IORT Technologies is the world’s leading manufacturer of Intraoperative Electron Radiation Therapy (IOERT) self-shielded mobile linear accelerators used to deliver a large single fraction of radiation to the tumor bed in the operating room at the time of cancer surgery. This technique has proven to be very effective in early stage breast cancer and locally advanced or recurrent cancers including rectal, head and neck, GYN, pancreas, gastric, G/U, and soft tissue and extremity sarcomas.

Society of Surgical Oncology  
9525 West Bryn Mawr Avenue, Suite 870  
Rosemont, IL 60018  
Phone: 847-427-1400; Fax: 847-427-9656  
www.surgonc.org

Celebrating our 75th Anniversary, SSO is the premier organization for surgeons and health care providers. Stop by the booth to purchase 75th Anniversary commemorative apparel or make a donation to the 75 for 75 campaign. Also, while visiting the booth you will meet the membership staff and The SSO Foundation and Annals of Surgical Oncology team. In 2014 the Society was awarded the coveted “Accreditation with Commendation” from the ACCME. SSO offers a variety of programs and services including the monthly journal, Annals of Surgical Oncology, the Surgical Oncology Self-Assessment Program (SOSAP), Maintenance of Certification - Part 2 credits, an online Career Center with job postings, and training programs for Fellows and Residents. You’re invited to join SSO; go to surgonc.org to complete an application today. SSO 2015 Special: If you join in the next 30 days, SSO will waive the $150 application fee.
Springer
233 Spring Street
New York, NY 10013
Phone: 212-460-1500; Fax: 212-460-1700
www.springer.com

Springer publishes the Annals of Surgical Oncology, the official journal of SSO. Come by to get your sample copy! Don't forget to check out the website at annsurgoncol.org. Also, browse some of our leading books, including the new AJCC Cancer Staging Atlas, 2nd Edition.

Strategic Business Holdings “SBH”
9620 Research Dr.
Irvine, CA 92618
Phone: 949-305-3300; Fax: 949-600-8874
www.sbhsurgical.com

SBH is a medical device company focused on a streamlined supply chain and operational efficiency, offering a comprehensive line of premium surgical handheld instruments for use in ENT, micro, neuro, ophthalmic, plastic, reconstructive, vascular and thoracic surgery. SBH also offers a wide range of surgical retractor systems, such as abdominal, bariatric, liver.... At SBH, we pledge an uncompromising commitment to the excellence. For more information visit us online at sbhsurgical.com.

Stryker
77 Great Valley Parkway
Malvera, PA 19355
Phone: 484-354-6782
www.stryker.com

Stryker presents Vitagel RT3 Surgical Hemostat, formulated to control bleeding with recombinant thrombin and autologous plasma, and contains microfibrillar collagen to facilitate healing. Together with our customers, we are driven to make healthcare better.

The JAMA Network
330 N. Wabash Avenue, Suite 39300
Chicago, IL 60611
Phone: 312-464-4868; Fax: 312-464-2580
www.jamanetwork.com

Building on a tradition of editorial excellence, The JAMA Network brings JAMA together with 10 specialty journals to offer enhanced access to the research, viewpoints and medical news shaping medicine today and into the future. JAMA Oncology, a new peer-reviewed journal, will publish in early 2015.
ThermaSolutions, Inc.  
Booth 426  
1889 Buerkle Road  
White Bear Lake, MN 55110  
Phone: 651-209-3900; Fax: 651-209-3903  
www.thermasolutions.com

ThermaSolutions Inc. is recognized as the global leader in hyperthermic medical technology providing fully integrated systems specifically designed and manufactured for intraperitoneal hyperthermia (IPH). Currently utilized in more than 100 oncology centers throughout the U.S., Europe, Middle East and Asia, ThermaSolutions Inc. has established leadership through extensive research, development and product innovation. The ThermoChem™ family includes: the recently FDA-cleared HT-2000 and HT-1000.

Thompson Surgical Instruments, Inc.  
Booth 316  
10170 E Cherry Bend Rd.  
Traverse City, MI 49684  
Phone: 231-922-0177; Fax: 231-922-0174  
www.thompsonsurgical.com

Thompson Surgical is a leader in exposure and the original manufacturer of the table-mounted retractor. We understand the value of exposure in surgery and are dedicated to providing innovative, high quality systems that deliver safe, versatile and low-profile retraction. From pediatric to obesity, simple to complex exposures, we offer unlimited customization and safe, independent, retraction. The Thompson Retractor allows surgeons in multiple specialties to achieve uncompromised exposure.

Tissue Regenix  
Booth 122  
2611 North Loop 1604 West, Suite 201  
San Antonio, TX 78258  
Phone: 210-279-0745  
www.tissueregenixus.com

Tissue Regenix is an innovative company in the field of regenerative medicine. The patented decellularization ("dCELL™") technology removes DNA and other cellular material from animal/human tissue leaving an acellular tissue scaffold. The potential applications can address clinical needs such as wound care, vascular disease, heart valve replacement and knee repair.
Vector Surgical, LLC
20975 Swenson Drive, Suite 430
Waukesha, WI 53186
Phone: 262-798-7970; Fax: 262-798-7972
www.vectorsurgical.com

Vector Surgical offers devices that improve outcomes in cancer surgery. The Vector Surgical Tissue Orientation System, comprised of MarginMarker sterile inks and CorrectClips radiographic clips, provides secure and accurate designation of specimen margins in cancer surgery. Use of the system can result in more accurate re-excisions, fewer unnecessary re-excisions and lower cancer recurrence. SilversteinWrap is a unique post-surgical compression dressing that improves outcomes in breast surgery.

Wolters Kluwer
Two Commerce Square, 2001 Market Street
Philadelphia, PA 19103
Phone: 215-521-8781
www.lww.com

Lippincott Williams & Wilkins, a Wolters Kluwer Health company, is a leading international publisher of medical books, journals and electronic media. We proudly offer specialized publications and software for physicians, nurses, students and clinicians. Please visit booth 312 to browse our comprehensive product line or visit lww.com.

Xoft, a subsidiary of iCAD, Inc.
98 Spit Brook Rd., Ste. 100
Nashua, NH 03062
Phone: 603-882-5200; Fax: 603-880-3843
www.xoftinc.com

Breast cancer treatment in as little as one day. Breast Intraoperative Radiation Therapy (IORT) with the Xoft eBx® system delivers radiation therapy at the time of lumpectomy. Conformal targeting with Xoft’s stepping x-ray source attacks the cancer from directly within the lumpectomy cavity and minimizes dose to surrounding healthy tissue. The Xoft System is FDA cleared for treatment anywhere in the body including early stage breast cancer (APBI and IORT), skin cancer and gynecological cancers.
FACULTY INDEX

Abbott, A.M. ........................................ 28, 104, 115, 121, 123
Abdelsattar, Z........................................ 60
Ahmad, S.A........................................... 73
Ajani, J.A............................................. 89
Ajkay, N.................................................. 71
Al-Refaie, W........................................... 80
Alawadi, Z............................................. 42
Allen, P.J............................................. 29, 74
Aloia, T.A.............................................. 52, 57
Andtbacka, R........................................ 69, 112, 139
Ang, C.................................................... 61
Angelos, P............................................. 85
Ariyan, C.E............................................ 69
Attai, D.J.............................................. 75, 100
Aufforth, R............................................ 79
Aydin, N............................................... 55, 129
Badgwell, B.D....................................... 68
Balachandran, V.................................... 28, 60
Balch, C.M........................................... 29, 62, 90
Balch, G.C............................................ 56
Barden, G............................................. 47
Barrio, A............................................... 71
Bartlett, D.L......................................... 59, 90
Berger, A.C........................................... 69
Bilimoria, K.Y....................................... 43
Blumgart, L.H....................................... 29, 64
Boughey, J.C......................................... 83
Brady, M.S........................................... 53
Brennan, M.F....................................... 83, 88
Bullard Dunn, K.M................................. 76
Burns, W.............................................. 70
Callender, G.G..................................... 85
Cancer, W.G....................................... 85
Cardona, K.......................................... 89
Carty, S.E............................................ 58
Casadaban, L....................................... 47
Caudle, A............................................. 60
Chakravorty, V.................................... 80
Chang, G.J........................................... 76
Chang, J.C........................................... 46
Chauhan, A.......................................... 79
Chawla, A............................................ 63
Chepeha, D.......................................... 79
Cho, C.S............................................... 52
Choong, K........................................... 84
Cintolo, J.A.......................................... 86
Clarke, C............................................. 61
Cliffton, G........................................... 50
Coit, D.G............................................. 67
Conrad, C............................................ 81, 84
Crago, A.M........................................... 45
Crum, R................................................ 63
Curley, S............................................. 81
Danley, S............................................. 49
Datta, J............................................... 50, 125
Davis, J............................................... 70
De Andrade, J..................................... 50
De Wilt, J.H.W..................................... 76
Delman, K.A........................................ 43, 53
Dhir, M............................................... 88
Diaz-Botero, S..................................... 50
Dimick, J.B......................................... 85
Doherty, G.M....................................... 58
Drebin, J.A.......................................... 60, 67, 90
Eberlein, T.J........................................ 57
Elliber, F.C.......................................... 45
El Amadieh, T..................................... 84
Ellis, L.M............................................. 30, 77
Ellsworth, R........................................ 70, 91
Eng, O.................................................. 49
Ertel, A............................................... 81
Esserman, L.J...................................... 54, 67
Euhus, D.M......................................... 75
Evans, D.B.......................................... 59, 88
Falo, A................................................. 80
Feig, B.W............................................ 45
Fields, R.C.......................................... 68, 86
Fong, Y............................................... 44, 84
Fracol, M............................................. 50
Galandiuk, S...................................... 47
Gangi, A.............................................. 70, 79
Gass, J.................................................. 50
Gershensonald, J.E................................. 57, 67
Giuliano, A.E....................................... 41, 90
Goldin, A............................................. 80
Grandhi, M.S...................................... 88
Gray, K............................................... 80
Greene, J............................................ 69
Greenup, R.A....................................... 57, 93
Gronchi, A.......................................... 45
Hameed, U.......................................... 84
Hamner, J.B....................................... 88, 110, 127
Hansen, N.M....................................... 46
Harnsberger, C.................................... 80
Harris, J.............................................. 48
Henry-Tillman, R.S............................... 41
Herzig, D.O......................................... 56
Hochwald, S.N..................................... 48
Hoekstra, H........................................ 42
Hogg, M.............................................. 42
Hohenberger, P................................... 48, 121
<table>
<thead>
<tr>
<th>Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simkens, G.</td>
<td>48</td>
</tr>
<tr>
<td>Singla, S.</td>
<td>49, 104, 110</td>
</tr>
<tr>
<td>Slingluff, Jr., C.L.</td>
<td>53</td>
</tr>
<tr>
<td>Smith, B.L.</td>
<td>42</td>
</tr>
<tr>
<td>Smith, J.J.</td>
<td>47</td>
</tr>
<tr>
<td>Solorzano, C.C.</td>
<td>58</td>
</tr>
<tr>
<td>Sondak, V.K.</td>
<td>59</td>
</tr>
<tr>
<td>Sosa, J.A.</td>
<td>58</td>
</tr>
<tr>
<td>Stitzenberg, K.B.</td>
<td>57</td>
</tr>
<tr>
<td>Strong, V.E.</td>
<td>73, 89</td>
</tr>
<tr>
<td>Sturgeon, C.</td>
<td>57</td>
</tr>
<tr>
<td>Swallow, C.J.</td>
<td>45, 78</td>
</tr>
<tr>
<td>Tamm, E.P.</td>
<td>74</td>
</tr>
<tr>
<td>Temple, L.K.F.</td>
<td>80</td>
</tr>
<tr>
<td>Teshome, M.</td>
<td>27, 49</td>
</tr>
<tr>
<td>Thompson, A.M.</td>
<td>83</td>
</tr>
<tr>
<td>Tiesi, G.</td>
<td>49</td>
</tr>
<tr>
<td>Torphy, R.</td>
<td>68</td>
</tr>
<tr>
<td>Tripathy, D.</td>
<td>54</td>
</tr>
<tr>
<td>Tseng, J.F.</td>
<td>89, 112</td>
</tr>
<tr>
<td>Tyler, D.S.</td>
<td>86</td>
</tr>
<tr>
<td>Valente, S.</td>
<td>50</td>
</tr>
<tr>
<td>Van Zee, K.J.</td>
<td>83</td>
</tr>
<tr>
<td>Vauthey, J.</td>
<td>76</td>
</tr>
<tr>
<td>Vilar-Sanchez, E.</td>
<td>56</td>
</tr>
<tr>
<td>Vugts, G.</td>
<td>70</td>
</tr>
<tr>
<td>Wachtel, H.</td>
<td>79</td>
</tr>
<tr>
<td>Wanebo, H.</td>
<td>47, 109, 118</td>
</tr>
<tr>
<td>Weber, S.M.</td>
<td>52, 59</td>
</tr>
<tr>
<td>Weigel, R.J.</td>
<td>59, 60, 63</td>
</tr>
<tr>
<td>White, P.</td>
<td>48</td>
</tr>
<tr>
<td>White, R.R.</td>
<td>52</td>
</tr>
<tr>
<td>White, S.</td>
<td>84</td>
</tr>
<tr>
<td>WHitley, M.</td>
<td>48</td>
</tr>
<tr>
<td>Wilke, L.G.</td>
<td>54, 83</td>
</tr>
<tr>
<td>Winchester, D.J.</td>
<td>54</td>
</tr>
<tr>
<td>Wong, S.L.</td>
<td>53, 57</td>
</tr>
<tr>
<td>Woodward, W.A.</td>
<td>54</td>
</tr>
<tr>
<td>Wright, J.L.</td>
<td>30, 78</td>
</tr>
<tr>
<td>Wu, G.</td>
<td>84, 122</td>
</tr>
<tr>
<td>Yamashita, K.</td>
<td>69</td>
</tr>
<tr>
<td>Yen, T.W.F.</td>
<td>30, 78</td>
</tr>
<tr>
<td>Yoo, J.</td>
<td>79</td>
</tr>
<tr>
<td>Yoon, S.S.</td>
<td>48</td>
</tr>
<tr>
<td>Yopp, A.</td>
<td>81</td>
</tr>
<tr>
<td>You, Y.N.</td>
<td>47</td>
</tr>
<tr>
<td>Zager, J.S.</td>
<td>86</td>
</tr>
<tr>
<td>Zaheer, S.</td>
<td>79</td>
</tr>
<tr>
<td>Zeh, III, H.</td>
<td>42, 67</td>
</tr>
<tr>
<td>Zureikat, A.</td>
<td>42</td>
</tr>
</tbody>
</table>
EXHIBIT HALL B3
LOCATED IN GBCC 300 LEVEL

FLOOR PLANS
2014-2015
THE SSO FOUNDATION
BOARD OF DIRECTORS

OFFICERS
President Mitchell C. Posner, MD (2017)
Vice President Monica Morrow, MD (2017)
Treasurer Robert C.G. Martin, II, MD (2016)
Executive Vice President M. Eileen Widmer, CAE, CFRM

BOARD OF DIRECTORS
SSO President Ronald J. Weigel, MD, PhD (2016)
SSO Immediate Past President V. Suzanne Klimberg, MD (2015)
SSO President-Elect Jeffrey A. Drebin, MD, PhD (2017)
H. Richard Alexander, Jr., MD (2018)
Charles M. Balch, MD (2017)
David L. Bartlett, MD (2017)
Peter D. Beitsch, MD (2016)
Steven A. Curley, MD (2018)
Armando E. Giuliano, MD (2018)
Mehra Golshan, MD (2017)
Charles A. Staley, MD (2018)
Mark S. Talamonti, MD (2017)

STAFF
Executive Vice President M. Eileen Widmer, CAE, CFRM
Director of Operations Pamela A. Bowerman
Director, Corporate Relations Deborah A. Cohen
Corporate Relations Associate Patricia A. Price
Administrative Assistant Damaris Miranda

HEADQUARTERS OFFICE
9525 W. Bryn Mawr Avenue, Suite 870
Rosemont, IL 60018
P: 847-427-1400 • F: 847-427-1411
ssofoundation@surgonc.org
CONTRIBUTE TO THE 75 FOR 75 FUND
BE ELIGIBLE TO WIN ONE OF SEVERAL PRIZES!

Help commemorate the 75th Anniversary of SSO and support research and education with a donation to the 75 for 75 Fund. With your help, The SSO Foundation aims to raise $75,000 by the close of SSO 2015 in honor of 75 years of SSO.

To contribute, visit surgonc.org/75for75 or visit the SSO Membership Booth 419.

Donate during SSO 2015 and you’ll be eligible to win one of several prizes during a raffle to be held at the end of the Symposium. Prizes range from restaurant gift cards to hotel room nights to SSO membership. Already donated? Anyone who has previously donated to the 75 for 75 Fund has been entered into the raffle.

Want to increase your chances of winning? The more you donate, the more entries you receive.

<table>
<thead>
<tr>
<th>Donation Amount</th>
<th>Entries</th>
</tr>
</thead>
<tbody>
<tr>
<td>Up - $100</td>
<td>One Entry</td>
</tr>
<tr>
<td>$101 - $250</td>
<td>Two Entries</td>
</tr>
<tr>
<td>$251 - $500</td>
<td>Three Entries</td>
</tr>
<tr>
<td>$501 - $750</td>
<td>Four Entries</td>
</tr>
<tr>
<td>$751 - $1,000</td>
<td>Five Entries</td>
</tr>
<tr>
<td>Over $1,000</td>
<td>Six Entries</td>
</tr>
</tbody>
</table>

You do not need to be present to win. Visit The SSO Foundation Booth next to SSO Membership Booth (419) in the Exhibit Hall at SSO 2015 for a complete list.

About the 75 for 75 Fund

Your generous contribution will help support The SSO Foundation’s new research initiatives, including awards encompassing the spectrum of surgical oncology research to help foster the careers of promising young surgical oncology investigators. 75 for 75 fund contributions will translate into more robust funding from extramural sources for these promising researchers. This new initiative will be in addition to the Foundation’s already-established Clinical Investigator Awards program.
THE SSO FOUNDATION
MEMBER PARTNERS
2014-2015
(January 1, 2014 - February 28, 2015)

Donors
Josyln Albright, MD
Kathia Alejandro, MD
Stephan Ariyan, MD
Myron Arlen, MD
Sanjay Baldota, MD
Russell Berman, MD
Richard Bleicher, MD
Peter Blumencranz, MD
Pamela Bowerman
Ruben Boyajian, MD
Efrain Cambronero, MD
Aurelio Carrera, MD
W. Bradford Carter, MD
Blake Cady, MD
David Cornell, MD
Nicolas Droppelmann, MD
Timothy Eberlein, MD
Seferino Farias, MD
Jay Harness, MD
Alexandra Heerdt, MD
Jessik Hetu, MD
Hank Hill, MD
Michael House, MD
Eddy Hsueh, MD*
Steven Katz, MD
Troy Kimsey, MD
Tari King, MD
Augusto Leon, MD
Carrie Lubitz, MD
Lloyd Mack, MD
David Mangiameli, MD
Donald McCain, MD
Denise Johnson-Miller, MD
Monica Morrow, MD*
Nicholas Petrelli, MD
Mark Runfola, MD
Daniel Schiller, MD
Zahra Shafaei, MD
Yoshifumi Shimada, MD
Rubens Kesl Siqueira De Paiva, MD
Anthony Tufaro, MD
Yoshida Tsukihisa, MD
Julio Vaquerano, MD
Carmine Volpe, MD
Rebecca Wiatrek, MD
Sandra Wong, MD

75 for 75 Member Campaign
Nita Ahuja, MD
Eduardo Akaishi, MD
H. Richard Alexander, MD*
Kathryn Amirikia, MD
Peter Angelos, MD
Charlotte Ariyan, MD
Myron Arlen, MD
Bolanle Asiyaniwola, MD
Deanna Attai, MD
Rebecca Ann Auer, MD
Bruce Averbook, MD
Charles Balch, MD*
Carlton Barnett, MD
Paul Baron, MD
Robert Barone, MD
David Bartlett, MD
Harry Bear, MD
Juan Bedoya, MD
Peter Beitsch, MD
Kathleen Bell
Adam Berger, MD
Russell Berman, MD
Jose Bevilacqua, MD
Anton Bilchik, MD
Kirby Bland, MD
Jason Breaux, MD
Murray Brennan, MD*
Russell Brown, MD
Robert Buras, MD
Blake Cady, MD
Efrain Cambronero, MD
William Cance, MD*
Jacquelyn Carr, MD
Francisco Ochoa-Carrillo, MD
W. Bradford Carter, MD
Charles Cheng, MD
Moira Christoudias, MD
Mathew Chung, MD
Alfred Cohen, MD*
Daniel Coit, MD*
Michael Covelli, MD
Jean Couture, MD
Aimee Crago, MD
Steven Curley, MD
John Daly, MD*
Michael Disiena, MD
Jeffrey Drebin, MD*
Nicolas Droppelmann, MD

* Denotes members who have contributed $1,000 or more.
Dr. and Mrs. Tim Eberlein
James Economou, MD*
Robert Elliott, MD
Jesus Esquivel, MD
Douglas Evans, MD
Ryan Fields, MD
Michelle Fillion, MD
Susan Galandiuk, MD
Sabha Ganai, MD
Bernard Gardner, MD*
Jeffrey Gershenwald, MD
Armando Giuliano, MD
Benjamin Golas, MD
Melanie Goldfarb, MD
Mehra Golshan, MD
Kiyotoshi Gotoh, MD
James Goydos, MD
Michael Grant, MD
Stephen Grobmyer, MD
Dale Han, MD
Danielle Hari, MD
William Hawkins, MD
Todd Heaton, MD
Alexandra Heerdt, MD
Michael Henderson, MD
Hank Hill, MD
Richard Hoefer, MD
Herbert Hoover, MD
Michael House, MD
Karen Hurley, MA
James Huth, MD
Andre Ilbawi, MD
John Kane, MD
Anthony Kim, MD
Hong Jin Kim, MD
Tari King, MD
V. Suzanne Klimberg, MD*
Walter Lawrence, Jr., MD
Jeffrey Lee, MD
Augusto Leon, MD
Heather MacDonald, MD
Lloyd Mack, MD
William Sanchez
Maldonado, MD
Julie Margenthaler, MD
Robert Martin, MD
Laurence McCahill, MD
Martin McCarter, MD
Shaun McKenzie, MD
Tamra McKenzie, MD
Marissa Howard-McNatt, MD
Nipun Merchant, MD
Fabrizio Michelassi, MD*
Kristen Milke
Elizabeth Mittendorf, MD
David Caba-Molina, MD
John Monson, MD
Monica Morrow, MD*
John Mullen, MD
Mary Murray, MD
Faina Nakhlis, MD
Rogerio Neves, MD
John Niederhuber, MD
Spyridon Pagkratis, MD
Colette Pameijer, MD
Maryam Parviz, MD
Timothy Pawlik, MD
Lindsay Petersen, MD
Nicholas Petrelli, MD*
Christopher Pezzi, MD*
Giao Phan, MD
Jose Pimiento, MD
Hiram Polk, Jr., MD
Raphael Pollock, MD
Mitchell Posner, MD*
Diane Radford, MD
Chandrajit Raut, MD
Louis Rivera, MD
Kevin Roggin, MD*
Colin Rorrie
Norman Rosenblum, MD
Hector Martinez Said, MD
Roderich Schwarz, MD
Robert Schweitzer, MD*
Stephen Sener, MD
Maheswari Senthil, MD
Ranjna Sharma, MD
Elizabeth Shaughnessy, MD
David Shibata, MD
Hari Shukla, MD
Kerrington Smith, MD
Perry Soriano, MD
Charles Staley, MD
Robert Sticca, MD
Elizabeth Sullivan, MD
Mark Talamonti, MD*
Margaret Tarpley, MD
Paige Teller, MD
Anthony Tufaro, MD
Stefano Valabrega, MD
George Van Buren, MD
Julio Vaquero, MD
Harold Wanebo, MD
Sharon Weber, MD*
Ronald Weigel, MD*
Samuel Wells, MD*
Jane Wey, MD
Rebekah White, MD
M. Eileen Widmer, CAE
Lee Wilke, MD
David P. Winchester, MD*
Ronald Wolf, MD
Sandra Wong, MD*
William Wood, MD
Ashraf Zaghloul, MD
* Denotes members who have contributed $1,000 or more.
IN HONOR
John J. Talamonti
By Mark Talamonti, MD*
Mary F. Daly
By John Daly, MD*

IN MEMORIAM
Pearl Becker
By Steven Katz, MD

Donald L. Morton, MD Fund Contributors
Charlotte Ariyan, MD
Dr. and Mrs. Charles Balch*
Carl A. Bertelsen, MD
Miguel Angelo Brandao, MD
Hiram S. Cody, Ill, MD*
Dr. and Mrs. Daniel Coit
Willard M. Daggett, MD
Dr. and Mrs. David and Euhus*
Armando E. Giuliano, MD*
Jeffrey Gershenwald, MD
Dr. and Mrs. Frank L. Helen Gofrank Foundation*
Brian Griffiths, MD
Mary Gullixson
Richard Hoefer, MD
Yeu-Tsu M. Lee
Diane Radford, MD
Harvey and Donna Rosen
Dr. and Mrs. Daniel F. Roses
Allan Silberman, MD
Dr. Perry Shen
Ms. Gretchen A. Wayne*
Ms. Teresa Wayne*
Ms. Maylee Witham

As of February 28, 2015

* Denotes members who have contributed $1,000 or more.

FUTURE MEETINGS
MARCH 2-5, 2016
Boston, MA
MARCH 15-18, 2017
Seattle, WA
MARCH 21-24, 2018
Chicago, IL